AU2014200825A1 - N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors - Google Patents

Abstract

H:\rc tenvoven\NRPo,1bl\DCC\REC\60283407_LOC- 17/2/20>4 N3--Jeteroaryl substituted triazoles and N5-heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase A. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

Description

H:\rec\Interwoven\NRPortbl\DCC\REC\6028407_I.DOC-17/02/2014 N -HETEROARYL SUBSTITUTED TRIAZOLES AND NS-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS CROSS REFERENCE TO RELATED APPLICATIONS This application is a divisional of Australian Patent Application No. 2007342005, the entire content of which is incorporated herein by reference. This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60/975,443, filed September 26, 2007; and U.S. Provisional Patent Application No. 60/882,875, filed December 29, 2006, where these two provisional applications are incorporated herein by reference in their entireties. FIELD OF THE INVENTION This invention is directed to N 3 -heteroaryl substituted triazoles and N 5 -heteroaryl substituted triazoles and pharmaceutical compositions thereof which are useful as inhibitors of the receptor protein tyrosine kinase known as Axl. This invention is also directed to methods of using the compounds and compositions in treating diseases and conditions associated with Axl activity, particularly in treating diseases and conditions associated with angiogenesis and/or cell proliferation. BACKGROUND OF THE INVENTION All of the protein kinases that have been identified to date in the human genome share a highly conserved catalytic domain of around 300 aa. This domain folds into a bi lobed structure in which reside ATP-binding and catalytic sites. The complexity of protein kinase regulation allows many potential mechanisms of inhibition including competition with activating ligands, modulation of positive and negative regulators, interference with protein dimerization, and allosteric or competitive inhibition at the substrate or ATP binding sites. Axl (also known as UFO, ARK, and Tyro7; nucleotide accession numbers NM_021913 and NM_001699; protein accession numbers NP_068713 and NP_001690) is a receptor protein tyrosine kinase (RTK) that comprises a C-terminal extracellular ligand-binding domain and N-terminal cytoplasmic region containing the catalytic domain. The extracellular domain of Axl has a unique structure that juxtaposes immunoglobulin and fibronectin Type III repeats and is reminiscent of the structure of neural cell adhesion molecules. Axl and its two close relatives, Mer /Nyk and Sky (Tyro3 / Rse / Dtk), collectively known as the Tyro3 family of RTK's, all bind and are stimulated to varying degrees by the same ligand, Gas6 (growth arrest specific-6), a -76kDa WO 2008/083354 PCT/US2007/089153 secreted protein with significant homology to the coagulation cascade regulator, Protein S. In addition to binding to ligands, the Axl extracellular domain has been shown to undergo homophilic interactions that mediate cell aggregation, suggesting that one important function of AxI may be to mediate cell-cell adhesion. 5 AxI is predominantly expressed in the vasculature in both endothelial cells (EC's) and vascular smooth muscle cells (VSMC's) and in cells of the myeloid lineage and is also detected in breast epithelial cells, chondrocytes, Sertoli cells and neurons. Several functions including protection from apoptosis induced by serum starvation, TNF-a or the viral protein EIA, as well as migration and cell differentiation have been ascribed to AxI 10 signaling in cell culture. However, AxI-/- mice exhibit no overt developmental phenotype and the physiological function of Axi in vivo is not clearly established in the literature. Angiogenesis (the formation of new blood vessels) is limited to functions such as wound healing and the female reproductive cycle in healthy adults. This physiological process has been co-opted by tumors, thus securing an adequate blood supply that 15 feeds tumor growth and facilitates metastasis. Deregulated angiogenesis also a feature of many other diseases (for example, psoriasis, rheumatoid arthritis, endometriosis and blindness due to age-related macular degeneration (AMD), retinopathy of prematurity and diabetes) and often contributes to the progression or pathology of the condition. The overexpression of AxI and/or its ligand has also been reported in a wide 20 variety of solid tumor types including, but not limited to, breast, renal, endometrial, ovarian, thyroid, non-small cell lung carcinoma, and uveal melanoma as well as in myeloid leukemia's. Furthermore, it possesses transforming activity in NIH3T3 and 32D cells. It has been demonstrated that loss of AxI expression in tumor cells blocks the growth of solid human neoplasms in an in vivo MDA-MB-231 breast carcinoma xenograft 25 model. Taken together, these data suggest AxI signaling can independently regulate EC angiogenesis and tumor growth and thus represents a novel target class for tumor therapeutic development. The expression of Axl and Gas6 proteins is upregulated in a variety of other disease states including endometriosis, vascular injury and kidney disease and AxI 30 signaling is functionally implicated in the latter two indications. Axl - Gas6 signaling amplifies platelet responses and is implicated in thrombus formation. AxI may thus potentially represent a therapeutic target for a number of diverse pathological conditions including solid tumors, including, but not limited to, breast, renal, endometrial, ovarian, thyroid, non-small cell lung carcinoma and uveal melanoma; liquid tumors, including but 35 not limited to, leukemias (particularly myeloid leukemias) and lymphomas; 2 WO 2008/083354 PCT/US2007/089153 endometriosis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis; visual impairment due to macular degeneration; diabetic retinopathy and retinopathy of prematurity; kidney disease (including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant 5 rejection), rheumatoid arthritis; osteoporosis, osteoarthritis and cataracts. SUMMARY OF THE INVENTION This invention is directed to certain N-heteroaryl substituted triazoles and Wheteroaryl substituted triazoles which are useful as AxI inhibitors, methods of using such compounds in treating diseases and conditions associated with Axi activity and 10 pharmaceutical compositions comprising such compounds. Accordingly, in one aspect this invention is directed to a compound of formula (1):

R

3 R2 N - N R N wherein: R', R 4 and R- are each independently selected from the group consisting of hydrogen, 15 alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R5)R 7 , and -C(=NR')N(R6)R7;

R

2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 20 heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaryalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR, -R 9 O-R"-OR, -R9-O-R 1

-O-R"-OR

8 , -R 9 O-R-=CN, -R 9

-O-R

10 -C(O)OR', -R9O-Rlo-C(O)N(R')R7, -R 9

-O-R

1 -S(0)pR 8 (where p is 0, 1 or 2), -R9-O-R'0-N(R6-)R 7, -R'-O-R'O-C(NR"')N(R")H, -R9-OC(O)-R", -R-C(O)R1, 25 -R-C(O)OR 8 , -R 9

-C(O)N(R

6 )R, -R9-C(O)-R 0

-N(R

6 )R , -R 9

-N(R

6 )R ,

~R-N(RS)-R-N(R)R

7 , -R"-N(R 6 )C(O)OR, -R-N(R 6

)C(O)-R"-N(R')R

7 ,

-R

9 -N(R6)C(O)R8, -R-N(R 6 )S(O),R, (where t is 1 or 2), -RO-S(O)OR (where t is I or 2), -R 9

-S(O),R

8 (where p is 0, 1 or 2), and -R"-S(O)tN(R 6

)R

7 (where t is 1 or 2); R7 is selected from the group consisting of aryl and heteroaryl, where the aryl and the 30 heteroaryl are each independently optionally substituted by one or more 3 WO 2008/083354 PCT/US2007/089153 substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted 5 cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted 10 heteroarylalkynyl, -R -OR , -R 13 -OC(O)-R , -R 3 -O-R -N(R ) 2 , -R -N(R ) 2 , -R"-C(O)R"2, -R"3-C(O)OR 1, -R'3-C(O)N(R 12)2, -- R1-.C( O)N(R 12)-R 14-N(R 12)R'3 -R"-C(O)N(R )-R' -OR , -R -N(R )C()OR, -Ri?-N(R'-)C(O)R

-R

1 -N(R)S(O)tR (where t is 1 or 2), -R 1 -S(O)IOR (where t is 1 or 2),

-R

1 -S(O)pR (where p is 0, 1 or 2), and -R"-S(O)tN(R 2

)

2 (where t is 1 or 2); 15 each R and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally 20 substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 10 -OR*, -R 10 -CN, -R'0-N0 2 , -R 0-N(R3) 2 , 25 -R 1 0 -C(O)OR' and -R"-C(O)N(R8) 2 , or any R and R?, together with the common nitrogen to which they are both attached, form an optionally substituted N heteroaryl or an optionally substituted N-heterocyclyl; each R is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally 30 substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylaikenyl, optionally substituted 35 heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted 4 WO 2008/083354 PCT/US2007/089153 heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally 5 substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each Rio is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene 10 chain; each R" is hydrogen, alkyl, cyano, nitro or -OR 8 ; each Ri is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted 15 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R's, together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 3 is independently selected from the group consisting of a direct bond, an 20 optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R 1 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; 25 as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof. In another aspect, this invention is directed to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of formula (1), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically 30 acceptable salt thereof. In another aspect, this invention is directed to methods of treating a disease or condition associated with Axi activity in a mammal, wherein the methods comprise administering to the mammal a therapeutically effective amount of a compound of formula (1), as described above, as an isolated stereoisomer or mixture thereof, or a 35 pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a 5 WO 2008/083354 PCT/US2007/089153 pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (1), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof. In another aspect, this invention provides assays to determine a compound of the 5 invention effectiveness in inhibiting Axi activity in a cell-based assay. DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated: 10 "Amino" refers to the -NH 2 radical. "Carboxy" refers to the -C(O)OH radical. "Cyano" refers to the -CN radical. "Nitro" refers to the -NO 2 radical. "Oxa" refers to the -0- radical. 15 "Oxo" refers to the =0 radical. "Thioxo" refers to the =S radical. "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms, preferably one to eight carbon atoms or one to six carbon atoms, and 20 which is attached to the rest of the molecule by a single bond, for example, methyl, ethyl, n-propyl, 1i-methylethy (iso-propyl), n-butyl, n-pentyl, 1,1-dirnethylethyl (t-butyl), 3-methylhexyl, 2-methylhexy, and the like. Unless stated otherwise specifically in the specification, an alkyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR 20 , 25 -OC(O)-R , -N(R" 0

)

2 , -C(O)R , -C(O)OR , -C(O)N(R 2

)

2 , -N(R 0 )C(O)OR

-N(R

20

)C(O)R

20 , -N(R 2 ,)S(O)R 20 (where t is 1 or 2), -S(O).OR 20 (where t is 1 or 2),

-S(O),R

20 (where p is 0, 1 or 2), and -S(O)N(R) 2 (where t is 1 or 2) where each R 20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl. 30 "Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, for example, ethenyl, prop-1-enyl, 6 WO 2008/083354 PCT/US2007/089153 but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR 20

-OC(O)-R

2 0 , -N(R ) 2 , -C(O)RO, -C(O)OR , -C(O)N(R) 2 , -N(R 20 )C(O)OR, 5 -N(R 2 )C(O)R", -N(R 2 0)S(O)tR 2 0 (where t is I or 2), -S(O)tOR 20 (where t is 1 or 2), -S(O)R 20 (where p is 0, 1 or 2), and -S(O)N(R 20

)

2 (where t is I or 2) where each R 20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl. "Alkynyl" refers to a straight or branched hydrocarbon chain radical consisting 10 solely of carbon and hydrogen atoms, containing at least one triple bond, optionally containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentyny, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl radical may be optionally 15 substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR"', -OC(O)-R 2, -N(R20) 2 , -C(O)R 2 , -C(O)OR, 20 -C(O)N(R 2

)

2

-N(R

2 0)C(O)OR2 0 , -N(R 20

)C(O)R

20 , -N(Rm' 0

)S(O)R

20 (where t is I or 2), -S(O) OR 2 (where t is 1 or 2), -S(O),R 2 (where p is 0, 1 or 2), and -S(O) 1 N(R ) 2 (where t is 1 or 2) where each R 2 0 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, 20 aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl. "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like. The 25 alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon in the alkylene chain or through any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted by one or 30 more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR 0 , -OC(O)-R 20 , -N(R) 2 , -C(O)R

-C(O)R

20 , -C(O)N(RW) 2 , -N(R 20

)C(O)OR,

20

-N(R

20

)C(O)R

20 , -N(R 2

,)S(O),R

20 (where t is 1 or 2), -S(O)tOR 20 (where t is 1 or 2), -S(O),R 20 (where p is 0, 1 or 2), and -S(O)iN(R 2 0 )q (where t is 1 or 2) where each R 20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, 35 cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalky. 7 WO 2008/083354 PCT/US2007/089153 "Alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one double bond and having from two to twelve carbon atoms, for example, ethenylene, propenylene, n-butenylene, and the like. The 5 alkenylene chain is attached to the rest of the molecule through a double bond or a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain may be optionally substituted by one 10 or more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR 2 0 , -OC(O)-R", -N(R 0

)

2 , -C(O)R,

-C(O)OR

20 , -C(O)N(R2)2, -N(R )C(O)OR 2 , -N(R 20

)C(O)R

20 , -N(R 2 )S(O)tR 2 3 (where t is 1 or 2), -S(O)tOR 2 0 (where t is 1 or 2), -S(O),R 20 (where p is 0, 1 or 2), and -S(O)tN(R0) 2 (where t is I or 2) where each R 20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, 15 cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl. "Alkynylene" or "alkynylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one triple bond and having from two to twelve carbon atoms, for example, propynylene, n-butynylene, and the like. The alkynylene 20 chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain may be optionally substituted by one or more of the 25 following substituents: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR 20 , -OC(O)-R" 0 , -N(R 2 ) 2 ,

-C(O)R

0 , -C(O)OR, 20

-C(O)N(R

20

)

2 , -N(R 2 )C(O)OR"', -N(R 2 0)C(O)R", -N(R 2 0 )S(O)tR 0 (where t is 1 or 2), -S(O)tOR 20 (where t is 1 or 2), -S(O)R 20 (where p is 0, 1 or 2), and -S(O)tN(R 2 )2 (where t is 1 or 2) where each R 0 is independently hydrogen, alkyl, 30 haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyylalkyl, heteroaryl or heteroarylalkyl. "Alkoxy" refers to a radical of the formula -OR, where R, is an alkyl radical as defined above containing one to twelve carbon atoms. The alkyl part of the alkoxy radical may be optionally substituted as defined above for an alkyl radical, 35 "Alkoxyalkyl" refers to a radical of the formula -Rb-O-R, where R, is an alkyl 8 WO 2008/083354 PCT/US2007/089153 radical as defined above and Rb is an alkylene chain as defined above. The oxygen atom may be bonded to any carbon in the alkyl radical or the alkylene chain. The alkyl part of the alkoxyalkyl radical may be optionally substituted as defined above for an alkyl radical and the alkylene chain part of the alkoxyalkyl radical may be optionally 5 substituted as defined above for an alkylene chain. "Aryl" refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 14 carbon atoms and at least one aromatic ring. For purposes of this invention, the ary! radical may be a monocyclic, bicyclic, or tricyclic ring system, which may included spiro ring systems. An ary radical is commonly, but not necessarily, attached to the parent 10 molecule via an aromatic ring of the aryl radical. For purposes of this invention, an "aryl" radical as defined herein can not contain rings having more than 7 members and cannot contain rings wherein two non-adjacent members thereof are connected by a direct bond or through an atom or a group of atoms (i.e., a bridged ring system). Aryl radicals include, but are not limited to, aryl radicals derived from acenaphthylene, anthracene, 15 azulene, benzene, 6,7,8,9-tetrahydro-5H-benzo[7]annuiene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, and phenanthrene. Unless stated otherwise specifically in the specification, the term "optionally substituted aryl" is meant to include aryl radicals optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, 20 haloalkynyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally 25 substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R -OR , -R %OC(O)-R', -RiN(R ) 2 , -R -C(O)R , -R -C(O)OR",

-R

21 -C(O)N(R2 0

)

2 , -R 2 1 O-R 22 C(O)N(R21) 2 , -R 21 -N(R 2

)C(O)OR

2 0 . -R 2 1-N(R) 20 C(O)R 2 , -R 21

N(R

20 )S(O)R 20 (where t is 1 or 2), -R 2 1 -S(O)jOR 20 (where t is 1 or 2), -R 21

-S(O),R

20 30 (where p is 0, 1 or 2), and -R 21 -S(O)tN(R 20

)

2 (where t is 1 or 2), where each R 20 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted 35 heteroarylalkyl, or two R 20 's, together with the common nitrogen to which they are both 9 WO 2008/083354 PCT/US2007/089153 attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl, each R 21 is independently a direct bond or a straight or branched alkylene or alkenylene chain, and R 22 is a straight or branched alkylene or alkenylene chain. 5 "Aralkyl" refers to a radical of the formula -Rb-Re where R! is an alkylene chain as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. The alkylene chain part of the aralkyl radical may be optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical may be optionally substituted as described above for an aryl. 10 "Aralkenyl" refers to a radical of the formula -Rd-R, where Rd is an alkenylene chain as defined above and R, is one or more aryl radicals as defined above. The aryl part of the aralkenyl radical may be optionally substituted as described above for an aryl. The alkenylene chain part of the aralkenyl radical may be optionally substituted as defined above for an alkenylene group. 15 "Aralkynyl" refers to a radical of the formula -RR, where Re is an alkynylene chain as defined above and Re is one or more aryl radicals as defined above. The aryl part of the aralkynyl radical may be optionally substituted as described above for an aryl. The alkynylene chain part of the aralkynyl radical may be optionally substituted as defined above for an alkynylene chain. 20 "Aryloxy" refers to a radical of the formula -OR, where R, is an aryl as defined above. The aryl part of the aryloxy radical may be optionally substituted as defined above. "Aralkyloxy" refers to a radical of the formula -ORf where Rf is an aralkyl radical as defined above. The aralkyl part of the aralkyloxy radical may be optionally substituted 25 as defined above. "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, more preferably from five to seven carbons and which is 30 saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, C10 radicals such as adamantanyl and decalinyl, and C7 radicals such as norbornanyl, norbornenyl, as well as substituted polycyclic radicals for example substituted C7 radicals such as 35 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in 10 WO 2008/083354 PCT/US2007/089153 the specification, the term "optionally substituted cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, 5 optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted 10 heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 2

'-OR

20 . -R 21

-OC(O)-R

20 , -R 21

-N(R

20

)

2 ,

-R-C(O)R

2 0, -R-C(O)OR 20 , -R 1

-C(O)N(R

2

)

2 , -R 21

-N(R

20

)C(O)OR

2 ,

-R

21

-N(R

20

)C(O)R

2 0 , -R'l-N(R 2 0)S(O)-R 2 0 (where t is 1 or 2), -R 2 1 -S(O)iOR 20 (where t is 1 or 2), -RS 21 -(O)pR 2 0 (where p is 0, 1 or 2), and -R 2 1 -S(O)tN(R2 0 )2 (where t is 1 or 2), 15 where each R 20 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 20 's, together with the common nitrogen to 20 which they are both attached, may optionally form an optionally substituted N heterocyclyl or an optionally substituted N-heteroaryl, and each R 21 is independently a direct bond or a straight or branched alkylene or alkenylene chain. "Cycloalkylalkyl" refers to a radical of the formula -RbR. where Rb is an alkylene chain as defined above and RI is a cycloalkyl radical as defined above. The alkylene 25 chain and the cycloalkyl radical may be optionally substituted as defined above. "Cycloalkylalkenyl" refers to a radical of the formula -RdRg where Rd is an alkenylene chain as defined above and R9 is a cycloalkyl radical as defined above. The alkenylene chain and the cycloalkyl radical may be optionally substituted as defined above. 30 "Cycloalkylalkynyl" refers to a radical of the formula -ReRg where Re is an alkynylene radical as defined above and Rg is a cycloalkyl radical as defined above. The alkynylene chain and the cycloalkyl radical may be optionally substituted as defined above. "Halo" refers to bromo, chloro, fluoro or iodo. 35 "Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one 11 WO 2008/083354 PCT/US2007/089153 or more halo radicals, as defined above, for example, trifluoromethyl, difluoromethyl, trichloromethy, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like. The alkyl part of the haloalkyl radical may be optionally substituted as defined above for an alkyl radical. 5 "Haloalkoxy" refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above, for example, trifluoromethoxy, difluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, and the like. The alkoxy part of the haloalkoxy radical may be optionally substituted as defined above for an alkoxy radical. 10 "Haloalkenyl" refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above. The aikenyl part of the haloalkyl radical may be optionally substituted as defined above for an alkenyl radical. "Haloalkynyl" refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above. The alkynyl part of the haloalkyl radical 15 may be optionally substituted as defined above for an alkynyl radical. "Heterocyclyl" refers to a stable 3- to 18-membered non-aromatic ring radical which comprises one to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, 20 tricyclic or tetracyclic ring system, which may include spiro, fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, 1,4-diazepanyl, decahydroisoquinolyl, 25 imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, octahydro-1H-pyrrolo[3,2-cpyridinyl, octahydro-1H-pyrrolo[2,3 c]pyridinyl, octahydro-1H-pyrrolo[2,3.-b~pyridinyl, octahydro-1H--pyrrolo[3,4-b]pyrid inyl, octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-.pyrido(1,2-a]pyrazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, 30 pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, thienyl[1,3]dithianyl, trithianyl, tetrahydropyranyl, thiomorpholiny, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, azetidinyl, octahydropyrrolo[3,4-c]pyrrolyl, octahyd ropyrrolo[3,4-b]pyrrolyl, decahydroprazino[1,2-a]azepinyl, azepanyl, azabicyclo[3.2.1]octyl, and 2,7-diazaspiro[4.4]nonanyl. Unless stated otherwise 35 specifically in the specification, the term " optionally substituted heterocyclyl" is meant to 12 WO 2008/083354 PCT/US2007/089153 include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted 5 aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, 10 optionally substituted heteroarylalkynyl, -R 21 -OR, -RO 2 1

-C(O)-R

2 0 , -R 2 1

-N(R

2

)

2 , -R -C(O)R 2 , -R C(O)OR 20 , -R -C(O)N(R 20

)

2 , -R -N(R 20

)C(O)OR

20 , -R 2 1N(R20)C(O)R20, -R 2

N(R

2

))S(O)R

2 0 (where t is 1 or 2), -R 2 S(O)tOR2O (where t is 1 or 2), -R 2 1 _S(O)pR 20 (where p is 0, 1 or 2), and -R2 1 -S(O)iN(R 2 )2 (where t is I or 2), where each R 2 0 is independently selected from the group consisting of hydrogen, alkyl, 15 haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R20's. together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N 20 heterocyclyl or an optionally substituted N-heteroaryl, and each R 2 1 is independently a direct bond or a straight or branched alkylene or alkenylene chain. "N-heterocyclyl" refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. An 25 N-heterocyclyl radical may be optionally substituted as described above for heterocyclyl radicals. "Heterocyclylalkyl" refers to a radical of the formula -RbRh where Rb is an alkylene chain as defined above and Rt, is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to 30 the alkyl radical at the nitrogen atom. The alkylene chain of the heterocyclylalkyl radical may be optionally substituted as defined above for an alkyene chain. The heterocyclyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for a heterocyclyl radical. "Heterocyclylalkenyl" refers to a radical of the formula -RdRh where Rj is an 35 alkenylene chain as defined above and Rh is a heterocyclyl radical as defined above, and 13 WO 2008/083354 PCT/US2007/089153 if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkenylene chain at the nitrogen atom. The alkenylene chain of the heterocyclylalkenyl radical may be optionally substituted as defined above for an alkenylene chain. The heterocyclyl part of the heterocyclylalkenyl radical may be 5 optionally substituted as defined above for a heterocycly radical. "Heterocyclylalkynyl" refers to a radical of the formula -R.R , where Re is an alkynylene chain as defined above and Rh is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkynyl radical at the nitrogen atom. The alkynylene chain part of the 10 heterocyclylalkynyl radical may be optionally substituted as defined above for an alkynylene chain. The heterocyclyl part of the heterocyclylaikynyl radical may be optionally substituted as defined above for a heterocyclyl radical. "Heteroaryl" refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the 15 group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. A heteroaryl radical is commonly, but not necessarily, attached to the parent molecule via an aromatic ring of the heteroaryl radical. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be 20 optionally oxidized; the nitrogen atom may be optionally quaternized. For purposes of this invention, the aromatic ring of the heteroaryl radical need not contain a heteroatom, as long as one ring of the heteroaryl radical contains a heteroatom. For example, 1,2,3,4-tetrahydroisoquinolin-7-y is considered a "heteroaryl" for the purposes of this invention. For purposes of this invention, a "heteroaryl" radical as defined herein can not 25 contain rings having more than 7 members or rings wherein two non-adjacent members thereof are connected by a direct bond or through an atom or a group of atoms ([ e., a bridged ring system), Examples of heteroaryl radicals include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindoly, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyi, benzothiazolyl, benzothiadiazolyl, benzo[b[1,4jdioxepinyl, 30 benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiopheny), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyciopenta[4,5]thieno[2,3-d]pyrimidinyl, 35 5,6-dihydrobenzo[i]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 14 WO 2008/083354 PCT/US2007/089153 T,8'-dihydro-5'H-spiro[[1 3]dioxolane-2,6'-quinoline]-3'-yl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5 naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, phenanthridinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3, 4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d~pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, 10 quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 2,3,4,5-tetrahydrobenzo[b]oxepinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridinyl, 6,7,8,9-tetrahydro-5H-pyrido[3,2-c]azepinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 15 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, 1,2,3,4-tetrahydroisoquinolin-7-y, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-cpyridinyl, thieno[3,2-d]pyridazinyl and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, the term " 20 optionally substituted heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, 25 optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted 30 heteroarylalkynyl, -R -OR20, -R 21

-OC(O)-R

20 , -R 21

-N(R

2 0

)

2 , -R 2 1

-C(O)R

20 , -R2.-C(O)OR 2 1, -R -C(O)N(R 20

)

2 , -R -N(R 2

)C(O)OR

20 , -R"-N(R )C(O)R 2 , -R 2 1

-N(R

2 ')S(0)tR 2 (where t is 1 or 2), -R 21 -S(O)tOR 2 0 (where t is 1 or 2), -R21S(O)pR 20 (where p is 0, 1 or 2), and

-R

2 1 -S(O)tN(R 2 0

)

2 (where t is I or 2), where each R 2 0 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally 35 substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, 15 WO 2008/083354 PCT/US2007/089153 optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 20 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl, and each 5 R 2 1 is independently a direct bond or a straight or branched alkylene or alkenylene chain. "N-heteroaryl" refers to a heteroary radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. An N-heteroaryl radical may be optionally substituted as described above for heteroaryl radicals. 10 "Heteroarylalkyl" refers to a radical of the formula -RbR, where Rb is an alkylene chain as defined above and R, is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkyl radical may be optionally substituted as defined above for a heteroaryl. The alkylene chain part of the heteroarylalkyl radical may be optionally substituted as defined above for an alkylene chain. 15 "Heteroarylalkenyl" refers to a radical of the formula -RdRi where Rd is an alkenylene chain as defined above and R; is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkenyl radical may be optionally substituted as defined above for a heteroaryl. The alkenylene chain part of the heteroarylalkenyl radical may be optionally substituted as defined above for an aikenylene chain. 20 "Heteroarylalkynyl" refers to a radical of the formula -RRi where R, is an alkynylene chain as defined above and RI is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkynyl radical may be optionally substituted as defined above for a heteroaryl. The alkynylene chain part of the heteroarylalkynyl radical may be optionally substituted as defined above for an alkynylene chain. 25 "Hydroxyalkyl" refers to an alkyl radical as defined above which is substituted by one or more hydroxy radicals (-OH). "Hydroxyalkenyl" refers to an alkenyl radical as defined above which is substituted by one or more hydroxy radicals (-OH). "Hydroxyalkenyl" refers to an alkynyl radical as defined above which is 30 substituted by one or more hydroxy radicals (-OH). Certain chemical groups named herein may be preceded by a shorthand notation indicating the total number of carbon atoms that are to be found in the indicated chemical group. For example; C 7

C

12 alkyl describes an alkyl group, as defined below, having a total of 7 to 12 carbon atoms, and C 4

-C

2 cycloalkylalkyl describes a cycloalkylalkyl group, 35 as defined below, having a total of 4 to 12 carbon atoms. The total number of carbons in 16 WO 2008/083354 PCT/US2007/089153 the shorthand notation does not include carbons that may exist in substituents of the group described. "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction 5 mixture, and formulation into an efficacious therapeutic agent. "Mammal" includes humans and domestic animals, such as cats, dogs, swine, cattle, sheep, goats, horses, rabbits, and the like. Preferably, for purposes of this invention, the mammal is a human. "Optional" or "optionally" means that the subsequently described event or 10 circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted ary!" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution. When a functional group is described as "optionally substituted," and in 15 turn, substitutents on the functional group are also "optionally substituted" and so on, for the purposes of this invention, such iterations are limited to five, preferably such iterations are limited to two. "Pharmaceutically acceptable excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor 20 enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals, "Pharmaceutically acceptable salt" includes both acid and base addition salts. 25 "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic 30 acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfonic acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2 hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, 35 glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo 17 WO 2008/083354 PCT/US2007/089153 glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2 sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, erotic acid, oxalic 5 acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like. "Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or 10 otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from 15 organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanoi, 2-diethylaminoethanol, dicyclohexylamine, 20 lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline 25 and caffeine. A "pharmaceutical composition" refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, for example, humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor. 30 "Therapeutically effective amount" refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of a disease or condition of interest in the mammal, preferably a human. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease or 35 condition and its severity, and the age of the mammal to be treated, but can be 18 WO 2008/083354 PCT/US2007/089153 determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure. "Treating" or "treatment" as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of 5 interest, and includes: (i) preventing the disease or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it; (ii) inhibiting the disease or condition, i.e., arresting its development; 10 (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or (iv) stabilizing the disease or condition, As used herein, the terms "disease" and "condition" may be used interchangeably or may be different in that the particular malady or condition may not have a known 15 causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians. The compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centres and may thus give rise to enantiomers, 20 diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional 25 techniques, such as HPLC using a chiral column. When the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. A "stereoisomer" refers to a compound made up of the same atoms bonded by 30 the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another. A "tautomer" refers to a proton shift from one atom of a molecule to another atom 35 of the same molecule. The present invention includes tautomers of any said compounds. 19 WO 2008/083354 PCT/US2007/089153 "Atropisomers" are stereoisomers resulting from hindered rotation about single bonds where the barrier to rotation is high enough to allow for the isolation of the conformers (Eliel, E. L; Wilen, S. H. Stereochemistry of Organic Compounds; Wiley & Sons: New York, 1994; Chapter 14). Atropisomerism is significant because it introduces 5 an element of chirality in the absence of stereogenic atoms. The invention is meant to encompass atropisomers, for example in cases of limited rotation around the single bonds emanating from the core triazole structure, atropisomers are also possible and are also specifically included in the compounds and/or prodrugs of the invention. The chemical naming protocol and structure diagrams used herein are a modified 10 form of the I.U.P.A.C. nomenclature system wherein the compounds of the invention are named herein as derivatives of the central core structure, i.e., the triazole structure. For complex chemical names employed herein, a substituent group is named before the group to which it attaches. For example, cyclopropylethyl comprises an ethyl backbone with cyclopropyl substituent. In chemical structure diagrams, all bonds are identified, 15 except for some carbon atoms, which are assumed to be bonded to sufficient hydrogen atoms to complete the valency. For purposes of this invention, the depiction of the bond attaching the R 3 substituent to the parent triazole moiety in formula (1), as shown below:

R

3 N N N R1 R5 20 is intended to include only the two regioisomers shown below (compounds of formula (1a) and (Ib)): R3 R3 N-N N-N RI R and N N R5 N N / N N R4 R4 R 4 (la) (Ib) The numbering system of the ring atoms in compounds of formula (la) is shown below: 20 WO 2008/083354 PCT/US2007/089153 2 1 /R3 N--N R 3/ 5 R5 N N (1a) R1 4 R4 44 For example, a compound of formula (la) wherein R 1 , R 4 and R 5 are each hydrogen, R2 is 2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl and R 3 is isoquinolin-1-yl; ie a compound of formula (la) having the following formula: N O N \-\ I N-N 5 N N 2 is named herein as 1-(isoquinolin-1-yl)-N-(2-(pyrrolidin-1-ylmethyi)benzo[d]oxazol-5-yl) 1-1,2,4-triazole-3,5-diamine. The numbering system of the ring atoms in compounds of formula (Ib) is shown below: R 1 2 N-N R, 5 \3 R-5 N N N N b 10 R For example, a compound of formula (Ib) wherein R', R 4 and R6 are each hydrogen, R 2 is 2-(pyrrolidin-1-ylmethyl)benzod]oxazol-5-yl and R 3 is isoquinolin-1-yl, i.e., a compound of formula (Ib) having the following formula: -N N 4 I N-N N I ' H N 15 is named herein as 1-(isoquinolin-1-yl)-N 0 -(2-(pyrrolidin-1-ylmethyl)benzofdoxazol-5-y) 1 H-1,2,4-triazole-3,5-diamine. 21 WO 2008/083354 PCT/UJS2007/089153 EMBODIMENTS OF THE INVENTION Of the various aspects of the invention, as set forth above in the Summary of the Invention, certain embodiments are preferred. Accordingly, one embodiment is wherein the compound of formula (1) is a 5 compound of formula (la): R3 N-N R N R5 I N wherein:

R

1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R', -C(O)N(R4)R7, and -C(=NR6)N(R')R'; 10 R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted 15 heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR3, -R 9

-O-R

10 -OR,

-R

9

-O-R

1 0

-O-R

1 0 -OR, -R9-O-R'-CN, -R'-O-R -C(O)OR,

-R

9 -O-R'G-C(O)N(R6)R7, -R9-O-R 1 0

-S(O),R

8 (where p is 0, 1 or 2), -R'-O-R' -N(R')R', -R9-O-R' -C(NR")N(R")H, -R9-OC(O)-R', -R"-C(O)R',

-R

9

-C(O)OR

8 , -R 9 -C(O)N(R)R , ~R 9

-C(O)-R

0

-N(R

6 )R , ~R 9

-N(R

6 )R , 20 -R 9 -N(R6)-R 10 -N(R3)R 7 , -R-N(R)C(O)ORa, -R9-N(R')C(O)-R'O-N(R)R',

-R

9

-N(R

6 )C(O)R, -RS-N(R6)S(O)tR 8 (where t is 1 or 2), -R9-S(O)tOR 8 (where t is 1 or 2), -R9-S(O)PR3 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6

)R

7 (where t is 1 or 2);

R

3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more 25 substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted 30 cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted 22 WO 2008/083354 PCT/US2007/089153 heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkyny, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R' 3 -OR , -R 1 3-OC(O)-R", -R -O-R"-N(R)2 -R'-N(R) 2 , 5 -R-C(O)R 2 , -R 1 -C(O)OR 2, -R"-C(O)N(R 2

)

2 , -R 1

-C(O)N(R

2

)-R

14

-N(R

12

)R

13 , -R'3C(O)N(R")-R' OR' -R'3N(R )C(O)OR , -R"-N(R )(OR

-R

13

-N(R

12 )S(O)R 12 (where t is 1 or 2), -R 13 -S(O)jOR 1 2 (where t is 1 or 2), -R 13 S(O),R (where p is 0, 1 or 2), and -R 13 -S(O) N(R 12

)

2 (where t is I or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, 10 alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally 15 substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R' 0

-OR

8 , -R'KCN, -R"-NO 2 , -R 1

-N(R

8

)

2 , -Rl 0 -C(O)OR" and -R 10

-C(O)N(R

8

)

2 , or any R 6 and R , together with the common 20 nitrogen to which they are both attached, form an optionally substituted N heteroaryl or an optionally substituted N-heterocyclyl; each R3 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted 25 aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylaikenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted 30 heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R 9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted 35 straight or branched alkynylene chain; 23 WO 2008/083354 PCT/US2007/089153 each R 1 0 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; 5 each R" is hydrogen, alkyl, cyano, nitro or -OR 8 ; each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 10 heteroaryl and optionally substituted heteroarylalkyl, or two R2", together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 1 3 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally 15 substituted straight or branched alkenylene chain; and each R 1 4 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain. Another embodiment of a compound of formula (la), as set forth above, is the 20 compound of formula (la) wherein: R', R 4 and R5 are each independently selected from the group consisting of hydrogen,

-C(O)N(R)R

7 , and -C(=NR')N(R)R ;

R

2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally 25 substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylaikyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R-OR, -R 9

-O-R

1 '-OR', -R-O-R'"-O-R 0 -OR8, -R 9 -O-R'1-CN, -R'-O-R"-C(O)OR, 30 -R'-O-RI"-C(O)N(R6)R 7 , -R9-O-R'"-S(O)pR 8 (where p is 0, 1 or 2), -Rc-O--R'O-N(R-)R 7, -R9-0-R OC(NR")N(R")H, -R*-OC(O)-R3', -R*-C(O)R", -R'-C(O)OR, -R 9 -C(O)N(R)R, -R 9 -C(O)-RiQ-N(R6)R , -R 9 -N(R)R ,

-R'-N(R)-R'O-N(R

6 )R, -R'-N(R)C(O)OR3, -R9-N(R6)C(O)-R'-N(Re)R, -RL.N(R)C(O)R', -R 9

-N(R)S(O),R

8 (where t is 1 or 2), -R?-S(O)OR (where t is 1 35 or 2), -R9-S(O)pR 8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(RO)R (where t is 1 or 2); 24 WO 2008/083354 PCT/US2007/089153

R

3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted 5 aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 3 'OR, -R 13

-OC(O)-R

12 , -R 3 -O-R'4-N(R 12

)

2 , -RN(2 -RC()R -R1-3C(O)OR12 -R"-C(O)N(R12)2, 10 -R 3 -C(O)N(R )-R -N(R )R 3 , -R 1 3 -C(O)N(R )-R -OR'?, -R 13

-N(R

1 )C(O)OR',

-R

1 3

-N(R

12

)C(O)R'

2 , -RQN(R 12 )S(O)R 12 (where t is 1 or 2), -R 13

-S(O).OR

1 2 (where t is 1 or 2), -R 1 3 -S(O)pR" (where p is 0, 1 or 2), and -Ri-S(O)tN(R 2

)

2 (where t is 1 or 2); each Rd and R 7 is independently selected from the group consisting of hydrogen, alkyl, 15 haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclyalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1

~OR

8 . -R 10 -CN,

-R

1 0

-NO

2 , -R"-N(R) 2 , -R 10 -C(O)OR3 and -R 10 -C(O)N(R3) 2 , or any Rd and RT, 20 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 25 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylialkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R") is independently an optionally substituted straight or branched alkylene chain; 30 each R" is hydrogen, alkyl, cyano, nitro or -OR; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 35 heteroaryl and optionally substituted heteroarylalkyl, or two R 2 , together with the 25 WO 2008/083354 PCT/US2007/089153 common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and 5 each R 14 is independently an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula ([a), as set forth above, is the compound of formula (la) wherein:

R

1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen,

-C(O)N(R

6

)R

7 , and -C(=NR)N(R)R 7 ; 10 R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 4,5-dihydro-1 H-benzo[b]azepin--2(3H)-onyl, 6,7,.8,9-tetrahydro-5H-pyrido[3,2-d]azepinyi, 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 5,6.7,8-tetrahydroquinolinyl, IH-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 15 7',8-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, and 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted 20 cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylaikyl, optionally substituted heteroarylalkenyl, -R9-OR 8 , -R4-O-R 1 -OR', -R9-O-REO-R'~OR', -R9-O-R'O-CN,

-R

9 -O-Rlo-C(O)ORs, -R-O--R 1

C(O)N(R

6

)R

7 , -R 9

-O-R'O-S(O),R

8 (where p is 0, 1 25 or 2), -R"-O-R' 0

-N(R

6 )R7, -R9-O-R 0

-C(NR")N(R

1 )H, -R 9 -OC(O)-R', -R"-C(O)R 8 , -Rg-C(O)OR', -R 9

-C(O)N(R

6 )R', -R 9 -C(O)-RlKN(R6)R7, -R'-N(R 6 )R7, -R"-N(R6)-R ON(R')R ~, R9-N(R6)C(O)ORS, -R"-N(R')C(0)-Rl"N(R6)R7, -Ra-N(RS)C(O)R 8 , -R 9

-N(R

6 )S(O)tR8 (where t is I or 2), -R'-S(O)tQR (where t is I or 2), -R 9

-S(O),R

8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(Rc)R7 (where t is 1 or 2); 30 R 3 is aryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 35 heteroaryl, optionally substituted heteroarylalkyl, -R 1 OR , -R 1 3-OC(O)-R", 26 WO 2008/083354 PCT/US2007/089153 -R -O-R -N(R )2, -R -N(R )2, -R'3C(OD)R , -R"-C(O)OR, -RCON(22 -R"-C(O)N(R )-R'-N(R 1 2

)R'

3 , -R"-C(O)N(R )-R _OR 12 , -R 13

-N(R

1 )C(O)OR 2,

-R

1

--N(R

1 2

)C(O)R

12 , -R' 3

-N(R

12 )S(O)R 12 (where t is 1 or 2), -R 3 _S(O)tOR1 2 (where t is 1 or 2), -R'-S(O),R 2 (where p is 0, 1 or 2), and -R 13

-S(O),N(R

2

)

2 5 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted araikyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally 10 substituted heteroaryl, optionally substituted heteroarylalkyl, -R"oOR8, ~R 1 '-CN,

-R

10

-NO

2 , -R 1

Q-N(R

8 )2, -R 10 -C(O)OR and -R 10 -.C(O)N(R3) 2 , or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, 15 haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an 20 optionally substituted straight or branched alkylene chain; each R' 0 is independently an optionally substituted straight or branched alkylene chain; each R' 1 is hydrogen, alkyl, cyano, nitro or -OR 8 ; each R2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, 25 optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 12 , together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; 30 each R 1 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R 1 4 is independently an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein: 35 R', R 4 and R5 are each hydrogen; 27 WO 2008/083354 PCT/US2007/089153

R

2 is 2,3-dihydrobenzo[b][1,4]dioxinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, -R 9 -OR, -R'-OC(O)-.R", .- R-C(O)R 8 , -R 9 -C(O)OR', -R 9 -C(O)N(R)R -R"-N(RS)R 7 ,

-R'-N(R)C(O)OR

8 , -R 9 -N(R)C(O)R8, -R9-N(RG)S(O),R 8 (where t is 1 or 2), 5 -R 9 -S(O)OR' (where t is 1 or 2), -R9-S(O)pR 8 (where p is 0, 1 or 2), and

-R'-S(O).N(R

6

)R

7 (where t is 1 or 2);

R

3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, 10 optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 -OR, -Rl 3 -OC(O)-R , -R"-N(R ) 2 , -R' 3 -C(O)R,

-R"

3 -C(O)OR , -R 1 -C(O)N(R')2, -R -N(R )C(O)OR", -R 1 '-N(R"')C(O)RC,

-R"

3 -N(R )S(O)tR 2 (where t is I or 2), -R 1 3-S(O)tOR 12 (where t is 1 or 2), 15 -R 3 -S(O)R 12 (where p is 0, 1 or 2), and -R- 13 S(O)tN(R 12

)

2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally 20 substituted heteroaryl, optionally substituted heteroarylalkyl, -R'O-OR, -R 1 0 -CN, -R 0

-NO

2 , -R 1

"-N(R')

2 , -R' 1 -C(0)OR' and -R' -C(O)N(R) 2 , or any Ra and R', together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, 25 haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalky, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R" is independently selected from the group consisting of a direct bond and an 30 optionally substituted straight or branched alkylene chain; each R'" is independently an optionally substituted straight or branched alkylene chain; each R 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted 35 heterocycyl, optionally substituted heterocyclylalkyl, optionally substituted 28 WO 2008/083354 PCT/US2007/089153 heteroaryl and optionally substituted heteroarylalkyl, or two R 1 , together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 1 9 is independently selected from the group consisting of a direct bond and an 5 optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) which is N 3 -(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1 -phenyl-1 H 1,2,4-triazole-3,5-dianine. Another embodiment of a compound of formula (la), as set forth above, is the 10 compound of formula (la) wherein:

R

1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R, and -C(=NR6)N(R 6 )R;

R

2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 15 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyr'ido[3,2-d]azepinyl, 5,6,7,8-tetrahydro-1,6-naphthtyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 7',8'-dihydro-5'H-spiro[[l ,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno(2,1-b]pyridinyl, and 20 6,7,8,9-tetrahydro-5H-cyclohepa[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted 25 heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R'-ORa, -R 9 -O-RQ-OR, -R 9

-O-R

1

O-R'

3

-OR

8 , -R 9 -0-RO-CN, -RB-O~R-C(O)OR", -RCOQ-RkC(O)N(R7)R, -R~O--R'S(O)pR' (where p is 0, 1 or 2), -R 9 -O-Rl 0 -N(RO)R', -R"-O-R-C(NR )N(R 1 1 )H, -R 9 -OC(O)-R8, -R 9 -C(O)R', -RW-C(O)OR", -R'-C(O)N(R6)R', -R9-C(O)-R"-N(R )R 7, -R9-N(R")R , 30 -R-N(R 6

)-RR-N(R

6

)R

7

-R'-N(R

6 )C(O)OR8, -R 9

-N(R

6

)C(O)-R"

0

-N(R

6

)R

7 , -R9-N(R 6 )C(O)R', -R9-N(R 6 )S(O)tR8 (where t is 1 or 2), -R-S(O)tOR8 (where t is 1 or 2), -R 9 -S(O),R8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6

)R

7 (where t is 1 or 2);

R

3 is heteroaryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, 35 nitro, optionally substituted aryl, optionally substituted aralkyl, optionally 29 WO 2008/083354 PCT/US2007/089153 substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R" 3

-OR

2 , -R"-OC(O)-R, -R"3-O-R 14-N(R"12)2, -R 13-N(R 12)2, -R"3-C(O)RI2 -R' -C(O)OR 1 2 -R"-C(O)N(Ri )2., 5 -R 13 -C(O)N(R )-R -N(R")R 13 , -R 13 -C(O)N(R )-R'-OR -R%-N(R 1 )C(O)OR

-R

13

-N(R

2

)C(O)R

12 , -R' 3 -N(R 2 )S(O)R 12 (where t is 1 or 2), -R 1 -S(O)tOR 12 (where t is I or 2), -R 3 -S(O)pR 2 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R'1) 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, 10 halcalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R-OR, -R 10 -CN,

-R

1 0

-NO

2 , -R 10 -N(R')2, -RI-C(O)OR and -R"-C(O)N(R 8 )2, or any R 6 and R , 15 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each Ra is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 20 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 0 is independently an optionally substituted straight or branched alkylene chain; 25 each R 1 is hydrogen, alkyl, cyano, nitro or -OR 8 ; each R' 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted 30 heteroaryl and optionally substituted heteroarylalkyl, or two R 12 's, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R" 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched aikylene chain; and 35 each R 1 4 is independently an optionally substituted straight or branched alkylene chain. 30 WO 2008/083354 PCT/US2007/089153 Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein:

R

4 and R' are each independently selected from the group consisting of hydrogen,

-C(O)N(R

6 )R', and -C(=NR 6

)N(R

6 )R'; 5 R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b][1, ]dioxinyi, 4,5-dihydro-1 H-benzo[bjazepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyrido[3,2-d]azepinyl, 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 10 7',8'-dihydro-5'H-spiro[[1 ,3]dioxoiane-2,6'-quinoline-3'-y, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, and 6,7,8,9-tetrahydrocyclohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted 15 cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9

-OR

8 , -R 9 -O-R0"-OR,. -R 9

-O-R

1 -O-R-0R, -R 9

O--R

1 -CN, -R9-O-R" 0 -C(O)OR, -R'-O-R"-C(O)N(R")R', -R-0-R 1 -S(O)pR8 (where p is 0, 1 20 or 2), -R-O-R" 0

-N(R)R

7 , -R*-O-R 10

-C(NR"')N(R'

1 )H, -R 9 -OC(O)-R', -R-C(O)Ra,

-R

9 -C(O)OR', -R 9 -C(O)N(R")R , -R 9

-C(O)--RQ-N(R

6 )R , -R 9

-N(R

6 )R -R-N(R6)-R'-N(R 6

)R

7 , -R 9 -N(R6)C(O)OR", -R9-N(R 6 )C(O)-R" -N(R 6 )R', -R'9-N(R5)C(O)R 8 , -R9-N(R')S(O)tR8 (where t is 1 or 2), -R'-S(O).OR' (where t is 1 or 2), -R"-S(O)pR 8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R)R 7 (where t is 1 or 2); 25 R 3 is selected from the group consisting of pyridinyl, pyrimidinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-d]pyrimidiny, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, 30 optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 z-OR , -Rl-OC(O)-R,

-R'

3 -O-R"-N(R. )2, -R" 3 -N(R ) 2 , -R 13

-C(O)R

1 , -R -C(O)OR", -RI-C(O)N(R ), 35 -R-C(O)N(R )-R1~N(R )R", -RC(O)N(R)-R-OR, -R-N(R3)C(O)OR, 31 WO 2008/083354 PCT/US2007/089153

-R

1 3-N(R")C(O)R", -R 3

-N(R

12 )S(O)iR 12 (where t is 1 or 2), -R 1 S(O)tOR (where t is 1 or 2), -R 13

-S(O),,R

2 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R2)2 (where t is I or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, 5 haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 0

-OR

8 , -R 10 -CN,

-R

13

-NO

2 , -RE-N(R) 2 , -R 10 -C(O)OR8 and -Rl 0 -C(O)N(R3) 2 , or any R 6 and R , 10 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R6 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 15 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each RlU is independently an optionally substituted straight or branched alkylene chain; 20 each R" is hydrogen, alkyl, cyano, nitro or -OR 8 ; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylaikyl, optionally substituted 25 heteroaryl and optionally substituted heteroarylalkyl, or two R , together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocycly! or an optionally substituted N-heteroaryl; each R 1 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and 30 each R 1 4 is independently an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein:

R

1 , R 4 and R 5 are each hydrogen;

R

2 is selected from the group consisting of benzo[b]thiophenyl, 35 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl, 2,3-dihydrobenzo[b][1,4]dioxiny and 32 WO 2008/083354 PCT/US2007/089153 benzoxazolyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 5 heterocyclylaikenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR, -R9-OC(O)-R, -R*-C(O)R', -R 9 -C(O)OR, -R9-C(O)N(R 6

)R

7 , -R*~N(R 6 )R7, -R 9

-N(R

6 )C(O)OR8,

-R*-N(R

6 )C(O)R3, -R 9

-N(R

6 )S(O)tR8 (where t is 1 or 2), -R 9

-S(O)OR

8 (where t is 1 or 2), -R-S(O),R8 (where p is 0. 1 or 2), and -R 9 -S(OtN(R 6 )R7 (where t is 1 or 2); 10 R 3 is selected from the group consisting of isoquinolinyl, quinazolinyl and thieno[3,2 d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 15 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR , -R 13 -OC(O)-R, -RE(R)s-R"C()R, -R13-C(O)OR , -R3-C(O)N(RG~

-R

1 -N(R )C(O)OR, -R 1 -N(R )C(O)R, -R 1

-N(R

2 )S(O)tR" (where t is 1 or 2),

-R'

3 -S(O)ORl (where t is 1 or 2), -R' 3 -S(O)pR 2 (where p is 0, 1 or 2), and 20 -R 1 -S(O)!N(R')2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally 25 substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 E-OR, -R" 0 CN,

-R

1 0 -NO2, -R 10 -N(Ra) 2 , -R 10

-C(O)OR

8 and -R 0 -. C(O)N(R 8

)

2 , or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, 30 haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylialkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an 35 optionally substituted straight or branched alkylene chain; 33 WO 2008/083354 PCT/US2007/089153 each R 10 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylaikyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted 5 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocycyl or an optionally substituted N-heteroaryl; and each R 3 is independently selected from the group consisting of a direct bond and an 10 optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (1a), as set forth above, is the compound of formula (la) which is selected from the group consisting of: 1-(isoquinolin-1-yl)-NC(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-y)-1H-1,2,4-triazole 3,5-diamine; 15 1-(6-chloroquinazolin-4-y)-N-(2-(pyrrolidin-1 -ylmethyi)benzo[djoxazoi-5-yl)-i H-1,2,4 triazole-3,5-diamine;

N

3 -(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1 -(isoquinolin-1 -yl)-1H-1.2,4-triazole-3,5 diamine;

N

3 -(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-I -(6,7-dimethoxyquinazolin-4-yl)-1 H-1,2,4 20 triazole-3,5-diamine; 1-(6,7-d imethoxyquinazoline-4-y)-Ne-(4,5-dihydro-1 H-benzo[b]azepin-2(3H)-on-8-yi)-I H 1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-y)-N-(2-(1-(4-(2-(dimethylamino)ethyl)piperazin-1 yl)oxomethyl)benzo[b]thiophen-5-yl)-1 H-1,2,4-triazole-3,5-diamine; 25 Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein:

R

1 , R 4 and R5 are each hydrogen;

R

2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, 30 optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR', -R 9

-OC(O)-R

8 , -R 9

-C(O)R

8 , -R'-C(O)OR',

-R

9 -C(O)N(R')R, -R-C(O)-R 0

N(R

6 )RI, -R 9

N(R

6

)R

7 , 35 -R 9 -N(R")C(O)OR", -R 9

-N(R')C(O)-R

10

-N(R

6 )R7, -R 9

-N(R

6 )C(O)R, 34 WO 2008/083354 PCT/US2007/089153

-R

9 -N(R')S(O)tR 8 (where t is I or 2), -R9-S(O)tOR (where t is 1 or 2), -R9-S(O)jR 8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R 7 (where t is 1 or 2);

R

3 is selected from the group consisting of pyridinyl and pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of 5 alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R"'-OR, -Rk-OC(O)-R", -R )2-N(R) -R 1 -C(O)R", 10 -R -C(O)OR 12 , -R 13

-C(O)N(R

12

)

2 , -R 13

-N(R

12

)C(O)OR

1 2 , -R 13

-N(R

12

)C(O)R

1 2 ,

-R

13 -N(R1 2 )S(O)tR 1 2 (where t is 1 or 2), -R 1 3 -S(O)tOR1 2 (where t is 1 or 2),

-R

13 -S(O)pR 2 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R1 2

)

2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, 15 optionally substituted cycloalkyl, optionally substituted cycloalkyialkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 u-OR 8 , -R 1 -CN, -R"-N0 2 , -R 10

-N(R

8

)

2 , -R 10 -C(O)OR' and -RloC(O)N(R8) 2 , or any R6 and R , together with the common nitrogen to which they are both attached, form an 20 optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalky, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 25 heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, 30 haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylaikyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R , together with the common nitrogen to which they are both attached, may optionally form an 35 optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and 35 WO 2008/083354 PCT/US2007/089153 each R 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (Ia) selected from the group consisting of: 5 1 -(5-trifluoromethylpyridin-2-yl)-N 3 -(6-(4-cyclopropylmethylpiperazin-1 -yl)pyridin-3-yl)-1 H 1,2,4-triazole-3,5-diamine; and 1-(6-phenylpyrimidine -4-yl)-N 3 (3-methyl-2-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-5-yl) 1 H-1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (1a), as set forth above, is the 10 compound of formula (la) wherein: R", R 4 and R 5 are each independently selected from the group consisting of hydrogen, -C(O)N(R)R', and -C(=NR')N(R)R 7 ;

R

2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, 15 optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9

-OR

8 , -R'-OC(O)-R 8 , -R'-C(O)R', -R'-C(O)OR 8 ,

-R

9 -C(O)N(R')R, -R-C(O)-Rlu-N(R 6 )R , -REN(R 6 )R, -REN(RG)-R 0

N(R

6 )R 20 -R-N(R)C(O)OR", -R 9

-N(R")C(O)-R

0

-N(R)R

7 , -R 9

-N(R

6 )C(O)R,

-R

9 -N(R )S(O)tR8 (where t is 1 or 2), -R 9 -S(O)tOR 8 (where t is 1 or 2), -R 9 -S(O)pR 8 (where p is 0, 1 or 2), and -R9-S(O)tN(R 6 )R7 (where t is 1 or 2);

R

3 is quinazolinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, 25 optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 3 -OR , -R 13 -OC(O)-R, -R"-N(R 12)2 -- R"-C(O)R 1, -R 13C( O)OR 2,-R"-C(O)N(R 12)2, 30 -R 1

N(R

12

)C(O)OR

2 , -R 13

-N(RI

2 )C(O)R 12, -R 1

-N(R

12 )S(O)R 12 (where t is I or 2),

-R

1 -S(O).OR1 2 (where t is 1 or 2), -R 1 -S(O)R 12 (where p is 0, 1 or 2), and

-R

1

-S(O).N(R'

2

)

2 (where t is 1 or 2); each R 6 and R is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, 35 optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally 36 WO 2008/083354 PCT/US2007/089153 substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroary, optionally substituted heteroarylalkyl, -RQo-OR8, ~R 1 -CN. -R'*-N0 2 , -R 10

-N(R)

2 , -R 1 -C(O)OR and -R 10

-C(O)N(RL)

2 , or any R6 and R 7 , together with the common nitrogen to which they are both attached, form an 5 optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 10 heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, 15 haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two RS, together with the common nitrogen to which they are both attached, may optionally form an 20 optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (]a) which is selected from the group consisting of: 25 1-(6,7-dimethoxyquinazoline-4-y)-NP-(6-(4-(bicyclo[2.2. 1]heptan-2-yl)piperazin-1 yl)pyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-AP-(6-(4-(4-methylpiperazi-1 -yl)piperidin-1 -yl)pyridin 3-yl)-1H1--1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-y)-NP 3 -(6-(4-cyclopentyl-1,4-diazepan-1 -yl)pyridin-3-yl) 30 1 H-1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-y)-N(6-(4-pyrrolidin-1 -ylpiperidin-1 -yl)pyridine-3-yl)-1 H 1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyq uinazoline-4-yl)-N3-(6-(4-piperidin-I -ylpiperidin-1 -yl)pyridine-3-yl)-1 H 1,2,4-triazole-3,5-diamine; 37 WO 20081083354 PCT/IJS2007/089153 I -(6,7-di methoxyq uinazolinie-4-yI)-N3-(6-(4-(pyrroIidin-l -ylmethyI)piperidin- I -yI)pyridin-3 yl)-l H-I ,2,4-triazole-3,5-diamine; 1 -(5, 7-d imrethoxyq uinazoine-4-yI)-N 3 -(6-(dietLhylaminoethyimethylamino)pyrld in-3-yI)-1 Hl I ,2,4-triazole-3,5-diaimine; 5 1 -(6, 7-d i methoxyq uiriazolirne-4-yI)-N-(6-(2-diethylaminiomethylpyrrolidin- I -yl)pyrid in-3 yl)-I H-I ,2,4-triazole-3,5-diamine; 1 -(6, 7-dirnethoxyquinazoline-4-y)-N 3 -(6-(4-pyrrolidin-1 -yI)piperidin-l -yi)-5-methylpyridin 3-yi)-l -1,2,4.-triazole-3,5-diamine; I -(6,7-dirnethoxyquinaizoline-4-yI)-N' 3 -(6-(3-diethylamninopyrrolidin-I -yI)pyridin-3-y)-1 H 10 1 ,2,4-triazole-3,5-diarnine; I -(6,7-dirnethoxyquriazoine-4-y)-N'3-(6-(4-(bicyclo[2.2, I]heptLan-2-y)-1 4-diazepan-1 yI)pyridin-3-yl)-I H-i ,2,4-triazole-3,5-diamine: i -(2-methylquinazolin-4-yI)-N 3 -(6-(4-(pyrrolidin- I -yI)piperidin-1 -yI)-5-methylpyridin-3-yI) 1 H-I ,2,4.-iriazole-3,5-diarnine; 15 1 -(6-fluoroquinazolin-4-y)-N 2 -(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yI)-5-methylpyridin-3-yl) 1 H-I ,2,4-triazole-3,5-diamnine; i -(6,7-d imethoxyq uinazoline-4-yI)-N 3 -(6-bromopyrid in-3-yI)-5-(3-(6-brornopyrid in-3-yi)-2 cyanoguanadino)-l H-I ,2,4-triazole-3-amine; 'I -(5,'7-dimethoxyq uinazoline-4-yI)-N 3 -(6-bromopyridin-3-yI)-I, H-I ,2,4-triazole-3, 5 20 diamine; 1 -(6, 7-d im ethoxyq u inazoine-4-yI)-N 3 -(6-(3-(4-(4-m ethyl pi perazi n- 1 -yI)pIperidin-I yi~prcpenyl)pyridin-3-y)-1 H-I 2,4-triazole-3,5-diamine; 1 ,-iehxqinzln--i- -6-31-ieii- -ylpiperidin-1 yi~prcpenyl)pyridin-3-yl)-1 H-i 2,4-triazole-3,5-diamine; 25 I, -(6,7-dimethoxyquinazoline-4-yi)-N 3 -(6-(3-(4-dirnethylami nop:iperidin-l yI)propenyl)pyrdin--3-y)--1 H-I ,2,4-tr-azoe-35-diamine; I -(6,7-dimethoxyquinazoline-4-yi)-N 3 -(6-(3-(3-(diethylamino)pyrrolidin-I yl)propenyI)pyridin-3-y)-1 H-i ,2,4-triazole-3,5-diamine; I -(6,7-dimethoxyquinazoine-4-yi)-N-(6-(3-(3-(dimethylamino)pyrroidin-1 30 yI)propenyl)pyridin-3-y)-1 H-i ,2,4-triazole-3,5-diamine; 1 -(6,7-dimethoxyquingazoline-4-y)-N 2 .-(6-(3-piperidin-i! -ylproper-nyl)pyridin-3-yI)-I H-i ,2,4 triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yI)-N 3 -(6-(3-(4-pyrrolidin-I -yipiperidin-i yl)propenyl)pyridin-3-yl)-1 H-I ,2,4-triazole-3,5-diamine; 35 1--(6,7-dimethoxyq uinazoline-4-yI)-NV-(6-(3-(4-cyclkpentyl.Diperazin-I -yI)propenyl)pyridin 38 WO 2008/083354 PCT/US2007/089153 3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-N(2-(3-(4-isopropylpiperazin-1 -yl)propen-1 yl)pyridine-5-yl)-1H-1,2,4-triazole-3,5-diamine; and 1-(6,7-dimethoxyquinazoline-4-yl)-N-(2-(4-cyclopropylrethyl-3-(S)-methylpiperazin-1 5 yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein: R". R 4 and R 5 are each hydrogen;

R

2 is pyridinyl optionally substituted by one or more substituents selected from the group 10 consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R-OR3, -R9-OC(O)-R8, -R 9 -C(O)R', -R 9 -C(O)OR3, 15 -R 9

-C(O)N(R

6 )R', -R 9

-C(O)-R

0 -N(R)R, -R-N(R')R -R9-N(R')-R O-N(R )R

-R

9 -N(R)C(O)OR' -R 9

-N(R

6

)C(O)-R

0

-N(R

6

)R

7 , -R9-N(R6)C(O)R',

-R

9

-N(R

5

)S(O),R

8 (where t is 1 or 2), -R--S(O)tOR" (where t is 1 or 2), -R-S(O),RS (where p is 0, 1 or 2), and -Rc-S(O)tN(R 6

)R

7 (where t is I or 2);

R

3 is selected from the group consisting of isoquinolinyl and phenanthridinyl, each 20 optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally 25 substituted heteroarylalkyl, -R -OR , -R' 3 -OC(O)-R , -R 13

-N(R")

2 , -R 1 -- C(O)R' , -R-'C(O)OR 2,-R"-C(O)N(R"12)2, -R"-N(R 1)C( O)OR 2,-R"-N(R 12)C(O)R"^,

-R

13

-N(R

12 )S(O)tR 2 (where t is 1 or 2), -R"-S(O),OR 12 (where t is 1 or 2), -R'-S(O)pR 2 (where p is 0, 1 or 2), and -R 1 3-S(O)tN(R 12

)

2 (where t is 1 or 2); each R 6 and R' is independently selected from the group consisting of hydrogen, alkyl, 30 haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -RI-OR, -R-CN,

-R

10

-NO

2 , -R 1

-N(R

8

)

2 , -RlcC(O)OR' and -RlO-C(O)N(R) 2 , or any R 6 and R , 35 together with the common nitrogen to which they are both attached, form an 39 WO 2008/083354 PCT/US2007/089153 optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 5 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; 10 each R' is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 1 2 S, together with the 15 common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the 20 compound of formula (la) which is selected from the group consisting of: 1-(isoquinolin-1 -yl)-N-(6-(4-(bicyclo[2.2. ]heptan-.2-y!)piperazin-1 -yl)pyridin-3-yl)-1 H 1,2,4-triazole-3,5-diamine; 1-(isoquinolin-1-yl)-N 3 -(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5 diamine; and 25 1 -(phe nanthridin-6-yl)-N3-(6-(4-(pyrrolidi n-1-yl)piperidin-1 -yl)-5-methylpyridi n-3-yi)-1 H 1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (Ila), as set forth above, is the compound of formula (la) wherein: R', R 4 and R 5 are each hydrogen; 30 R 2 is selected from the group consisting of pyridinyl and 1H-pyrrolo[2,3-b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally 35 substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted 40 WO 2008/083354 PCT/US2007/089153 heteroarylalkenyl, -R9-OR 8 , -R-OC(O)-R, -R9-C(O)R 8 , -R-C(O)OR8,

-R

9

-C(O)N(R

6 )R -R 9

-C(O)-R'N(R)R

7 , -R 9

-N(R

6 )R', -R"-N(R)-R N(R )R -R9-N(R)C(O)OR8, -R 9

-N(R

6

)C(O)-R

0

-N(R

6 )R, -R9-N(R 6

)C(O)R

8 ,

-R

9

-N(R

6

)S(O),R

8 (where t is 1 or 2), -R9S(O)tOR 8 (where t is 1 or 2), -R-S(O)lR 5 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R (where t IS 1 or 2); R3 is selected from the group consisting of thieno[3,2-d]pyrimidinyl and thieno[3,2-di]pyridazinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally 10 substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R' 3

-OR

1 2 , -R"-OC(O)-R, 1 2 -R'3N(R )2, -R'3C(O)R'2, -R'3C(O)OR,-RC )NRs

-R"-N(R

12

)C(O)OR

12 , -R 1

-N(R

12

)C(O)R

2 , -R' 3

N(R

12 )S(O)tR 2 (where t is 1 or 2), 15 -R 13

-S(O)IOR

12 (where t is 1 or 2), -R 13 -S(O)R 12 (where p is 0, 1 or 2), and

-R

1 3

-S(O)N(R

12

)

2 (where t is 1 or 2); each R6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally 20 substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10

'OR

8 , -R 1 0 -CN,

-R

10 -NO-, -R 1

-N(R)

2 , -Rl-C(O)OR8 and -R 10 C(O)N(R3) 2 , or any R6 and R together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted Nheterocyclyl; 25 each R9 is independently selected from the group consisting of hydrogen, alkyl, alkenyi, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; 30 each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 10 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, 35 optionally substituted aryl, optionally substituted aralkyl, optionally substituted 41 WO 2008/083354 PCT/US2007/089153 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two Rm, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and 5 each R" 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) which is selected from the group consisting of: 1-(2-chioro-7-methyithieno[3,2-d]pyrimidine-4-yl)-N(6-(4-cyclopentyl-1,4-diazepan-1 10 yl)pyridin-3-yl)-l 1-1-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimdi ne-4-yl)-N-(6-(4-methylpiperazin-I -yl)pyridin-3 y)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno3,2-d]pyrimidine-4-y)-NC-(6-(4-(pyrrolidin-1 -yl)piperidin-1 yl.)pyridine-3-yl)-1 -i-1,2,4-triazole-3,5-diamine; 15 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-NC(6-(4-(4-methylpiperazin-I yl)piperidin-1 -yl)pyridine-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-mtethylthieo[3,2-d]pyrimtidine-4-yl)-N(6-(4-(bicyclo[2.2.1]heptan-2 yl)piperazin-1 -yl)pyridin-3-yl)-1 -1-,2,4-triazole-3,5-diamine; i -(2-chloro-7-methylthieno[3,2-dpyrimidine-4-yl)-N-(6-(4-pperidin-1 -ylpiperidin-1 20 yl)pyridine-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimid in-4-yil)-N3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H 1,2,4-triazole-3,5-diarmine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N 3 -(6-(4-(pyrroiidin-1 -ylmethyl)piperidin 1 -yl)pyridin-3-yl)-I H-1,2,4-triazole-3,5-diamine; 25 1-(2-chloro-7- iethylthieno[3,2-d]pyrimidin-4-yl)-N3-(6-(4-(azepan-1 -yl)piperidin-1 yl)pyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-dlpyrimidin-4-yl)-N'-(6 (diethylaminoethylrnethylamino)pyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylth ieno[3,2-d]pyrimid in-4-yl )-N-(6-(2-diethylaminomethylpyrrolidin-i 30 yl)pyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N 3 -(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5 methylpyridin-3-yi)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N-(6-(3-diethylaminopyrrolidin-1 yl)pyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 42 WO 20081083354 PCT/IJS2007/089153 1 -(2-chloro-7,-methylthienQ[3,2-d~pyrimidin-4-yI)-PA(6-(4-(bicyclo[2.2. 1 ]heptan-2-y)-1+4 diazepan-1 -yI)pyridin-3-y)-1 H-I ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimid in-4-yi)-A-(6-(4-cyclopropylmethylpi perazin- 1 yI)pyridin-3-yI)-1 H-I! 2,4-triazole-3,5-diamine; 5 1 -(2-ohloro-7-methylthieno[3,2-dlpyrimidine-4-yO-N 3 -(6-(5-bicyclo[22. I ]heptan-2 yloctahydropyrrol [3,4-c]pyrrolyipyrid ine-3-yi)-1 H-i ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrirrmidin-4-y)-N 3 -(6-(4-cyclopropylpiperaz n-1 yI)pyridin-3-yi)-1 H-I.2,4-triazole-3,5-diamine; I -(2-chlorQ-7-rnethylthienc [3,2-d]pyrimidine-4-yI)-NW-(5-methyI-6-(4-bicyclo[2.2. 1 Iheptan 10 2-ylpiperazin-1 -yl,)pyridine-3-y)-1 H-I 2,4-triazole-3,5-dia Mine; 1 -(-ehlhin 32d yimdie--i-3(-ehl6(-iyl[ 2. 1 ] heptan-2 ylip",erazin-1 -yI)pyridine-3-yi)-l H-i ,2,4-triazole-3,5-d ia mine; 1 -(7-mnethylithieno [3 r2-d] pyri mid ine-4-y-.N 3 -(6-(4-(( 1 S,2S,4R)-bicyclo[2.2. 1 ]heptan-2 yl)piperazin-l -yI)pyridin-3-y)-l H-I ,2+4triazole-3,5-diamnine; 15 1 -(2-chloro-7-rnethylthieno[3,2-d~pyrimidine-4-y)-N3-(6-( I -bicyclo[2.2,1I]heptan-2 ylpiperidin-4-yI)pyridine-3-yI)-i H-i ,2,4-triazole-3,5-diamine; I -(7-methyittheno[3,2-d]pyrimidine-4-y)- N-(6-( 1-bicyclo[2.2. I ]heptan-2-ylipiperidin--4yl)pyridine-3-yi)-l H-i ,2,4-triazola-3. 5-diam ine; 1 -(7-mrethylthierno[3 ,2-d]pyrimidine-4-yI)-.N 3 -(63-(l1-(bicyo[2 .2.1 ]heptan-2-y )-5 20 methylpiperidin-4-yl)pyridine-3-yI)-I -I 12,4-triazole-3,5-diamine; I-(7-rnethylthieno[3,2-d]pyrimidine-4-yI)-.N 3 -(6-(4-(cyclopropylmethyI)piperazin- yl)pyridine-3-y)-1 H-I 2,4-triazole-3,5-diamine; I-(7-methylthieno13 ,2-d]pyrimidine-4-yI)-N" 3 -(6-(4-(cyclopropylmethy )piperazin-I -yI)-5 methylpyrid ine-3-yl)- 1 H-I ,2,4-triazole-3,5-diamine; 25 1 -(2-chloro-7-mnethylthierno[3,2-d]pyrimidin-4-yl)-N 3 -(6-(4-(cyclo 'propylmethyl)piperazin-I yl!)-5-methylpyridin-3-y)-l H-I ,2,4-triazole-3,5-diarinie; I -(7-methylthieno[3, 2-d]pyrimidin-4-yi)-N 3 -(2-(3-(S)-mpethiyl-4-( I S, 224R) bicyclIo[2.2, 1,]heptan-2-ylpiperazin-I -yI)-3-mnethylpyridin-5-yl)-l H-I,2,4-triazole 3,5-diamine; 30 -- (2-chloro-7-methylthieno[3,2-d]pyrirnidin-4-y1)-N-(2-(3-(S)-methyl-4-(2S) bicyclIo[2.2. 1 ]heptan-2-yipiperazin-1 -yI)-3-methylpyridin-5-y )-1 H-I ,2,4-triazole 3,5-diamine; I -(thieno[3,2-d]pyrimidin-4-y)-NP-(2-(3-(S)-methyl-4-(2S)-bicyclo[2.2. I ]heptan-2 yipiperazin-I -yI)-3-methylpyridiri-5-yl)-I H-i ,2,4-triazole-3,5-diamine; 35 I-(2-chloro-7-methyIthieno[3,2-djpyrimid in-4-y1)-NW-(2-(4-(2S)-bicyck4[2.2. 1 jheptan-2 43 WO 20081083354 PCT/IJS2007/089153 ylpiperazin-l -yi)3-chloropyridirv-5-yI)-l H-I 2,4-triazole-3,5-diamiine; I -(7-rnethylthieno[3,2-d]pyrim idin-4-yl)-N 3 -(2-(4-(2 S)-bicyclo[2.2, I]heptan-2-yipiperazin 1 -yI)-3-chloropyrdin-5-y)-1 -1,I2,4-triazoIe-3,5-diamnine; I -(7-rnethylthieno[3,2-d]pyrimridin-4-yI)-NP3-(2-(4-(2S)-bicyclo[2.2. 1 ]heptan-2-ylpiperaziri 5 1 -yl)-3-mnethylpyridin-5-y)-1 H-I .2,4-triazole-3.5-diamine; I -(4-methylthieno[3,2-djpyridazine -7-yi )-iV 3 -(2-(4-( 1 ,2S,4R)-bicyclo[2.2 1 jheptan-2 ylpiperazin-1 -yl)-3-mnethylpyridin-5-yl)-1 H-I ,2,4-triazole-3,5-diamine; I -(2-ch loro-7-methylth ieno[3, 2-dl pyri mid in-4-yI)-NP-(2-(4-cyclopropylmethy-3-( S) methylpiperazin-i1 -yI)pyridin-5-yI)-l H-I ,2,4-triazole-3,5-diamine; 10 1 -(7-rnethylthienoE3,2-d~pyrirnildini-4-yR)-N'3-(2-(4-cycloprop r neliyl-3-( S)-rniethylpiperazini 1 -yl)pyridin-5-yl)~I H-I ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N3-(2-(4-cyclopropyimethy-3-( S) methylpiperazin-1 -yI)pyridin-5-yI)-I H-I ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d~pyrirniidifn-4-y)-tW-(2-brornopyridini-5-yi )-1 H-I 2,4-triazole-3,5 15 diarnine; 1 -(7-methvlthieno[3,2-dlpyrimidin-4-yl)-NW-(2-(3-(pyrroidin-1 -yI)propen-I -yIlpyridin-5-yI) I H-I ,2,4-triazole-3,5-diamine; I -(7-rrnethylthieno[3,2-d]pyrirn id ir-4-yI)-N'-(2-(3-(3-dimetthylarn incpyrrohidi n-I -yI)propa-n 1 -yI)pyridin-5-yl)-1 H-i ,2.4-triazole-3,5-diamnine; 20 1 -(7-methylthieno[3,2-dlpyrimidin-4-yi)-NV3-(2-(3-(3-diethylaminopyrrolidin-1 -yl)propen-I yl)pyridin-5-yl)-I H-i ,2,4-triazole-3,5-diamine; I -(7-rniethylthieno[3,2-dpyrimidin-4-y)-N 2 -(2-(3-(4-pyrrolidin- -yl-piperidin-I -yI)propen-1 yl)pyridin-5-yI)-I H-i .2,-triazole-3,5-diarnine; I -(7-methylthieno[3,2-dlpyrim idin-4-yi)-N'-(2-( 3-(4-methylpiperazin- I -yI)propen-I 25 yl)pyridin-5-yI)-I H-I 2,4-triazole-3,5-diamine; I -(7-rniethylthieno[3,2-d]pyrimidin-4-yi)-N 3 -(2-(3-(4-isopropylpiperazin-1 -yI)propen-i yl)pyridMr-5-yl)-i, H-I ,2,4-triazole-3-,5-diamirne; I -(7-methylthieno[3,2-d]pyrimid in-4-yI)-NW-(2-(3-(4-cyclo.pentylpiperazin-I -y )propen- I yi)pyridin-5-yl)-i, H-I 2,4-triazole-315-diamine; 30 1 -(7-methylthieno[3,2-dlpyrimidin-4-yi)-N 3 -(2-(3-(rnorpholin-4-yI)propen-l -yl)pyridln-5-yl) 1 H-I ,2,4-triazole-3,5-diarnine 1 -(7-methylthieno[3, 2-d jpyrirnidini-4-yI)-N 3 -(2-( 3-(piperid in-1 -yl )propen- I -yI)pyrid in-5-yI> 1 H-I ,2,4-triazole-3,5-diamine; I -(7-methylthieno[3,2-.d~pyrimidin-4-vl)-N 3 -(2-(3-(4-(4-rnethylpiperazin- -yl)piperidin-I 35 yl)propen-1 -yI)pyridin-5-yl)-I H-I 2,4-triazole- 35--diamirne; and 44 WO 2008/083354 PCT/US2007/089153 1-(7-methylithieno[3,2-d]pyrimidin-4-y)-NC-(2-(3-(4-piperidin-1 -ylpiperidin-1 -yl)propen-1 yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein: 5 R, R 4 and R5 are each hydrogen;

R

2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally 10 substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR 8 , -R9-OC(O)-Ra, -R 9

-C(O)R

8 , -R'-C(O)OR',

-R

9 -C(O)N(R6)R 7 , -R 9

-C(O)-R

1

-N(RO)R

7 , -R 9

-N(R

6

)R

7 , -R-N(R>)R-N(R 6 )R',

-R

9

-N(R

6 )C(O)OR8, -R 9

-N(R

6 )C(O)-R"--N(R )R 7 , -R 9 -N(R )C(O)R3,

-R

9

-N(R

6 )S(O)XR (where t is I or 2), -R9-S(O)IOR8 (where t is 1 or 2), -R 9 -S(O)pR 8 15 (where p is 0, 1 or 2), and -R9-S(O)tN(R 6

)R

7 (where t is 1 or 2);

R

3 is selected from the group consisting of furo[3,2-c]pyridinyl and 6,7-dihydro-5H cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally 20 substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylaikyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 -OR, -R -OC(O)-R , -R -N(R ) 2 , -R"-C(O)R 2 , -R"-()OR, ~R'3-C(O)N(R )2, -R"-N(R )(OOR, -R1-(R)CO)" 25 -R 13

-N(R

12 )S(O)R 12 (where t is 1 or 2), -R 1 -S(O)tOR 2 (where t is 1 or 2),

-R-

13 S(O)pR1 2 (where p is 0, 1 or 2), and -R 1-S(O)tN(R 2

)

2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally 30 substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R*O-OR, -R'-CN,

-R

10 -N0 2 , -R 10 -N(Ra) 2 , -R 10 -C(O)OR" and -R 1

-C(O)N(R

8

)

2 , or any RC and R, together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; 35 each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, 45 WO 2008/083354 PCT/US2007/089153 haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; 5 each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each RI is independently an optionally substituted straight or branched alkylene chain; each R 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, 10 optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R", together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and 15 each R 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (1a) which is selected from the group consisting of: i-(furo[3,2-c]pyridine-4-yl)-N 3 -(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5-methylpyridin-3-yl) 20 1H-1 ,2,4-triazole-3,5-diamine; and 1-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-N3-(6-(4-(pyrrolidin-1 yi)piperidin-1-yl)-5-methylpyridin-3-y)-1H-1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (1a) wherein: 25 R 1 , R 4 and R5 are each hydrogen; R2 is 6,7,8,9-tetrahydro-5H-pyrido[3,2-a]azepny optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, 30 optionally substituted heterocyclylalkeny, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl,

-R

9

-OR

8 , -R9-OC(O)-R", -R"-C(O)R", -R--C(O)OR', -R-C(O)N(R6)R', -R9-C(O)-R" 1

-N(R

6 )R7, -Rt-N(R6)R 7 , -Re9N(R6)-Rl-N(R)R', -R-N(R)C(O)OR 8 , -R9N(R6)C(O)-R'-N(R )R -R 9

-N(R

6 )C(O)R', -R"-N(Rc)S(O)R5 (where t is 1 or 35 2), -R9-S(O);OR (where t is 1 or 2), -R 9 -S(O)pR (where p is 0. 1 or 2), and 46 WO 2008/083354 PCT/US2007/089153

-R"-S(O),N(R

6 )R7 (where t is 1 or 2);

R

3 is selected from the group consisting of thieno[3,2-d]pyrimidinyl and quinazolinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally 5 substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R'-OR", -R"-OC(O)-R2, -R 1 -N(R")2, -R 1 -C(O)R 1 , -R'3-C(O)OR12, -R"-C(O)N(R 12)2, -R"3-N(R1")C(O)OR"', -R"-N(R 1)C( O)R '1, 10 -R"-N(R )S(O)tR (where t is I or 2), -R -S(O),OR (where t is 1 or 2),

-R-

13 S(O)pR (where p is 0. 1 or 2), and -R"-S(O),N(R 1

)

2 (where t is 1 or 2); each R" and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally 15 substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -RiO-ORs, -RI-CN,

-R

1

-NO

2 , -R"-N(R) 2 , -R 1 OC(O)OR3 and -R 1 -C(O)N(Ra)2, or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; 20 each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylaikyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; 25 each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each Ri is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, 30 optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R , together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and 35 each R" is independently selected from the group consisting of a direct bond and an 47 WO 2008/083354 PCT/US2007/089153 optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ila), as set forth above, is the compound of formula (la) which is selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N 3 -(7-cyclopentyl-6,7,8,9-tetrahydro 5 5H-pyrido[3,2-d]azepin-3-yl)-1H-1,2,4-triazole-3,5-diamine; and 1-(6,7-dimethoxyquinazoline-4-y)-N 3 -(7-cyclopentyl-6,7,8,9-tetrahydro-5H-pyrido[3,2 dlazepin-3-yl)- H-1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula ([a) wherein: 10 R', R 4 and R 5 are each hydrogen;

R

2 is 5,6,7,8-tetrahydro-1,6-naphthyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, 15 optionally substituted heterocyclylalkeny, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl,

-R

9 -OR, -R9-OC(O)-R 8 , -R9-C(O)R, -R 9

-C(O)OR

8 , -R'-C(O)N(R 6

)R

7 , -R9-C(O)-R*"-N(R 6

)R

7 , -R 9

-N(R

6 )R , -R*-N(R 6

)-R

0 -N(Rc)R, -R 9

-N(R

6

)C(O)OR

8

-R

9

-N(R

6

)C(O)-R

10 -N(R6)R", -R 9

-N(R

6

)C(O)R

8 , -R-N(R 6 )S(O)tR' (where t is 1 or 20 2), -R-S(O)tOR" (where t is 1 or 2), -R-S(O),R 8 (where p is 0, 1 or 2), and

-R

9

-S(O):N(R

6 )R7 (where t is 1 or 2); R3 is selected from the group consisting of isoquinolinyl and thieno[3,2--d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally 25 substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR , -R 1 OC(O)-R", -R 13 -N(R ) 2 , -R' 3 -C(O)R, -RC 2)R, -R'3C(O)N(R 1 2)2, -R"-N(R 1)C(O )OR 1, -R' 'N(R )C(O)R, 30 -R 3 -N(R )S(O)tR (where t is 1 or 2), -R 1 3-S(O)tOR (where t is 1 or 2),

-R

13 -S(O)pR' (where p is 0, 1 or 2), and -R S(O) N(R") 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally 35 substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally 48 WO 2008/083354 PCT/US2007/089153 substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 4-OR', -R 1 ~CN,

-R

1 4-NO2, -R 10

-N(R)

2 , -R 1 4-C(O)OR 8 and -R 10

-C(O)N(R

8

)

2 , or any R' and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; 5 each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; 10 each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, 15 optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R' together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and 20 each R 1 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula ([a), as set forth above, is the compound of formula (la) which is selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N3-(6-methyl-5,6,7,8-tetrahydro-1,6 25 naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1 -(isoquinolin-1 -yl)-NS-(6-mnethiyl-5,6,7,8-tetrahydro-1,6-naphthiyridin-3-yl)-1 H-1,2,4 triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrirmidine-4-yl)-N 3 -(6-benzyl-5,6,7,8-tetrahydro-1,6 naphthyridin-3-yl)-1 H-1,2,4-triazoie-3,5-diamine; 30 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N3-(6-(ethylcarboxy)-5,6,7,8-tetrahydro 1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N-(6-(dimethylaminomethylcarbonyl) 5,6,7,8-tetrahydro-1 6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-NC(5,6,7,8-tetrahydro-1,6-naphthyridin 35 3-yl)-1 H-1,2,4-triazole-3,5-diamine; 49 WO 2008/083354 PCT/US2007/089153 I -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N-(6-(dimethylaminomethylcarbonyl) 5,6,7,8-terahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrirmidine-4-yl)-N-(6-(2-dimethylarminoethyl)- 5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 5 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-W-(6-cyclopentyl-5,6,7,8-tetrahydro 1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-rmethylthieno[3,2-a]pyrirmiidin-4-yl)-N(6-(1-methylpi peridin-4-ylcarbonyl) 5,6,7,8-tetrahydro-1,6-naphthyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-dpyrimidine-4-yi)-W-(6-(1 -methylpiperidin-4-yl)-5,6,7,8 10 tetrahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-rmethylthieno[3,2-cdpyrirmidin-4-yl)-N-(6-(piperidin-4-ylcarbonyl)-5,6,7,8 tetrahydro-1, 6-naphthyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-dpyrimidin-4-y)-N-(6-(1-methylpiperidin-4-yl)carbonyl-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 15 1-(7-methylthieno[3,2-d]pyrimidin-4-yI)-N 3 -(6-cyclopentyl-5,6,7,8-tetra hydro- 1,6 naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N(6-cyclopropylmethyl-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-dpyrimidin-4-y)-N3-(6-bicyclo[2.2. I ]heptan-2-yl-5,6,7,8 20 tetrahydro-1,6-naphthyridin-3-yl)-1 H- 1,2,4-triazole-3,5-diamine; and 1-(2-chloro-7-methylthieno[3,2-dpyrimidin-4-yl)-N3(6-(dimethylaminomethyl)carbonyl 5,6,7,8-tetrahydro-1,6-naphthyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein: 25 R 1 , R 4 and R are each hydrogen;

R

2 is selected from the group consisting of 6,7,8,9-tetrahydro-5H-cycloheptab]pyridinyl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, 5,6,7,8-tetrahydroquinolinyl, and 7',8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3'-y, each optionally substituted by one or more substituents selected from the group consisting of 30 cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9

-OR

8 , -R9-OC(O)-R', -R 9

-C(Q)R

8 , -R-C(O)OR 8 , 35 -R 9

C(O)N(R

6

)R

7

-R*-C(O)-R

0 .-N(R)R , -R 9

-N(R

6

)R

7 , -R9-N(R6)-R 0 -N(R)R, 50 WO 2008/083354 PCT/US2007/089153 -R'-N(R6)C(O)OR8, -R"-N(R6)C,(O)-R"-N(R6)R 7,-R9-N(R')C(O)RS, -R'-N(R6)S(O)tR 8 (where t is 1 or 2), -R9-S(O)tOR (where t is 1 or 2), -R 9

-S(O),R

8 (where p is 0, 1 or 2), and -R9-S(O)N(R)R 7 (where t is 1 or 2);

R

3 is thieno[3,2-d]pyrimidinyl optionally substituted by one or more substitutents selected 5 from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -RiOR , -R" -OC(O)-R", 10 -RN(R 2

)

2 , -R 1

C(O)R

12 , -R 3

C(O)OR'

2 , -R 13

C(O)N(R")

2 ,

-R

1 3 -N(R 2 )C(O)OR"2, -R 13 -N(R 2

)C(O)R

12 , -R 1

-N(R

12

)S(O),R

12 (where t is 1 or 2),

-R

13 -S(O)tOR 12 (where t is 1 or 2), -R 13 S(O)pR 12 (where p is 0, 1 or 2), and

-R

1 -S(O)tN(R ) 2 (where t is 1 or 2); each R6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, 15 haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -RlO-ORa, -R 10 -CN,

-R

1 -N0 2 , -R"-N(R3) 2 , -R.

0 -C(O)OR' and -R'-C(O)N(R 8

)

2 , or any R 6 and R7, 20 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 25 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl. and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 t is independently an optionally substituted straight or branched alkylene chain; 30 each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R, 12 together with the 35 common nitrogen to which they are both attached, may optionally form an 51 WO 20081083354 PCT/IJS2007/089153 optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 1 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (la), as set forth above, is the 5 compound of formula (la) which is selected from the group consisting of: I -(2-chloro-7-methylthieno[3,2-dlpyrimidine-4-y)-N,-(6-(pyrrolidin-1 ylcarbonyl)-5,6,7,8 tetrahydroquinolin-3--yl)-I H-I .2,4.-triazole--3,5-diaminle; I -{2-chloro-7-methylthieno[3,2-d] pyrimidin-4-yI)-N 3 -(6-(2-(dimethylaminlo)-I oxyethylam-ino)-5,6,7,8-tetrahydroquinolin-3-y)-1 -11,2,4-triazole-3,5-diamine; 10 I -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N 3 -(6-amino-5,6.'7,8-tetrahydroquinolin 3--yl)-l H- I ,2,-tiazole-3,5-diamine; I -(2-chloro-7--mehylthieno[3,2--d]pyrimidine-4-yl)-N 3 -(6-( 1 -methylpiperidin-4-ylarnino) 5,6,78-tetrahydroquinolin-3-yl)-1 H-I ,2,4-triazole-3,5-diamine; I -(2-chloro-7-meLhylthieno[3,2-d~pyrimidin-4-yl)-N 3 -(7,8'-d ihydro-5' 15 spiro[i ' I]diloxolane-2,6'-quinoline]-3'-yi)-1 H-I 2,4-triazole-3,5-diamin ; 1 -(12-ch loro-7-metLhylthieno [3, 2-d] pyri mid in-4-yI)-NV3-(6-(pyrrolid in- 1l-yl )-4b,5,6,7, 7a,8 hiexahydropentaleno[2, 1-bjpyridin-3-y)-1 H-I ,2,4-triazole-3,5-diarnine; I -(2-chiloro-7-methylthieno[3, 2-dj.pyrimidin-4-yl)-NV 3 -(6-(4-methylpiperazin-1 -yl )-5, 6, 7,8 tetrahydroquinolin-3-yi)-i H-i ,2,4-triazole-3,5-diamine; 20 1 -(2-chlioro-7-rneiylthiienio[3,2-dpyrimidin-4-y)-N 3-(6-cyclopentylaminio-5,6,7,8 tetrahydroquinolin-3-yl)-1 H-I ,2,4-triazole-3,5-diarnine; 1 -(2-chioro-7-methyltLhieno[3,2-d 'pyrimidine-4-yl)-N 3 -(7-(pyrrolidin-l -yl)-6,7,8,9 tetrahydro-5H-cycloheptafblpyridin-3-y)- I H-i ,2,-triazole-3,5-diamine; 1 -(2-chiloro-7-rnethy[Lthienlo[3,2-dpyriridin-4-yl)-N 3 -(6-pyrrolidin-1 -yl-5,6,7,8 25 tetra hyd roq uinolIin-3-yl)- I H-I ,2,4-triazole-3,5-diarnine; I -(7-methylthieno[3,2-d~pyrimidin-4-y)-N 3 -(6-( I -methylpiperidin-4-ylamr.ino)-5,6,7,8 tetra hyd roq uinoin-3-yl)-1I H-I ,2,4-triazole-3,5-diarnine; 1 -(7-rmethlyltthienlor3,2-d]pyriridini-4-y)-N 3 -(6-pyrrolidin-I -yl-5,6,7,8-tetrahydr.oqujinolin-3 yI)-l H-i ,2,4-triazole-3,5-diamine; 30 1 -(7-methylthienor3,2-djpyrimid in-4-yl)-N -(6-( 1-methyl piperidin-4-yl)carbonylamino 5,6,7,8-tetrahydroquinolin-3-yl)-i H-I 2,4-triazole-3,5-diamine; I -(7-mnetthylthiienio[3,2-d]pyrim id in-4-yl>-N 3 -(6-cyclopentylamino-5, 6,7,8 tetra hyd roq uino lin-3-yl)- 1 H-I ,2,4-triazole-3.5-diamine; I -(2-chloro-7-methylthieno[3, 2-d]pyrimidin-4-yl )-N 2 -(6-cyciohexylamino-5,6,7 13 35 tetra hydroq u inoli n-3-vl)-l1 H-I 1,2,4-triazole-3,5-d ia mine; 52 WO 2008/083354 PCT/US2007/089153 1-(2--chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N -(6-bicyclo(22. 1 ]heptan-2-yl-amino 5,6,7,8-tetrahydroquinolin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl )-N6(6-bis-(cyclopropylmethy)amino 5,6,7,8-tetrahydroquinolin-3-yl)-lH-1,2,4-triazole-3,5-diamine; and 5 1-(7-methylthieno3,2-d]pyrimidin -4-yl)-N(7-(pyrrolidin-1 -yl)-6,7,8,9-tetrahydro-5H cyclohepta b]pyridine--3-yl)-1 H-1,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (la), as set forth above, is the compound of formula (la) wherein:

R

1 , R 4 and R are each hydrogen; 10 R 2 is pyrimidinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted 15 heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -ORs, -R 9 -OC(O)-R,

-R

9 -C(O)R6, -R 9 -C(O)OR, -R 9 -C(O)N(R')R7, -R 9

-C(O)-R

10

-N(R

6 )R7, -R 9

-N(R

6 )R', -R9-N(R6)-R""'-N(R 6)R', -RW-N(RW)C(O)OR', -R9-N(R')C(O)-R"-N(R6)R",

-R'-N(R

6 )C(O)R, -R 9 -N(R6)S(O)tR 8 (where t is 1 or 2), -R"-S(O)OR (where t is I or 2), -R9-S(O)pR 8 (where p is 0, 1 or 2), and -R9-S(O)tN(R)R 7 (where t is 1 or 2); 20 R 3 is selected from the group consisting of quinazolinyl and thieno[3,2-d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally 25 substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R -OR, -R"-OC(O)-R , -R 13 -N(R )2, -R 3 -C(O)R, -R 'C(O)OR, -R"-C(O)N(R) 2 , -RD-N(R )C(O)OR", -R -N(R )C(O)R,

-R

1

'-N(R

12 )S(O)R 12 (where I is 1 or 2), -R 1 -S(O)tOR 2 (where t is 1 or 2), -R' -S(Q)pR 12 (where p is 0, 1 or 2), and -R 13 -S(O)jN(R 12

)

2 (where t is 1 or 2); 30 each R6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -0R, -R 10 -CN, 35 -R 1 -NO2, -RO-.N(R) 2 , -R 10

-C(O)OR

8 and -R 0

-C(O)N(R

8

)

2 , or any R 6 and R 7 , 53 WO 2008/083354 PCT/US2007/089153 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally 5 substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylaikyl; each RO is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; 10 each R 10 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted 15 heteroaryl and optionally substituted heteroarylalkyl, or two R 1 , together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. 20 Another embodiment of a compound of formula (1a), as set forth above, is the compound of formula (1a) which is selected from the group consisting of: 1-(6,7-dirmethoxyquinazoline-4-yl)-N 3 -(2-(4-pyrrolidin-1 -ylpiperidin-I -yl)pyrimidin-5-yl)-1 H 1,2,4-triazole-3,5-diamine; 1 -(6,7-di methoxyqu;nazoline-4-y)-N(2-(4-piperidin-1-ylmethy!piperidin-1 -yl)pyrimidin-5 25 yl)-1H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N-(2-(4-pyrrolidin-1 ylpiperidin-1 yl)pyrimidin-5-yl)-1H-1,2,4-triazole-3,5-diamine; and I-(2-chloro-7-methylthieno[3,2-djpyrimidin-4-yl)-N (2-(4-(piperidin-1-ylmethyl)piperidin-1 yi)pyrimidin-5-yl)-1H-1,2,4-triazole-3,5-diamine. 30 Another embodiment of the invention, as set forth above in the Summary of the Invention, is where the compound of formula (1) is a compound of formula (Ib): 54 WO 2008/083354 PCT/US2007/089153

R

3 N-N N N (b) R N wherein: R', R 4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R 8 , -C(O)N(R 6 )R, and -(NR)N(R)R 7 ; 5 R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted 10 heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR3, -R 9

-O-R

0 -OR, -R'-0-R 10 -O-R 0-OR8, -R 9 -O-R'O-CN, -R 9

-O-R

0

-C(O)OR

8 , -R9-0-R 1

C(O)N(R

6 )R7, ~R 9 -0-R 10

-S(O),R

8 (where p is 0, 1 or 2), -R'-0-R'ON(R')R 7, -R9-O-R'0C(NR'1)N(R11)H, -R9-OC(IO)-RII, -R9-C(O)RaI -R'-C(O)ORW, -R'-C(O)N(R')R 7, -Rg-C(O)-R"-N(R6)R 7, -R'-N(R6)R7, 15 -R 9

-N(R

6

)-R

1

-N(R

6

)R

7 , -R 9 -N(R)C(O)OR, -R 9

-N(R

6

)C(O)-R-N(R)R

7 ,

-R

9

-N(R

6 )C(O)Ra, -R 9 -N(R6)S(O),R 8 (where t is 1 or 2), -R'-S(O)tOR (where t is 1 or 2), -R9-S(O)pR 8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R 7 (where t is 1 or 2);

R

3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more 20 substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted 25 cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocycylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R' 3 -OR , -R OC(O)-R2, -R O-RN(R ) 2 , -R -N(R ) 2 , 30-RC(O)R,-R"C(O)OR, -RC(O)N(R -R'C(O)N(R)-R' N(R)R3, -R'3~C(O)N(R )-R OR, -RNR)C(O)ORK RNR)() 55 WO 2008/083354 PCT/US2007/089153 -R'3.N(R 12 )S(O)R 12 (where t is 1 or 2), -R 1 -S(O)tOR 12 (where t is I or 2), -R'3-S(O)pR 2 (where p is 0, 1 or 2), and -R 13

-S(O);N(R

12

)

2 (where t is 1 or 2) each Rb and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally 5 substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally 10 substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -Rlu-OR, -R 1 ECN, -R,-NO 2 , -R 0

-N(R)

2 ,

-R

1 KC(O)OR" and -R"'-C(O)N(R8) 2 , or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N 15 heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, 20 optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted 25 heteroarylalkynyl; each R 9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; 30 each R 1 0 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R 11 is hydrogen, alkyl, cyano, nitro or -OR3 35 each R 12 is independently selected from the group consisting of hydrogen, alkyl, 56 WO 2008/083354 PCT/US2007/089153 haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R' 2 $, together with the 5 common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and 10 each R is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain. Another embodiment of a compound of formula (lb), as set forth above, is the compound of formula (Ib) wherein: 15 R" R 4 and R- are each independently selected from the group consisting of hydrogen,

-C(O)N(R

6 )R', and -C(=NR)N(R 6 )R; R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl. optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 20 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R 9 -O-R 0 -OR,

-R

9 -O-R"O-O-R -OR 8 , -R 9 -O-R-CN, -R-0-R 1 -C(O)OR ,

-R

9 -0-R 10 -C(O)N(R6)R 7 , -R2-0-R"O-S(O),R 8 (where p is 0, 1 or 2), 25 -R2-O-R"-N(R)R 7 , -R 9 -0-R 1

-C(NR

1 )N(R")H, -R 9 -OC(O)-R, -RI-C(O)R',

-R

9

-C(O)OR

8 , -R-C(O)N(R6)R , -R 9 -C(O)-R-N(R)R -Rk-N(R 6

)R

7 - R -- N(R 6

)-R

0

-N(R

6

)R

7 , -R-N(R)C(O)OR 8 , -R 9

-N(R

6

)C(O)-R

0 N(R)R ,

-R

9

-N(R

6 )C(O)R', -R"-N(R 6 )S(O)tR 8 (where t is 1 or 2), -R 9 -S(O):OR' (where t is 1 or 2), -R 9 -S(O)pR 8 (where p is 0, 1 or 2), and -R-S(O) 1

N(R

6 )R' (where t is 1 or 2); 30 R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally 35 substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally 57 WO 2008/083354 PCT/US2007/089153 substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R' 3 OR", -R 1 -OC(O)-R", -R1 3

-O-R

14

-N(R

2

)

2 ,

-R

3

-N(R

12

)

2 , -R 13

-C(O)R

12 , -R 13

C(O)OR

12 , -R 1

-C(O)N(R

12

)

2 , -R1'C(0)N(R")-R1 N(R )R13, -R'3C(O)N(R )-R OR , -R'3N(R )C(O)OR, 5 -R 13

-N(R

12

)C(O)R

2

-R

1 -. N(R 12 )S(O)R 12 (where t is I or 2), -RE'-S(O)OR 1 2 (where t is 1 or 2), -RQS(O)pR (where p is 0, 1 or 2), and -R 13 -S(O).N(R ) 2 (where t is 1 or 2); each R 6 and R T is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, 10 optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 0 -OR', -R 0 --CN, -R")-N0 2 , -R 10 N(Ra)2, -R 10

-C(O)OR

8 and -R 1

KC(O)N(R

8

)

2 , or any R and R 7 , together with the common nitrogen to which they are both attached, form an 15 optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 20 heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each Rlc is independently an optionally substituted straight or branched alkylene chain; each R" is hydrogen, alkyl, cyano, nitro or -OR 8 ; 25 each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R ', together with the 30 common nitrogen to which they are both attached, may optionally form an optionally substituted N--heterocyclyl or an optionally substituted N-heteroaryl; each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R1 4 is independently an optionally substituted straight or branched alkylene chain. 35 Another embodiment of a compound of formula (lb), as set forth above, is the 58 WO 2008/083354 PCT/US2007/089153 compound of formula (Ib) wherein: R, R4 and R 5 are each independently selected from the group consisting of hydrogen,

-C(O)N(R

6 )R, and -C(=NR 6

)N(R

6 )R';

R

2 is a heteroaryl selected from the group consisting of benzoxazoly, pyridinyl, 5 isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzob][1 ,4]dioxinyl, 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyrido[3,2-dlazepinyl, 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 7',8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3'-yi, 10 4b,5,6,7,7a,8-hexahydropentaleno[2,1I-b]pyridinyl, and 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted 15 heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR', -R 9 -OC(O)-Ra, -R-C(O)R", -R 9 -C(O)OR", -Rf-C(O)N(R)R', -R-C(O)-R"-N(R 6 )R -R 9

-N(R

6

)R

7 , -R-N(R)C(O)OR, -R-N(R 6

)C(O)-R

0

-N(R

6 )R -R 9

N(R

6

)C(O)R

8 20 -R 9

-N(R

6 )S(O)tR 8 (where t is 1 or 2), -R'-S(O);OR 8 (where t is 1 or 2), -R"-S(O)pR3 (where p is 0, 1 or 2), and -Rl-S(O)tN(R 6

)R

7 (where t is 1 or 2);

R

3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, 25 optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R"-OR -R"-OC(O)-R , -R 3

-N(R")

2 -R-C(O)R

-R

13 -C(O)OR 2 7 -R 13

-C(O)N(R

12

)

2 , -R"-N(R 12

)C(O)OR

12 , -R"-N(R 2

)C(O)R

12 ,

-R

3 -N(R )S(O)tR (where t is 1 or 2), -R 1 -S(O)tOR (where t is I or 2), 30 -R" 3 -S(O)pR" (where p is 0, 1 or 2), and -R'3-S(O),N(R") 2 (where t is 1 or 2); each R3 and R' is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyi, optionally 35 substituted heteroaryl, optionally substituted heteroarylalkyl, -R,-OR 8 , -R 10 -CN. 59 WO 2008/083354 PCT/US2007/089153 -R'4-NO2, -R' -N(R') 2 , -R' 0 -C(O)OR' and -R 1

-C(O)N(R

8

)

2 , or any R 6 and R', together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, 5 haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an 10 optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted 15 heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 1 2 ', together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R" 3 is independently selected from the group consisting of a direct bond and an 20 optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ib), as set forth above, is the compound of formula (Ib) wherein:

R

1 , R 4 and R5 are each independently selected from the group consisting of hydrogen,

-C(O)N(R

6

)R

7 , and -C(=NR)N(R)R 7 ; 25 R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 4,5-dihydro- H-benzo[b]azepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyrido[3,2-d]azepiny, 5,6,7,8-tetrahydro-1,6-naphhyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 30 7',8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, and 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted 35 cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted 60 WO 2008/083354 PCT/US2007/089153 heterocyclyalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalky, optionally substituted heteroarylalkenyl, -R-OR 8 , -R"-OC(O)-R 8 , -R-C(O)Re, -Rg-C(O)OR, -R'-C(0)N(R6)R 7, -R9-C(O)-R."-N(R6)R 7, -RW-N(RW)R' -RS-N(R6)-R"-N(R6)RW, 5 -R'-N(R)C(O)OR', -R 9 -N(R)C(O)-Rl-N(R 6 )R7, -R 9 -N(R)C(O)R,

-R

9

-N(R

6

)S(O)+R

8 (where t is 1 or 2), -R 9 -S(O)tOR* (where t is I or 2), -R9-S(O)pR 8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R' (where t is 1 or 2);

R

3 is a heteroaryl selected from the group consisting of pyridinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3.2-d]pyrimidinyl, thieno[3,2-d pyridazinyl, 10 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally 15 substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -- R OR -R 13 -OC(O)-R' , -R"-N(R ) 2 , -R 1 -C(O)R -RC(O)ORl -R-C(O)N(R ) 2 , -R"-N(R)C(O)R -R' 3 -N(R )C(O)R,

-R

13

-N(R

12 )S(O)tR 12 (where t is 1 or 2), -R 3 -S(O)jOR 12 (where t is 1 or 2), -R 13 S(O)R 12 (where p is 0, 1 or 2), and -R"-S(O)tN(R 2

)

2 (where t is 1 or 2); 20 each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroaryalkyl, -R 10 -OR, -R 1 0 -CN, 25 -R 10

-NO

2 , -R-N(R') 2 , -RQC(O)OR3 and -R 0 C(O)N(R3), or any R6 and R 7 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally 30 substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; 35 each R 10 is independently an optionally substituted straight or branched alkylene chain; 61 WO 2008/083354 PCT/US2007/089153 each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted 5 heteroaryl and optionally substituted heteroarylalkyl, or two R 1 2, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 1 I is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. 10 Another embodiment of a compound of formula (Ib), as set forth above, is the compound of formula (Ib) selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5 methyipyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(4-methylthieno[2,3-d]pyridazin-7-yl)-N-(2-(4-(1 S,2S,4R)-bicyclo[2.2. 1]heptan-2 15 ylpiperazin-1- yl)-3-methylpyridin-5-yl)-1H--1,2,4-triazole-3,5-diamine; and 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-N (2-(3-(4-(4-methylpiperazin-1-yl)piperidin-1 yl)propen-1 -yl)pyridin-5-y)-1 H-1,2,4-triazole-3,5-diamine. Other preferred embodiments of R1, R 2 , R 3 , R 4 and R6 of the compounds of formula (Ib) are the same as set forth above for R', R 2 , R 3 , R 4 and R 5 of the compounds 20 of formula (la). In any of the embodiments disclosed above, a particular embodiment is directed to compounds of the invention wherein the optionally substituted heteroaryls for R 2 are selected from the group consisting of optionally substituted benzoxazolyl, optionally substituted pyridinyl, optionally substituted isoquinolinyl, optionally substituted 25 pyrimidinyl, optionally substituted 2,3-dihydrobenzo[b][1,4]dioxinyl, optionally substituted 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-ony, optionally substituted 6,7,8,9-tetrahydro-5H-pyrido3,2-d]azepinyl, optionally substituted 5,6,7,8-tetrahydro-1,6-naphthyridinyl, optionally substituted 5,6,7,8-tetrahydroquinolinyi, optionally substituted 1 H-pyrrolo[2,3-bjpyridinyl, benzo[b]thiophenyl, optionally 30 substituted 7',8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'quinoline]-3'-y, and optionally substituted 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl. Of this embodiment, a particular embodiment is where the optional substituents for these heteroaryls are optionally substituted heterocycyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl. Of this embodiment, a particular embodiment is where 35 the optional substituents on the optionally substituted heterocycly, optionally substituted 62 WO 2008/083354 PCT/US2007/089153 heterocyclylalkyl and optionally substituted heterocyclylialkenyl are optionally substituted heterocyclyl C3-C 6 monocyclic cycloalkyl radicals, C 3

-C

6 monocyclic cycloalkylalky radicals, C7-C1 polycyclic cycloalkyl radicals, such as norbornanyl, norbornenyl, as well as substituted C 7

-C

1 5 polycyclic cycloalkyl radicals, such as 5 7,7-dirmethyl-bicyclo[2.2.1]heptanyl. In any of the embodiments disclosed above, a particular embodiment is directed to compounds of the invention wherein the optionally substituted aryls and heteroaryls for R3 are selected from the group consisting of optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted 10 isoquinolinyl, optionally substituted quinazolinyl, optionally substituted phenanthridinyl, optionally substituted thieno[3,2-d]pyrimidinyl, optionally substituted thieno[3,2 d]pyridazinyl, optionally substituted 6,7-dihydro-5-1-cyclopenta [4,5]thieno[2,3 d]pyrimidinyl, and optionally substituted furo[3,2-c]pyridinyl. In any of the embodiments disclosed above, a particular embodiment is directed 15 to compounds of the invention wherein the optionally substituted heteroaryls for R3 are selected from the group consisting of optionally substituted isoquinolinyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted quinazolinyl, optionally substituted phenanthridinyl, optionally substituted t1ieno[3,2-d]pyrimidinyl, optionally substituted thieno[3,2-d]pyridazinyl, optionally substituted 6,7-dihydro-5H 20 cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, and optionally substituted furo[3,2-c]pyridinyl and wherein the optionally substituted heteroaryis for R 2 are selected from the group consisting of optionally substituted benzoxazolyl, optionally substituted pyridinyl, optionally substituted isoquinolinyl, optionally substituted pyrimidinyl, optionally substituted 2,3-dihydrobenzo[b[1,4]dioxinyl, optionally substituted 25 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl, optionally substituted 6,7,8,9-tetrahydro-5H-pyrido[3,2-d]azepiny, optionally substituted 5,6,7,8-tetrahydro-1,6-naphthyridiny, optionally substituted 5,6,7,8-tetrahydroquinolinyl, optionally substituted 1 H-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, optionally substituted 7',8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3'-yl, and optionally 30 substituted 4b,5,6,7,7a,8-hexahydropentaleno[2,1-blpyridinyl. Of this embodiment, a particular embodiment is where the optional substituents for these heteroaryls are optionally substituted heterocycyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylaikenyl, particularly optionally substituted piperidinylalkenyl, optionally substituted pyrrolidinylalkenyl, optionally substituted piperazinylalkenyl and 35 optionally substituted morpholinoalkenyl. Of this embodiment, a particular embodiment 63 WO 2008/083354 PCT/US2007/089153 is where the optional substituents on the optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl are optionally substituted heterocyclyl, C 3 -Cb monocyclic cycloalkyl radicals, C,-C 6 monocyclic cycloalkylalkyl radicals, C 7 -C1 polycyclic cycloalkyl radicals, such as norbornanyl, 5 norbornenyl, as well as substituted CrC, 5 polycyclic cycloalkyl radicals, such as 7,7-dimethyl-bicyco[2.2.1 ]heptanyl. Of the various aspects of the pharmaceutical compositions of the invention comprising a pharmaceutically acceptable excipient and a compound of formula (I), as set forth above in the Summary of the Invention, certain embodiments are preferred. 10 One embodiment of these pharmaceutical compositions is wherein the compound of formula (I) therein is selected from any one embodiment of the compound of formula (Ia), as set forth above, or from any combination of embodiments of the compound of formula (la), as set forth above, or the compound of formula (1) therein is selected from any one embodiment of the compound of formula (Ib), as set forth above, or from any 15 combination of embodiments of the compound of formula (ib), as set forth above. Of the various aspects of methods of treating a disease or condition associated with AxI activity in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (1), certain embodiments are preferred. 20 One embodiment of these methods is the method wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy of prematurity, kidney disease, osteoporosis, osteoarthritis and cataracts. 25 One embodiment of these methods is the method wherein a manifestation of the disease or condition is solid tumor formation in said mammal. One embodiment of these methods is the method wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung 30 carcinoma, and uveal melanoma. One embodiment of these methods is the method wherein a manifestation of the disease or condition is liquid tumor formation in said mammal. One embodiment of these methods is the method wherein the disease or condition is myeloid leukemia or lymphoma. 35 One embodiment of these methods is the method wherein the disease or 64 WO 2008/083354 PCT/US2007/089153 condition is endometriosis. One embodiment of these methods is the method wherein the compounds of formula (1) utilized therein is selected from any one embodiment of the compound of formula (a), as set forth above, or from any combination of embodiments of the 5 compound of formula (1a), as set forth above, or the compound of formula () therein is selected from any one embodiment of the compound of formula (Ib), as set forth above, or from any combination of embodiments of the compound of formula (Ib), as set forth above. Another embodiment of the invention are those methods of treating a disease or 10 condition associated with AxI activity by administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis, visual impairment due 15 to macular degeneration, diabetic retinopathy or retinopathy of prematurity, kidney disease (including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant rejection), osteoporosis, osteoarthritis and cataracts. Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal a therapeutically 20 effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer, uveal melanoma, myeloid leukemia and lymphoma. 25 Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal of therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is endometriosis. It is understood that any embodiment of the compounds of formula (Ia) and 30 compounds of formula (Ib), as set forth above, and any specific substituent set forth herein for a R 1 , R , R, R 4 , R 5 , R 6 , R7, R', R', R 10 , R", R, R 1 and R16 group in the compounds of formula (Ia) and the compounds of formula (Ib), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of formula (Ia) and compounds of formula (Ib) to form embodiments of the inventions not 35 specifically set forth above. In addition, in the event that a list of substitutents is listed for 65 WO 2008/083354 PCT/US2007/089153 any particular R group in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodment and/or claim and that the remaining list of substituents will be considered to be within the scope of the invention. 5 Specific embodiments of the invention are described in more detail in the following sections. UTILITY AND TESTING OF THE COMPOUNDS OF THE INVENTION The oncogenic RTK, Axi, was recently identified, using a retroviral-based functional genetic screening protocol, as a regulator of haptotactic migration, which is a 10 key event in angiogenesis. Axl inhibition by RNAi-mediated silencing blocked endothelial cell migration, proliferation and in vitro tube formation. These observations, which were disclosed at the American Association Cancer Research General Meeting, April 16-20, 2005, Anaheim, California, and The 7th Annual Symposium on Anti-Angiogenic Agents, February 10-13, 2005, San Diego, California; (Requirement for The Receptor Tyrosine 15 Kinase Ax! in Angiogenesis and Tumor Growth, Holland, S.J. Powell, M.J., Franci, C., Chan, E., Friera, A.M., Atchison, R., Xu, W., McLaughlin, J., SwiftS.E., Pali, E., Yam, G., Wong, S., Xu, X., Hu, Y., Lasaga, J., Shen, M., Yu, S., Daniel, R., Hitoshi, Y., Bogenberger, J., Nor, J.E., Payan, D.G and Lorens, J.B), were substantiated by an in vivo study which demonstrated that stable, shRNAi-mediated AxI knockdown impaired 20 formation of functional human blood vessels in a mouse model of human angiogenesis. These observations were published in a peer reviewed journal (Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nor JE, Payan DG, Lorens JB. "Multiple roles for the receptor tyrosine kinase axl in tumor formation." Cancer 25 Res. (2005) Vol 65 pp 9294-303. These observations are also disclosed in U.S. Published Patent Application 2005/0118604 and European Patent Application 1 563 094, the disclosures of which are incorporated in full by reference. AxI signaling, therefore, impacts multiple functions required for neovascularization in vitro, and regulates angiogenesis in vivo. Regulation of these pro-angiogenic processes required the 30 catalytic activity of Axl. Thus, Axi-mediated angiogenic stimulation would be amenable to modulation by a small molecule inhibitor of Axl catalytic activity. Accordingly, the compounds of the invention are small molecule inhibtiors of Axi catalytic activity, and are therefore useful in treating diseases and conditions which are associated with AxI catalytic activity including those diseases and conditions which are 66 WO 2008/083354 PCT/US2007/089153 characterized by angiogenesis and/or cell proliferation. In particular, the compounds of the invention and pharmaceutical compositions of the invention are useful in treating diseases and conditions which are alleviated by the modulation of Axi activity. For purposes of this invention, diseases and condtions which are alleviated by the 5 "modulation of AxI activity" includes diseases and conditions which are alleviated by a decrease in Axi activity and diseases and conditions which are alleviated by an increase in Axi activity. Preferably such diseases and conditions are alleviated by a decrease in Axl activity. Diseases and conditions which are alleviated by the modulation of Axi activity include, but are not limited to, solid tumors, including, but not limited to, breast, 10 renal, endometrial, ovarian, thyroid, and non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer and uveal melanoma; liquid tumors, including but not limited to, leukemias (particularly rnyeloid leukemias) and lymphomas; endometriosis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis; visual impairment due to macular 15 degeneration; diabetic retinopathy and retinopathy of prematurity; kidney disease (including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant rejection), rheumatoid arthritis; osteoarthritis, osteoporosis and cataracts. In addition to the foregoing, the compounds of the invention are useful in treating diseases and conditions which are affected by the following biological processes: 20 Invasion, migration, metastasis, or drug resistance as manifested in cancer; stern cell biology as manifested in cancer; invasion, migration, adhesion, or angiogenesis as manifested in endometriosis; vascular remodeling as manifested in cardiovascular disease, hypertension or vascular injury; bone homeostatasis as manifested in osteoporosis or osteoarthritis; viral infection as manifested, for example, in ebola virus 25 infection; or differentiation as manifested in obesity. The compounds of the invention may also be used to modulate inflammatory processes by treating sepsis, acting as vaccine adjuvants, and/or potentiating the immune response in immuno-compromised patients. The following animal models provide guidance to one of ordinary skill in the art in 30 testing the compounds of the invention for their use in treating the disease or condition indicated. The compounds of the invention may be tested for their use in treating leukemias and lymphomas by testing the compounds in the xenograft in SCID mouse model using human Axi-expresing cancer cell lines including, but not limited to, HeLa, MDA-MB-231, 35 SK-OV-3, OVCAR-8, DU145, H1299, ACHN, A498 and Caki-1, 67 WO 2008/083354 PCT/US2007/089153 The compounds of the invention may be tested for their use in treating leukemias in the xenograft in SCID or nu/nu mouse model using human Axi-expressing AML and CML leukemia cell lines. The compounds of the invention may be tested for their use in treating 5 endometriosis by using the syngenic mouse model of endometriosis (see Somigliana, E. et aL, "Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis", Hum. Reprod. (1999), Vol. 14, NO. 12, pp. 2944-50). The compounds may also be tested for their use in treating endometriosis by using the rat model of endometriosis (see Lebovic, D.I. et al., "Peroxisome proliferator-activated 10 receptor-gamma induces regression of endometrial explants in a rat model of endometriosis", Fertil. Steril. (2004), 82 Suppl 3, pp. 1008-13). The compounds of the invention may be tested for their use in treating restenosis by using the balloon-injured rate carotid artery model (see Kim, D.W. et a/., "Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury 15 model", Circulation (2004), Vol. 109, No. 12, pp. 1558-63, Epub 2004 Mar 8). The compounds of the invention may also be tested for their use in treating restenosis by using the percutaneous transluminal coronary angioplasty in apoE deficient mouse model (see von der Thusen, J.H. et a. "Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of 20 postangioplasty restenosis", Arterloscler. Thromb. Vasc. Biol. (2004), Vol. 24, No. 2, pp. 357-62). The compounds of the invention may be tested for their use in treating atherosclerosis/thrombosis in the ApoE deficient mouse model (see Nakashima, Y. et a/, "ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the 25 arterial tree", Arterioscler. Thromb. (1994), Vol. 14, No. 1, pp. 133-40). The compounds of the invention may also be tested for their use in treating thrombosis using the collagen-epinephrin-induced pulmonary thromboembolism model and the stasis induced venous thrombosis model (see Angelillo-Scherrer A. et al., "Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for 30 antithrombotic therapy", J Clin Invest. (2005) Vol 115 pp237-46). The compounds of the invention may be tested for their use in treating psoriasis by using the SCID mouse model or the human skin model of psoriasis (see Nickoloff, B.J. et al., "Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model", Am. J. Pathol. (1995), Vol. 146, No. 3, pp. 35 580-8). 68 WO 2008/083354 PCT/US2007/089153 The compounds of the invention may be tested for their use in treating age related macular degeneration or diabetic retinopathy by using the rat corneal angiogenesis model (see Sarayba MA, Li L, Tungsiripat T, Liu NH, Sweet PM, Patel AJ, Osann KE, Chittiboyina A, Benson SC, Pershadsingh HA, Chuck RS. Inhibition of 5 corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp Eye Res. 2005 Mar;80(3):435-42) or the laser-induced mouse choroidal neovasculation model (see Bora, P.S., et al., "Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration", Proc. Nat. Acad. Sci. U. S. A. (2003), Vol. 100, No. 5, pp. 2679-84, Epub 10 2003 Feb 14). The compounds of the invention may be tested for their use in treating retinopathy of prematurity in the mouse retinopathy of prematurity model (see Smith, L.E. et al., "Oxygen-induced retinopathy in the mouse", Invest. Ophthalmol. Vis. Sci. (1994), Vol. 35, No. 1, pp. 101-11). 15 The compounds of the invention may be tested for their use in treating glomerulonephritis or diabetic nephropathy in the rat anti-Thyl .1-induced experimental mesengial proliferative glomerulonephritis model (see Smith, L.E. et al. cited above). The compounds of the invention may be tested for their use in treating renal tranplant rejection by using a rat model of chronic renal transplant rejection (see Yin, J.L. 20 et a/, "Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection", Transplantation (2002), Vol. 73, No. 4, pp. 657-60). The compounds of the invention may be tested for their use in treating rheumatoid arthritis by using the CAIA mouse model (see Phadke, K. et al., "Evaluation of the effects of various anti-arthritic drugs on type il collagen-induced mouse arthritis 25 model", /mmunopharmacology (1985),Vol. 10, No. 1, pp. 51-60). The compounds of the invention may be tested for their use in treating osteoarthritis by using the STR/ORT mouse model (see Brewster, M. et al. "Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis", Arthritis. Rheum. (1998), Vol. 41, No. 9, pp. 30 1639-44). The compounds of the invention may be tested for their use in treating osteoporosis by using the ovariectornized rat model (see Wronski, T.J. et al., "Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats", Endocrinology (1989), Vol. 125, no. 2, pp 810-6) or the 35 ovariectomized mouse model (see Alexander, J.M. et a., "Human parathyroid hormone 69 WO 2008/083354 PCT/US2007/089153 1-34 reverses bone loss in ovariectomized mice", J Bone Miner Res (2001), Vol. 16, no. 9, pp 1665-73; Fujioka, M. et al., "Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice", J Nutr. (2004), Vol. 134, no. 10, pp 2623-7). The compounds of the invention may be tested for their use in treating cataracts 5 by using the H 2 0 2 induced model (see Kadoya, K. et al, "Role of calpain in hydrogen peroxide induced cataract", Curr. Eye Res. (1993), Vol. 12, No. 4, pp. 341-6) or the Emory mouse model (see Sheets, N.L et aL, "Cataract- and lens-specific upregulation of ARK receptor tyrosine kinase in Emory mouse cataract", Invest. Ophthalmrio. Vis. Sci. (2002), Vol. 43, No. 6, pp. 1870-5). 10 PHARMACEUTICAL COMPOSITIONS OF THE INVENTION AND ADMINISTRATION Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration of agents for serving similar utilities. The pharmaceutical compositions of the invention can be prepared by 15 combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. Typical routes of administering such pharmaceutical compositions include, without limitation, 20 oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Pharmaceutical compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. 25 Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of 30 Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this invention. 70 WO 2008/083354 PCT/US2007/089153 A pharmaceutical composition of the invention may be in the form of a solid or liquid. In one aspect, the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) may be liquid, with the compositions being, for example, an oral oil, injectable liquid or an aerosol, which is useful in, for 5 example, inhalatory administration. When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid. As a solid composition for oral administration, the pharmaceutical composition 10 may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition will typically contain one or more inert diluents or edible carriers, In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents 15 such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent. When the pharmaceutical composition is in the form of a capsule, for example, a 20 gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil. The pharmaceutical composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, 25 preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included. 30 The liquid pharmaceutical compositions of the invention, whether they be solutions, suspensions or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, 35 polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents 71 WO 2008/083354 PCT/US2007/089153 such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, 5 disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile. A liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained. Typically, this amount is at least 10 0.01% of a compound of the invention in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition. Preferred oral pharmaceutical compositions contain between about 4% and about 75% of the compound of the invention. Preferred pharmaceutical compositions and preparations according to the present invention are prepared so that a 15 parenteral dosage unit contains between 0.01 to 10% by weight of the compound prior to dilution of the invention. The pharmaceutical composition of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the 20 following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a pharmaceutical composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device. Topical formulations may contain a concentration of the compound of the invention from 25 about 0.1 to about 10% w/v (weight per unit volume). The pharmaceutical composition of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without 30 limitation, lanolin, cocoa butter and polyethylene glycol. The pharmaceutical composition of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, and may be 35 selected from, for example, sugar, shellac, and other enteric coating agents. 72 WO 2008/083354 PCT/US2007/089153 Alternatively, the active ingredients may be encased in a gelatin capsule. The pharmaceutical composition of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound. Suitable agents that may act in this capacity include a 5 monoclonal or polyclonal antibody, a protein or a liposome. The pharmaceutical composition of the invention may consist of dosage units that can be administered as an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump 10 system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One of ordinary skill in the art, without undue experimentation may determine preferred aerosols. 15 The pharmaceutical compositions of the invention may be prepared by methodology well known in the pharmaceutical art. For example, a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution, A surfactant may be added to facilitate the formation of a homogeneous solution or 20 suspension. Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system. The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount, which will vary depending upon a 25 variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy. Generally, a therapeutically effective daily dose is (for a 70 kg 30 mammal) from about 0.001 mg/kg (i.e., 0.07 mg) to about 100 mg/kg (i.e., 7.0 gm); preferaby a therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg/kg (i.e., 0.7 mg) to about 50 mg/kg (i.e., 3.5 gin); more preferably a therapeutically effective dose is (for a 70 kg mammal) from about 1 mg/kg (.e, 70 mg) to about 25 mg/kg (i.e., 1.75 gm). 35 Compounds of the invention, or pharmaceutically acceptable salts thereof, may 73 WO 2008/083354 PCT/US2007/089153 also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents. Such combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of the invention and one or more additional active agents, as well as administration of the compound of the 5 invention and each active agent in its own separate pharmaceutical dosage formulation. For example, a compound of the invention and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations. Where separate dosage formulations are used, the compounds of the invention and one or 10 more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens. PREPARATION OF THE COMPOUNDS OF THE INVENTION The following Reaction Scheme illustrates methods to make compounds of this 15 invention, ie., compounds of formula (I):

R

3 R2 R5 / N R' R 4 where R', R', R 3 , R 4 and R 5 are described above in the Summary of the Invention for compounds of formula (1), as isolated stereolsomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or N-oxides. In particular, the 20 following Reaction Scheme illustrates methods to make compounds of formula (Ia):

R

3 N-N R2 / N NR (1a) N N 1 where R 1 , R 2 , R 3 , R 4 and R5 are as described above in the Summary of the Invention for compounds of formula (la), as isolated stereoisomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or N-oxides, and methods to 25 make compounds of formula (Ib); 74 WO 2008/083354 PCT/US2007/089153 R-3 N-N RRD N (Ib) where R', R 2 : R 3 , R 4 and R 5 are as described above in the Summary of the Invention for compounds of formula (Ib), as isolated stereoisomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or N-oxides. It is 5 understood that in the following Reaction Schemes, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds. It will also be appreciated by those skilled in the art that in the processes described below the functional groups of intermediate compounds may need to be 10 protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkysily! or diarylalkylsilyl (for example, t-butyldimethylsilyl, t-butyldiphenysilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include benzyl, t-butoxycarbonyl, benzyloxycarbonyl, and the like. 15 Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or arylaikyl), p-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acids include alkyl, aryl or arylalkyl esters. Protecting groups may be added or removed in accordance with standard techniques, which are known to one of ordinary skill in the art and as described herein, 20 The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wuts, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley. As one of skill in the art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin. It will also be appreciated by those skilled in the art, although such protected 25 derivatives of compounds of this invention may not possess pharmacological activity as such, they may be administered to a mammal and thereafter metabolized in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds of this invention are included within the scope of the invention. 30 It is understood that one of ordinary skill in the art would be able to make the compounds of the invention by methods simliar to the methods described herein or by 75 WO 2008/083354 PCT/US2007/089153 methods known to one of ordinary skill in the art. It is also understood that one of ordinary skill in the art would be able to make in a similar manner as described below other compounds of formula (1) not specifically illustrated below by using the appropriate starting components and modifying the parameters of the synthesis as needed. In 5 general, starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TC, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, for example, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described in this invention. 1 H NMR spectra were 10 recorded in CDCI 3 , DMSO-d5, CD 3 OD, Acetone-d with trimethylsilane (TMS) as internal reference using Gemini 300 MHz instrument. Reagents and solvents were purchased from commercial sources and used without further purification. Flash column chromatography was conducted using silica gel (230-4.00 mesh) under a positive pressure of nitrogen. LCMS spectra for purity and mass were recorded using Waters 15 LCMS instruments. Deionized water was used to dilute the reactions and wash the products. Brine used was prepared by dissolving sodium chloride into deionized water to saturation point. Compounds of formula (1a), as set forth below in Reaction Scheme 1 below, where R', R 2 and R 3 are as defined above in the Summary of the Invention for 20 compounds of formula (1) and R 4 and R' are hydrogen, are generally prepared as illustrated below in Reaction Scheme 1 where R, R 2 and R 3 are as defined above in the Summary of the Invention for compounds of formula (1): REACTION SCHEME 1 -CN R 2 -N(R-)H NCN NNR3 R N(,)HR 3

-NHNH

2 - RiNA.K PhO OPh (B) R'N OPh D N NH 2 (A)

R

2 ()(C) (la) 25 Compounds of formula (A), formula (B) and formula (D) are commercially available or can be prepared by methods known to one skilled in the art or by methods disclosed herein. in general, compounds of formula (la) are prepared, as set forth by Reaction Scheme 1, by first treating a compound of formula (A) (1.1 equiv) with an equivalent 30 amount of an aniline of formula (B) in an polar solvent, including, but not limited to, isopropyl alcohol, at ambient temperatures overnight. The diarylisourea product of 76 WO 2008/083354 PCT/US2007/089153 formula (C) generally precipitates and isolation can be accomplished via filtration, washing with an appropriate solvent, and drying. Hydrazine hydrate of formula (D) (2 equivalents) is added to a slurry of the compound of formula (C) in an alcohol or other appropriate solvent. Generally, the ring formation reaction occurs at ambient 5 temperature and the product triazole of formula (1a) can be isolated by standard isolation techniques. Compounds of formula (la) can be subsequently treated with an appropriately substituted alkylating or acylating agent under standard conditions to form compounds of formula (la) where R 4 and R 5 are as described above in the Summary of the Invention for compounds of formula (1). 10 Compounds of formula (lb) can be prepared using the synthetic route outlined in Reaction Scheme 1 in varying amounts depending on the steric and electronic nature of

R

1 , R 2 and R 3 as well as the particular reaction conditions employed. In some instances, compounds of formula (ib) are isolated as minor isomers along with compounds of formula (la) as major isomers, e.g., during column chromatography as described herein. 15 All compounds of the invention which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one of ordinary skill in the art. Salts of the compounds of the invention can be converted to their free base or acid form by standard techniques known to one skilled in the art. 20 The following specific Synthetic Examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention. The number following each compound below refers to its number in Table 1 and Table 2, as discussed in more detail below. 77 WO 2008/083354 PCT/US2007/089153 SYNTHETIC EXAMPLE 1 Synthesis of 1-(isoquinolin-1-yl)W-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-y)-1H 1,2,4-triazole-3,5-diamine N'CN PhO OPh N NO 2 N NH2 .N \ N N' N~ N) N-N H N N N N H 2 H 5 A. _Synthe-sis oEf amino-2-[ j y y xazole N\ N

NH

2 To a solution of 5-nitro-2-[(pyrrolidin-1-yl)methylbenzoxazole (300 mg, 1.21 mmol) in a mixed solvent of EtOAc-MeOH (1:1, 70 mL) was added 10% Pd-C (40 mg), the flask was purged with argon, then the argon was replaced with H 2 , the reaction 10 mixture was stirred under H 2 atmosphere for 30 min. After filtration through Celite, washed with ethyl acetate. The solvents were evaporated to provide 263 mg (100%) of 5-amino-2-[(pyrrolidin-1-yl)methyl]benzoxazole as a yellow solid. B thesis of(Z-ohenv N'-cvano-N-(2-(pyrrolidin-1-Ilmethyl)benzodloxazol-5 VI)carbamimidate 15 A solution of 5-amino-2-[(pyrrolidin-1-.yl)methyl]benzoxazole (200 mg, 0.92 mmol) and diphenylcyanocarbonimidate (263 mg, 1.10 mmol) in isopropyl alcohol (3.5 mL) was stirred overnight at ambient temperature, the resulting white solid product, (Z)-phenyl N' cyano-N-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)carbamimidate, was filtered and used directly for the next step (290 mg, 87%). 78 WO 2008/083354 PCT/US2007/089153 C. Synthesis of 1-(isoguinolin-1-v)-N-(2-(pyrrolidin-1-vimeth ylbenzo[dloxazol-5-vI) 1 H-1 24-triazole-3,5-diamine A solution of (Z)-phenyl N'-cyano-N-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5 yl)carbamimidate (36 mg, 0.1 mmoi) and 1-hydrazinoisoquinoline in N-methyl-2 5 pyrrolldone (0.5 mL) was shaken at 100 *C for 3 hours. After cooling to ambient temperature, the volatiles were evaporated under reduced pressure. The residue was purified by HPLC eluding with acetonitrile - water to provide 1 -(isoquinolin-I -yl)-N13-(2 (pyrrolidin-1 -ylmethyl)benzo[d]oxazo-5-y)-1 H-1,2,4-triazole-3,5-diamine, compound #1; 'H NMR (CD 3 0D, 300 MHz) 8.98 (d, J = 8.4 Hz, 1 H), 8.36 (d, J = 5.7 Hz, I H). 7.99 (d, J 10 = 8.1 Hz, IH), 7.84-7.58 (m, 4H), 7.26 (dd, J = 2.4, 8.7 Hz, 1H), 6.99 (d, J = 9.0 Hz, 1H), 5.05 (s, 2H), 3.76 (m, 2H), 3.65 (m, 2H), 3.30 (m, 3H), 2.11 (m, 4H) ppm; MS (ES) 427.16 (M+H). SYNTHETIC EXAMPLE 2 In a similar manner as described above utilizing the appropriately substituted 15 starting materials and reagents, the following compounds of formula (la) were prepared: 1-(6-chloroquinazolin-4-yl)-N-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)-1 H-1,2,4 triazole-3,5-diamine, compound #2, MS (ES) 462.08 (M+H); N3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-phenyl-1 H-1,2,4-triazole-3,5-diamine, compound #3, tan solid; 1 H NMR (DMSO-d, 300 MHz) 8.65 (s, 1H), 7.57 (d, 2H), 20 7.55 (t, 2H), 7.30-7.22 (m, 2H), 6.93 (d, 1H), 6.68 (s, 2H), 4.19-4.14 (m, 4H) ppm; MS (ES) 310.2 (M+H); N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(isoquinolin-1-yl)-1 1-1-1,2,4-triazole-3,5 diamine, compound #4, yellow solid; MS (ES) 361.64 (M+H); N3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(6,7-diiethoxyquinazolin-4-yI)-1 H-1,2,4 25 triazole-3,5-diamine, compound #5, yellow solid; MS (ES) 422.05 (M+H). 1-(6,7-dimethoxyquinazoline-4-y)-N3-(6-(4-(bicyclo(2.2.1]heptan-2-yl)piperazin-1 yl)pyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #6, 1 H NMR (DMSO-d 3 , 300 MHz) 9. 13 (d, 2H), 9.10-9.00 (in 1 H), 8.80 (s, 1 H), 8.71 (s, I H), 8.20 (s, 1 H), 7.79 (d, 1H), 7.39 (s, 1H), 6.98 (d, 1H), 4.21-4.18 (m, 2H), 4.01-3.95 (m, 4H), 30 3.59-3.42 (m, 3H), 3.20-3.03 (m, 4H), 2.62-2.37 (m, 4H), 2.30 (s, I H), 2.04-1.98 (m, 1 H), 1.63-1.57 (m, 3H), 1.40 (s, 2H), 1.21 (d, 1 H) ppm; MS (ES) 543.44 (M+H); 79 WO 2008/083354 PCT/US2007/089153 1 -(isoquinolin-1 -yl)-N3-(6-(4-(bicyclo[2.2. I ]heptan-2-yi)piperazin-1 -yl)pyridin-3-yl)-1 H 1,2,4-triazole-3,5-diamirie, compound #7, "H NMR (DMSO-d 6 , 300 MHz) 9.23 (d, 1H), 8.80 (s, 1H), 8.39 (s, 1H), 8.31 (d, 1H), 8.10 (s, 1H), 8.00 (d, IH), 7.83-7.66 (m, 4H), 7.40 (s, 1H), 6.79 (d, 2H), 2.53-2.41 (m, 8H), 2,31 (s, 2H), 2.16 (s, 1H). 5 1.80-1.63 (m, 2H), 1.50-1.17 (m, 5H), 0.89 (d, 1H) ppm; MS (ES) 48223 (M+H); 1-(6,7-dimethoxyquinazoline-4-y)-N-(6-(4-(4-methylpiperazin-1 -yl)piperidin-1 -yl)pyridin 3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #8, 'H NMR (DMSO-d 6 , 300 MHz) 9.21 (s, 1H), 8.98 (s, 1H), 8.78 (s, 1H), 8.60 (d, 1H), 8.21 (s, 1H), 8.14 (s. 1H), 7.68 (d, 1H), 7.33 (s, 1H), 6.79 (d, 1H), 4.17 (d, 2H), 3.97 (d, 4H), 2.78-2.63 (m, 10 2H), 2.58-2.23 (m, 1OH), 2.20 (s, 2H), 1.80 (d, 2H), 1.41-1.37 (m, 2H) ppm; MS (ES) 546.26 (M+H); 1 -(6,7-dimethoxyquinazoline-4-yi)-W-(4,5-dihydro-1 H-benzo[b]azepin-2(3H)-on-8-yl)-1 H 1,2,4-triazoie-3,5-di!amine, compound #9, 1 H NMR (DMSO-d 6 , 300 MHz) 9.47 (s, IH), 9.34 (s, 1H), 9.04 (s, IH), 8.80 (s, 1H), 8.14 (br s, 2H), 7.43 (m, 1H), 7.36 (s, 15 1H), 7.20 (s, 1H), 7.08 (m, 1H), 3.98 (s, 3H), 3.90 (s, 3H), 2.59 (m, 2H), 2,13 (m, 2H), 2.05 (m, 2H) ppm; MS (ES) 447.1 (M+H); 1-(2-chloro-7-methylthieno[3,2-dpyrimidine-4-y)-N 3 -(6-(4-cyclopentyl-1,4-diazepan-1 yl)pyridin-3-yl)-1 H-1,2,4-triazoie-3,5-diamine, compound #10, 1 H NMR (DMSO-d 6 , 300 MHz) 9.48 (s, I H), 8.45 (m, 1 H), 8.21 (m, I H), 8.04 (m, 1 H), 7.98 (br s, 2H), 20 7.05 (m, 1H), 4.21 (m, 1H), 3.65 (m, 6H), 3.20 (m, 2H), 2.37 (s, 3H), 2.18 (m, 2H), 1.98 (m, 2H), 1.60 (m, 6H) ppm; MS (ES) 525.1 (M+H); 1-(6,7-dimethoxyq uinazoline-4-y)-N-(6-(4-cyclopentyl-1,4-diazepan-1 -yl)pyridin-3-yl) 1 H-1,2,4-triazole-3,5-diamine; compound #11, "H NMR (DMSO-d 6 , 300 MHz) 9.22 (s, 11H), 9.00 (m, 1H), 8.81 (s, 1H), 8.59 (m, 1H), 8.17 (br s, 2H), 7.82 (m, 25 1H), 7.37 (s, 1H), 6.90 (m, 1H), 4.12 (m, 1H), 3.99 (s, 3H), 3.96 (s, 3H), 3.58 (m, 6H), 3.17 (in, 2H), 2.17 (m, 2H), 1.99 (m, 2H),1.60 (m, 6H) ppm; MS (ES) 531.2 (M+H); 1-(2-chloro-7-rnethylthieno[3,2-d]pyrimidine-4-y!)-W-(7-cyclopentyl-6,7,8,9-tetrahydro 5H-pyrido[3,2-d]azepin-3-y)-1H-1,2,4-triazole-3,5-diamine, compound #12, 1H 30 NMR (DMSO-de, 300 MHz) 9.58 (s, 1H), 8.55 (s, 1H), 8.26 (s, 1H), 8.14 (m, IH), 7.97 (br s, 2H), 3.10 (m, 3H), 3.00 (m, 3H), 2.68 (Im, 1H), 2.36 (s, 3H), 1.85 (m, 2H), 1.60 (m, 4H), 1.38 (m, 4H) ppm; MS (ES) 496.2 (M+H); 1-(6,7-dimethoxyquinazoline-4-yl)-N 3 -(7-cyclopentyl-6,7,8,9-tetrahydro-5H-pyrido[3,2 dlazepin-3-y)-1 H-1,2,4-triazole-3,5-diamine, compound #13, 1 H NMR (DMSO-d 6 , 35 300 MHz) 9.73 (s, IH), 9.13 (s, 1H), 8.97 (s, 1H), 8.84 (m, 1H), 8.20 (br s, 2H), 80 WO 2008/083354 PCT/US2007/089153 7.77 (s, IH), 7.38 (s, 1H), 4.52 (m, 2H), 3.99 (s, 3H), 3,95 (s, 3H), 3.52 (m, 3H), 3.16 (m, 2H), 1.97 (m, 4H), 1.60 (m, 6H) ppm; MS (ES) 502.2 (M+H); 1-(2-chiloro-7-methylthieno[3,2-d]pyrimidine-4-y)-N 3 -(6-methyl-5,6,7,8-tetrahydro-1,6 naphthyridin-3-y)-1H-1,2,4-triazole-3,5-diamine, compound #14, lH NMR 5 (DMSO-de, 300 MHz) 9.57 (s, 1 H), 8.62 (s, 1 H), 829 (s, 1 H), 7.95 (br s, 2H), 7.80 (s, 1H), 3.55 (s, 2H), 2.82 (s, 2H), 2.69 (d, 2H), 2.37 (d, 6H) ppm; MS (ES) 428.05 (M+); I-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-N-(6-(4-methylpiperazin.-1-y!)pyridin-3 yi)-1H-1,2,4-triazole-3,5-diamine, compound #15, 'H NMR (DMSO-de, 300 MHz) 10 9.24 (d, IH), 8.47 (m, 1H), 8.23 (d, IH), 7.92 (m, 3H), 6.88 (m, 1H), 3.39 (m, 4H), 2.43-2.36 (m, 7H), 2.23 (m, 3H) ppm; MS (ES) 457.04 (M+); 1 -(isoquinolin-1 -yl)-N 3 -(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yi)-1 H-1,2,4 triazole-3,5-diamine, compound #16, 'H NMR (DMSO-de, 300 MHz) 9.26 (m, 2H), 8.48 (s, 1H), 8.31 (d, 1H), 8.01 (d, 1H), 7.82 (t, 1H), 7.70 (m, 3H), 7.48 (s, 15 2H), 3.47 (s, 2H), 2.79 (d, 2H), 2.67 (d, 2H), 2.34 (s, 3H) ppm; MS (ES) 373.45 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-N-(6-(4-(pyrrolidin-1-yl)piperidin-1 yi)pyridine-3-yI)-1H-1,2,4-triazole-3,5-diamine, compound #17, 'H NMR (DMSO da, 300 MHz) 9.20 (s, IH), 8.44 (s, 1H), 8.23 (s, 1H), 7.92 (m, 3H), 6,87 (d, 1H), 20 4.05 (s, 2H), 2.92-2.78 (n, 4H), 2.42 (s, 3H), 2.15 (m, 1H),1.88 (s, 4H), 1.66 (s, 4H), 1.40 (m, 2H) ppm; MS (ES) 511,01 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-N 3 -(6-benzyl-5,6,7,8-tetrahydro-1,6 naphthyridin-3-y)-1H-1,2,4-triazole-3,5-diamine, compound #18, lH NMR (DMSO-d, 300 MHz) 9.59 (s, IH), 8.60 (s, 1H), 8.08 (s, 1H), 7.95 (br s, 2H), 25 7.81 (s, 1H), 7.35 (m, 5H), 3.70 (s, 2H), 2,60 (s, 2H), 2.79 (m, 4H), 2.37 (s, 3H) ppm; MS (ES) 503.90 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N3-(6-(ethylcarboxy)-5,6,7,8-tetrahydro 1,6-naphthyridiin-3-yI)-1H-1,2,4-triazole-3,5-diaminie, compound #19, 'H NMR (DMSO-d 6 , 300 MHz) 9.58 (s, 1 H), 8.65 (d, 1 H), 8,26 (s, 1 H), 7.97 (s, 2H), 7.82 30 (d, IH), 4,11 (m, 2H), 2.98 (d, 2H), 2.81 (m, 3H), 2.37 (m, 3H), 2.13 (m, 1H), 1.89 (m, 1H), 1.21 (m, 3H) ppm; MS (ES) 485.36 (M+); 1-(2-chloro-7-rnethylthieno[3,2-d]pyrimidine-4-y)-N 3 -(6-(pyrrolidin-1 ylcarbonyl)-5,6,7,8 tetrahydroquinolin-3-y)-1H-1,2,4-triazole-3,5-diamine, compound #20, H NMR (DMSO-d 6 , 300 MHz) 9.52 (s, 1H), 8.66 (d, 1H), 8.26 (s, 1H), 7.96 (s, 2H), 7.77 81 WO 2008/083354 PCT/US2007/089153 (d, 1H), 3.52 (m, 2H), 2.84 (m, 4H), 2.36 (m, 3H), 1 91 (m, 1H), 1.88 (Im, 2H), 1.78 (m, 4H), 1.22 (s, 2H) ppm; MS (ES) 510.39 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-,N(6-(dimethylaminomethylcarbonyl) 5,6,7,8-tetrahydro-1 6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine, 5 compound # 21, 'H NMR (DMSO-d 6 , 300 MHz) 9.68 (d, I H), 8.70 (d, 1 H), 8.26 (s, 1H), 7.98 (br s, 2H), 7.90 (d,1H), 4.83 (s, 1H), 4.69 (s, 1H), 3.80 (m. 2H), 2.90 (t, 2H), 2.79 (t, 2H), 2.37 (s, 3H), 2.26 (d, 6H) ppm; MS (ES) 499.13 (M+H); 1-(2-chloro-7-nethylthieno[3,2-d]pyrimidine-4-yl)-N 2 -(6-(dimethylaminomethylcarbonyl) 5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine formic acid 10 salt (formic acid salt of compound #21); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N-(6-(4-(4-methylpiperazin-1 yl)piperidin-I -yl)pyridine-3-yi)-1 H- 1,2,4-triazole-3,5-diamine, compound #22, 'H NMR (DMSO-d 6 , 300 MHz) 9.20 (s, 1H), 8.44 (d, 1H), 823 (s, 1H), 8.17 (s, 1H), 7.92 (s,2H), 7.88 (d, 1 H), 6.86 (d, 1H), 4.18 (d, 2H), 2.70 (t, 2H), 2,37 (s, 3H), 15 2.30 (m, 9H), 2.12 (s, 3H), 1.82 (d, 2H), 1.38 (in, 2H) ppm; MS (ES) 540.15 (M+); 1-(6,7-dimethoxyquinazoline-4-y)-N3-(6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridine-3-y)-1H 1,2,4-triazoie-3,5-diamine, compound #23, 1 H NMR (DMSO-de, 300 MHz) 9.11 (s, 1H), 8.96 (s, 1H), 8.74 (s, 1H), 8.59 (d, 1H), 8.18 (s, 2H), 7.65 (d, 1H), 7.31 (s, 1H), 6.78 (d, IH), 4.02(d, 2H), 3.95 (d, 6H), 2.77 (m, 2H), 2.13 (m, 2H), 1.86 (m, 20 3H), 1.64 (s, 5H), 1.37 (m, 3H) ppm; MS (ES) 516.75 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yi)-N 3 -(6-(4-(bicyclo[2.2.1 ]heptan-2 yl)piperazin-1 -yl)pyridin-3-y)-1 H- 1,2,4-triazole-3,5-diamine, compound #24, 1H NMR (DMSO-dr, 300 MHz) 9.23 (s, IH), 8.44 (d, 1H), 8.22 (s, 1H), 7.92 (m, 3H), 6.64 (d.1H), 4.23 (m, 2H), 3.15 (m, 4H), 2.59 (m, 1H), 2.37 (s, 3H), 2.29 (s, 1H), 25 1.98 (m, 1H), 1.58 (m, 4H), 1.39 (s, 4H), 1.22 (d, 2H) ppm; MS (ES) 537.13 (M+); 1-(2-chioro-7-methylthieno[3,2-d]pyrimidine-4-y)-N 3 -(5,6,7,8-tetrahydro-1,6-naphthyrdin 3-yl)-IH-1,2,4-triazole-3,5-diamine, compound #25, 1H NMR (DMSO-.d 6 , 300 MHz) 9.84 (s, 1 H), 9.06 (s, 2H), 8.82 (s, 1 H), 8.23 (s, 1 H), 8.00 (s, 2H), 7.89 (s, 1H), 4.40 (s. 2H), 3.49 (s, 2H), 3,04 (t, 2H), 2,38 (s, 3H), ppm; MS (ES) 413.77 30 M+); 1-(6,7-dimethoxyquinazoline-4-yl)-N-(6-(4-piperidin-1 -ylpiperidin-1 -yl)pyrldine-3-y)-1 H 1,2,4-triazole-3,5-diamine, compound #27, 'H NMR (DMSO-d 6 , 300 MHz) 9.12 (s, 1H), 8.97 (s, 1H), 8,75 (s, 1H), 8.60 (s, 1H), 8.19 (s,2H), 7.65 (d,1H), 7.32 (s, 1H), 6.78 (d, IH), 4.17 (d, 2H), 3.97 (d, 6H), 2.66 (t, 3H), 2.42 (d, 4H), 2.75 (d, 35 2H), 1.46 (s, 6H), 1.38 (d, 2H) ppm; MS (ES) 531.50 (M+H); 82 WO 2008/083354 PCT/US2007/089153 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yi)-N-(6-(4-piperidin-I -ylpiperidin-l yi)pyridine-3-yi)-1H-1,2,4-triazole-3,5-diamine, compound # 28, 1H NMR (DMSO de, 300 MHz) 9.20 (s, 1H), 8.43 (s, 1H), 8.23 (s,1H), 7.91 (s, 2H), 7,88 (d, 1H), 6.85 (d, 1H), 4.20 (d, 2H), 2.67 (t, 3H), 2.43 (s, 4H), 2.37 (s, 3H), 1.76 (d, 2H). 5 1.45-1.37 (m, 8H) ppm; MS (ES) 525.11 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N'-(6-(2-(dirnethylamino)- 1 oxyethylamino)-5,6,7,8-tetrahydroquinolin-3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #29, 1H NMR (DMSO-d6, 300 MHz) 10.33 (s, 1H), 9.63 (s. 1H), 8.84 (s, 1H), 8.65 (d, 1H), 8.25 (s, 1H), 8.10 (d,2H), 4.20 (s, 2H), 3.87 (m, 2H), 3.22 (d, 10 1H), 3.07 (t, 2H), 2.80 (s, 6H), 2.40 (s, 3H), 2.04 (m, IH), 1.92 (m, 1H) ppm; MS (ES) 513.17 (M+); 1 -(2-chloro-7-methyithieno[3,2-djpyrimidin-4-yl)-N 3 -(6-amino-5,6,7,8-tetrahydroquinolin 3-yi)-1 H-1I,2,4-triazole-3,5-diamine, compound #30, 1 H NMR (DMSO-ds, 300 MHz) 9.98 (s, 1 H), 8.82 (s, 1 H), 8.23 (s, 1 H), 8.06 (d, 5H), 3.60 (s, 2H), 3.25 (d, 15 1H), 2.99 (d, 2H), 2.38 (s, 3H),2.10 (m, 1H), 1.95 (m, 1H) ppm; MS (ES) 428.09 (M+); I -(isoquinolin-1 -yI)-N 3 -(6-(4-methylpiperazin-1 -yl)pyridin-3-yi)-1 H-1,2,4-triazole-3,5 diamine, compound #31, 1 H NMR (DMSO-d6, 300 MHz) 9.24 (d, 1 H), 8.86 (br s, IH), 8.37 (d, 1H), 8.29 (d, 1H), 8.01 (d, 1H), 7.83-7.79 (m, 2H), 7.74-7.67 (m, 20 2H), 7.40 (br s, 2H), 6.80 (d, IH), 3.30 (m, 4H), 2.45 (m, 4H), 2.25 (s, 3H) ppm; MS (ES) 402.28 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrim idin-4-yl)-N 3 -(1 H-pyrrolo[2,3-b]pyridin-5-y)-1 H 1,2,4-triazole-3,5-diamine, compound #32, 'H NMR (CDaOD-CDC 3 , 300 MHz) 8.50 (m, 1 H), 8.29 (m, 1 H), 7.91 (m, 1 H), 7.68 (s, 1 H), 7.31 (m, I H), 6.44 (In, 1 H), 25 2.65 (m, 2H), 2.43 (s, 3H); MS (ES) 397.95 (M+H); 1-(2-chloro-7-methylthieno[3,2-dlpyrim idin-4-yl)-NP-(6-(4-(pyrrolidin-1 -ylmethyl)piperidin I -yl)pyridin-3-yl)-1 H-1 2,4-triazole-3,5-diamine, compound #33, 'H NMR (CD 3 0D, 300 MHz) 8.67 (s, IH), 7.98 (m, 2H), 7.42 (m, 1H), 4.23 (d, 2H), 3.73 (br s, 2H), 3.18 (m, 4H), 2.43 (s, 3H), 2.19 (m, 6H), 1.50 (m, 2H); MS (ES) 525.09 (M+H); 30 1-(6,7-dimethoxyquinazoline-4-yl)-N-(6-(4-(pyrrolidin-1 -ylmethyl)piperidin-1 -yl)pyridin-3 yi)-1H-1,2,4-triazole-3,5-diamine, compound #34, 'H NMR (CD 3 0D, 300 MHz) 8.98 (s, 1H), 8.84 (s, 1H), 8.50 (m, IH), 8.12 (I, 1H), 7.38 (m, 2H), 4.16 (m, 2H), 4.07 (s, 3H), 3.97 (s, 3H), 3.73 (m, 2H), 3.17 (i, 4H), 2.65 (m, 1H), 2.19 (m, 4H), 2.04 (m, 4H), 1.46 (m, 2H); MS (ES) 531.19 (M+H); 83 WO 2008/083354 PCT/US2007/089153 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N-(6-(4-(azepan-1 -yl)piperidin-1 yl)pyridin-3-yI)-1H-1,2,4.-triazole-3,5-diamine, compound #35, 'H NMR (CD 3 OD, 300 MHz) 8.57 (s, IH), 8.39 (s, 1H), 7.98 (m, 1H), 6.94 (In 1H), 4.38 (m, 1H), 3.53 (m, 2H), 2.93 (t, 2H), 2.43 (s, 3H), 2.20-1,60 (m, 16H); MS (ES) 539.07 5 ( M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N-(6 (diethylaminoethylmethylamino)pyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine, compound #36, 1 H NMR (CD 3 OD, 300 MHz) 8.75 (s, 1H), 8.47 (s, 1H), 8.00 (m, 1H), 6.92 (m, IH), 3.93 (m, 4H), 3.42 (m, 4H), 3.08 (s, 3H), 2.41 (s, 3H), 1.36 (m, 10 6H); MS (ES) 487.07 (M+H): 1-(6,7-dirmethoxyquinazoline-4-y)-N3-(6-(diethylaniinoethylmethylamino)pyridin-3-y)- H 1,2,4-triazole-3,5-diamine, compound #37, 1 H NMR (CD 3 OD, 300 MHz) 9.10 (s. 1 H), 8.75 (s, 1 H), 8.46 (s, 1 H), 8.40 (s, 1 H), 7.28 (m, 1 H), 6.79 (m, 1 H), 4.04 (s, 3H), 3.97 (s, 3H), 3.85 (m, 4H), 3.40 (m, 4H), 3.08 (s, 3H), 1.31 (m, 6H); MS (ES) 15 493.37 (M+H); 1-(2-chloro-7-rnethylthieno[3,2-d]pyrinidin-4-y)-N 3 -(6-(2-diethylaminomethylpyrrolidin-1 yl)pyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #38; lH NMR (CD 3 0D CDCl 3 , 300 MHz) 8.42 (m, 3H), 7.96 (m, 2H), 7.82 (m, 2H), 7.17 (m, 1H), 6.78 (m, 2H), 4.38 (m, 2H), 3.62 (m, 2H), 2.68-1.21 (m, 13H); MS (ES) 515.08 (M+H); 20 1-(6,7-dimethoxyquinazoline-4-y)-N-(6-(2-diethylaminomehylpyrrolidin-1 -yl)pyridin-3 yl)-1 H-1,2,4-triazole-3,5-diamine, compound #39: "H NMR (CD 3 OD, 300 MHz) 9.03 (s, 1H), 8.74 (s. 1H), 8.35 (s, 2H), 8.06 (m, 2H), 7.27 (s, 1H), 6.82 (m, 2H), 4.38 (Im, 2H), 4.03 (s, 3H), 3.90 (s, 3H), 3.60 (m, 2H), 2.40-1.80 (m, 4H), 1.30 (m, 6H); MS (ES) 519.18 (M+H); 25 1-(6,7-dimethoxyquinazoline-4-yl)-N-(2-(1-(4-(2-(dimethylamino)ethy)piperazin-1 yl)oxonethyl)benzo[b]thiophen-5-y)-1H-1,2,4-triazole-3,5-diamine, compound #40; 'H NMR (CDOD, 300 MHz) 9.09 (n, 1H), 8.72 (m, 1H), 8.39 (s, 2H), 8.11 (s, 1H), 7.73 (m, 1H), 7.61 (n, 1H), 7.47 (m, 1H), 7.21 (s, 1H), 4.00-3.84 (m, 6H), 3.54 (m, IH), 3.30 (s, 3H), 2.91 (s, 3H), 2.77 (m, 1H), 2.65 (m, 4H), 1.33 (m, 1H); 30 MS (ES) 603.14 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yi)-5 methylpyridin.-3--yI)-iH-1,2,4-triazole-3,5-diamine, compound #41; 1 H-NMR (DMSO-d 6 , 300 MHz) 9.50 (s, 1H), 8.40 (s. 1H), 8.27 (s, 1H), 7.97 (br. s, 3H), 3.55 (m, 2H), 3.41-3.37 (m, 2H), 3.26 (n, 1H), 3.13-3.09 (m, 2H), 2.75 (t, 2H), 84 WO 2008/083354 PCT/US2007/089153 2.38 (s, 3H), 2.30 (s, 3H), 2.15-2 11 (m, 2H), 2.02 (m, 2H), 1.86-1.73 (m, 4H) ppm; MS (ES) 525.20 (M); 1-(6,7-dimethoxyqui nazoline-4-yi)-N3-(6-(4-(pyrrolidin-1-yl)pipend rin-1-yI)-5-methylpyridin 3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #42; 'H-NMR (DMSO-d 6 , 300 MHz) 9.29 (br. s, 1H), 9.07 (s. 1H), 8.79 (s, 1H), 8.73 (s, 1H), 8.19 (br. s, 2H), 7.52 (s, 1 H), 7.36 (s, 1 H), 3.99 (s, 3H), 3.96 (s, 3H), 3.55 (m, 2H), 3.39-3.35 (m, 2H), 3,26 (m, 1H), 3.13-3.09 (m, 2H), 2.72 (t, 2H), 2.22 (s, 3H), 2.14-2.11 (m, 2H), 2.02 (m, 2H), 1.86-1.72 (m, 4H) ppm; MS (ES) 531.20 (M+H); 1 -(phenanthridin-6-y)-N 3 -(6-(4-(pyrrolidin-1 -yI)piperidin-1 -yi)-5-methyIpyridin-3-y)-1 H 10 1,2,4-triazole-3,5-diamine; compound #43; 'H-NMR (DMSO-de, 300 MHz) 9.26 (s, 1H), 9.23 (br. s, IH), 8.92 (d, J = 8.1 Hz, 1H), 8,79 (d, J = 7.2 Hz, 1H), 8.35 (s, 1H), 8.09 (d, J = 72 Hz, 1H), 800 (t, J = 7.2 Hz 1H), 7.87 (s, 1H), 7.83-7.71 (m, 3H), 7.46 (br. s, 2H), 3.55 (m, 2H), 3.39-3.35 (m, 2H), 3.25 (m, 1H), 3.11-3.08 (m, 2H), 2.78-2.70 (m, 2H), 2.24 (s, 3H), 2.12-2.10 (m, 2H), 2.01 (m, 2H), 1.85-1.71 15 (m, 4H) ppm; MS (ES) 520.27 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-W-(6-(3-diethylaminopyrrolidin-1 yl)pyridin-3-yi)-1H-1,2,4-triazole-3,5-diamine, compound #44; 1-(6,7-dimethoxyquinazoline-4-yl)-N(6-(3-diethylaminopyrrolidin-1 -yl)pyridin-3-yl)-1 H 1,2,4-triazole-3,5-diamine, compound #45; 20 1-(2-chloro-7-methylthieno[3,2-d]pyrimdin-4-y!)-N-(6-(4-(bcyclo[2.2.1 )heptan-2-yl)-1,4 diazepan-1-yl)pyridin-3-yI)-1H-1,2,4-triazole-3,5-diamine, compound #46; H NMR (DMSO-d 6 , 300 MHz) 9.54 (s, 1H), 8.45 (m, 1H), 8.18 (m, 1H), 8.02 (m, 3H), 7.08 (m, 1H), 3.55 (m, 6H), 3.14 (m, 2H), 2.55 (m, 2H), 2.35 (s, 3H), 2.24 (m, 3H), 1.98 (m, 1H), 1.54 (m, 3H), 1.37 (m, 3H), 1.22 (m, 1H) ppm; MS (ES) 551.1 (M+H); 25 1-(6,7-dimethoxyquinazoline-4-y)-N 3 -(6-(4-(bicyclo[2.2. 1 ]heptan-2-yl)-1,4-diazepan-1 yl)pyridin-3-yl)-l H-1,2,4-triazole-3,5-diamine, compound #47; 1 H NMR (DMSO-d 6 , 300 MHz) 9.08 (s, 1 H), 8.79 (im, 1 H), 8.64 (m, 2H), 8.20 (m, 2H), 8.02 (m, I H), 7.76 (m, 1H), 7.37 (n, IH), 3.97 (s, 3H), 3.86 (s, 3H), 3.53 (m, 1H), 3.09 (m, 2H), 2.24 (m, 4H), 1.94 (m, 4H), 1.58-1.28 (im, 12H) ppm: MS (ES) 557.2 (M+H); 30 1-(2-chloro-7-nethylthieno[3,2-d]pyrimidin-4-yi)-N 3 -(6-(4-cyclopropylmethylpiperazin-1 yI)pyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #48; 1 H NMR (DMSO-de, 300 MHz) 9.40 (s, 1H), 8.52 (m, 1H), 8.22 (m, 1H), 7.99 (m, 3H), 7.04 (m, 1H), 4.29 (m, 2H), 3.63 (m, 21-1), 3.09 (m, 6H), 2.35 (s, 3H), 1.08 (m, IH), 0.65 (m, 2H), 0.37 (m, 2H) ppm; MS (ES) 497.1 (M+H); 85 WO 2008/083354 PCT/US2007/089153 1-(5-trifluoromethylpyridin-2-yi)-N 3 -(6-(4-cyclopropylrmethylpiperazin-1 -yl)pyridin-3-yi)-1 H 1,2,4-triazole-3,5-diamine, compound #49; lH NMR (DMSO-d 6 , 300 MHz) 9.32 (s, 1H), 8.74 (s, 1H), 8.59 (m, 1H), 8.27 (m, 1H), 7.87 (m, 4H), 7.12 (m, 1H), 4.24 (m, 2H), 3.62 (m, 2H), 3.16 (m, 6H), 1.06 (m, 1H), 0.64 (m, 2H), 0.36 (m, 2H) ppm; 5 MS (ES) 460.6 (M+H); 1-(2-chioro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N 3 -(6-(2-dimethyiam i noethyl)- 5,6,7,8 tetrahydro-1,6--naphthyridin-3-yl)- 1H-1,2,4-triazole-3,5-diamine, compound #50; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-N 3 -(6-(I-methylpiperidin-4-yiamino) 5,6,7,8-tetrahydroquinolin-3-yi)-1 H-1,2,4-triazole-3,5-diamine, compound # 51; 10 1-(2-chioro-7-methylthieno[3,2-d]pyrimidine-4-yi)-N 3 -(6-cyclopentyl-5,6,7,8-tetrahydro 1,6-naphthyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #52; 1-(furo[3,2-c]pyridine-4-yl)-N 3 -(6-(4-(pyrrolidin-1-yl)piperidin-1-yi)-5-methylpyridin-3-yl) 1H-1,2,4-triazole-3,5-diamine, compound #53; 1 H-NMR (DMSO-d 6 , 300 MHz) 9.04 (br. s, 1H), 8.36 (d, J = 2.1 Hz, 1H), 8.25 (d, J = 5.7 Hz, 1H), 8.19 (d, J = 1.8 15 Hz, 1H), 7.89 (br. s, 2H), 7.78-7.76 (m, IH), 7.53-7.50 (m, 2H), 3.26 (m, 4H), 3.22 (m, 4H), 2.67 (m, 4H), 2.42 (m, 1H), 2.25 (s, 3H), 1.73 (m, 4H) ppm; MS (ES) 460.20 (M+H); 1-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-dpyrimidin-4-yI)-NC-(6-(4-(pyrrolidin-1 yl)piperidin-1-yi)-5-methylpyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound 20 #54; 1 H-NMR (DMSO-da, 300 MHz) 8.85 (br. s, 1H), 8.69 (s, 1H), 8.18 (s, 1H), 7.79 (br. s, 2H), 7.73 (s, 1H), 3.05-3.01 (m, 4H), 2.71 (m, 1 H), 2.65 (m, 4H), 2.42 (m, 4H), 2.28-2.25 (m, 2H), 2.20 (s, 3H), 1.96-1.92 (m, 2H), 1.72 (m, 4H), 1.58 1 54 (m, 4H) pprn; MS (ES) 517.15 (M+H); 1-(2-methylquinazoli n-4-yl)-N-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-nethylpyridin-3-yl) 25 1H-1.2,4-triazole-3,5-diamine, compound #55; "H-NMR (DMSO-d 6 , 300 MHz) 9.63 (d, J = 8.4 Hz, 1 H), 9.25 (br. s, 1 H), 8.26 (s, 1 H), 8.20 (s, 1 H), 7.94-7,84 (m, 2H), 7.66-7.61 (m, IH). 3.28 (m, 4H), 3.24 (m, 4H), 2.72 (s, 3H), 2.70 (m, 4H), 2.43 (m, 1H), 2.27 (s, 3H), 1.73 (m, 4H) ppm; MS (ES) 485.18 (M+H), 483.30 (M H); 30 1-(6-f!luoroquinazolin-4-yi)-N 3 -(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin-3-yl) 1 H-1,2,4-triazole-3,5-diamine, compound #56; 1 H-NMR (DMSO-d 6 , 300 MHz) 9.52 (d, J = 9.9 Hz, 1 H), 9.33 (br. s, I H), 8.93 (s, 1 H), 8.37 (br. s, 2H), 8.21 (s, 1 H), 8.04-8.01 (m, 1 H), 7.94 (s, 1 H), 3.28 (m, 4H), 3.24 (m, 4H), 2.68 (m, 4H), 2.56 (m, 1H), 2.28 (m, 4H), 2.28 (s, 3H), 1.73 (m, 4H) ppm; MS (ES) 489.15 35 (M+H), 487.14 (M-H); 86 WO 20081083354 PCT/IJS2007/089153 I -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yI)-NV3-(6-(5-bicyclo[2.2. I ]heptan-2 yloctahyd ropyrrol[3,4-olpyrro!yI'pyridine-3-yi)- I H-i ,2,4-triazole-3,5-diamine, compound #57-, I -(6,7-d imethoxyq uinazoline-4-y)-N 3 -(6-bromopyrid in-3-yI)-5-(3-(6-bromopyr ;d n-3-yUl-2 5 cyanoguanadino)-1 H-i ,2,4-tlriazole-3-amine, compound #58; MS (ES) 666.96 (Mi-H), 664.99 (M-H); I -(6,7-dimnethoxyquinazoline-4-yI)-N 3 -(6-bromopyridin-3-yQ-i H-I 2,4-iriazole-3:5 dianiine, compound #59; 'H NMR (CDC1 3 , 300 MHz) 9.58 (s, 1 H), 9.07 (s, 1 H), 8.81 IS, I H), 8.78 Is, 1 H), 8.32-8.11 (in. 2H), 7.91 (in, 1IH), 7.32 (in, 2H), 3.91 (s, 10 6H) ppm; MS (ES) 444.96 (M+H); I -(2-chloro-7-methylthieno[32^-pyrimidin-4-yI)-N 3 -(7',8'-dihydro-5'H spiro[ ,3]dioxolane-2'-6'-quinoine--3'-yi)-1 H-i ,2,4-triazole-3,5-diamine, compound #60; I -(2-oh oro-7-methylthieno[3, -djjpyrimidin-4-y )-N 3 -(6-( 1 -mnethyl pi perid in-4-ylca rbonyl) 15 5,6,7,8-tetrahydro-1,6-naphthyridin-3-yI)-1 H-I ,2,4-triazole-3,6-diamine, compound #61; I -(6,7-dimethoxyquinazoline-4-yi)-N 3 -(2-(4-pyrrolidin-1 -ylpiperidin-1 -yI)pyrinmid~in-5-yi)-1H I,2,4-triazole-3,5-diamine, compound #62; 1 H NMR (CD 3 OD, 300 MHz) 9.25 (mn, 1 H), 8.42 (mn, 1 H), 8.29 (in, 2H), 7.85 (mn, 1lH), 7.66 (in, 2H), 7.49 Is; 1IH), 4.06 Is, 20 3H), 4.03 (s, 3H), 3.83 (in, 4H), 3.30-2.80 Im, 7H), 2.06 (rm, 4H), 1.85 (rn, 2H); MS (ES) 518.20 (Mi-H); I-(6,7-dimethoxyqu$nazoine-4-yI)-N 3 -(2-(4-piperidin- i -ylmethy piperidin-I -yI)pyrimidin-5 yI')-1 H-I ,2,-triazole-3,5-diamine, compound #63;i H NMR (CD 3 OD, 300 MHz) 8.73 Is, I H), 8.65 (s, I H), 7.96 (s, 1IH), 7.65 (s, 1lH), 7.67 (in, 2H), 7.52 (in, 2H), 25 4.76 (in, 2H", 3.94 (in, 2H), 3.85 Is, 3H), 3.82 Is, 3H), 3.20-2,58 (in, 8H), 2.43 1.88 (in, 5F1), 1.43-1.28 (in, 4H1; MS (ES) 546.23 'M+1-); I 2clr--ehytin[,-~yrmdn4y)N-'-proii- -yI)-4b,5,6,7,7,q,8 hexah yd roper, taleno[2, 1I -b] pyrid in-3-yl)-1I H-I 1,2,4-triazoie-3, 5-d ia m ie, Compound #64; 30 1 -(6,7-dimethoxyquinazoline-4-y)-PA"(6-(3-(4-(4-mehylpiperazin- -yt)piperidin-1 yl)propenyI)pyridin-3-yl)-I H-I .2,4-triazole-3,5-diamine, compound #65; 'H NMR (DMSO-d 6 . 300 MHz) 9.65 Is, IH), 9.04 Is, 1 H), 8.88-8.75 (in, 2H), 8.31-8.14 (in. 3H), 7,94 (d, 1IH), 7.36 (in, 2H), 6.51 (mn, 2H), 3.98 (s, 6H), 2.91 Is, 3H), 2.55-2.10 (in, 12H), 1.73 (in, 2H), 1.41 (in, 3H), 1.23-1.08 (in, 2H) ppm; MS (ES) 586.27 35 (Mi-H), 584.39 (M-H); 87 WO 2008/083354 PCT/US2007/089153 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N-(6-(4-methylpiperazin-1 -yl)- 5

,

6

,

7

,

8 tetrahydroquinolin-3-y)-1H-1,2,4-triazole-3,5-diamine, compound #66; 1-(6,7-dimethoxyquinazoline-4-yl)-N 3 -(6-(3-(4-piperidin-1-ylpiperidin-1 yl)propenyl)pyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #67; 1H NMR 5 (DMSO-d 6 , 300 MHz) 9.66 (s, 1H), 9.04 (s, 1H), 886 (s, 1H), 8.80 (s, 1H), 8.35 8.13 (n, 2H), 7.94 (m, IH), 7.36 (m, 2H), 6.50 (m, 2H), 3.98 (s, 6H), 3.13 (m, 2H), 2.98 (m, 2H), 2.78 (m, 4H), 2.44 (m, 3H), 1.99 (m, 2H), 1.82 (m, 2H), 1.66-1.21 (m, 6H) ppm; MS (ES) 571.25 (M+H), 569.43 (M-H); 1-(2-chloro-7-methylthieno[3,2-dpyrimidin-4-y)-N(6-(4-cyclopropylpiperazin-1 10 yl)pyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #68; 1H NMR (DMSO-de, 300 MHz) 9.423 (s, 1H), 8.79 (br s, 2H), 8.52 (m, 1H), 8.23 (in, 1H), 7.98 (m, 1H), 7.04 (m, 1H), 3.62 (m, 4H), 3.02 (m, 4H), 2.36 (s, 3H), 2.04 (m, 1H), 0.99 (m, 2H), 0.84 (m, 2H) ppm; MS (ES) 483.1 (M+H); I-(6,7-dimethoxyquinazoline-4-y)-N-(6-(3-(4-dimethylaminopiperidin-1 15 yi)(propenyl)pyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #69; 1 H NMR (DMSO-de, 300 MHz) 9.65 (s, 1H), 9.04 (s, 1H), 8.86 (s, 1H), 8.81 (s, 1H), 8.24 (s, 2H), 8.18 (s, 1H), 7.96 (d, 1H), 7.36 (m, 1H), 6.50 (m, 2H), 3.98 (s, 6H), 3.11 (i, 2K), 2.92 (m, 2H), 2.51-2.25 (n, 3H), 1.96 (m, 2H), 1.77 (m, 2H), 1.47 (m, 2H), 1.21-1.05 (m, 2H) ppm; MS (ES) 531.26 (M+H), 529.44 (M-H); 20 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N(6-cyclopentylamino-5,6,7,8 tetrahydroquinolin-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #70; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-N 3 -(5-methyl-6-(4-bicyclo[2.2.1]heptan 2-ylpiperazin-1-yl)pyridine-3-y)-1H-1,2,4-t.riazole-3,5-diamine trifluoroacetic acid salt, compound #71; 25 1-(7-methylthieno[3,2-dpyrimidine-4-y)-N3-(5-methyl-6-(4-bicyclo[2.2.1]heptan-2 ylpiperazin-1 -yl)pyridine-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #72; 1-(7-methylthieno[3,2-d]pyrimidine-4-y)-N-(6-(4-((1 S,2S,4R)-bicyclo[2.2.1 ]heptan-2 yl)piperazin-1 -y)pyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine trifluoroacetic acid salt, compound #73; 'H-NMR (DMSO-de, 300 MHz) 9.29 (br. s, 1H), 8.87 (s, 1H), 30 8.54 (s, 1H), 8.14 (br. s, 2H), 8.03 (d, J = 9.3 Hz, 1H), 7.03 (d, J = 8.7 Hz, 1H), 3.58-3.48 (m, 4H), 3.20-3.08 (m, 4H), 2.43 (s, 3H), 2.29--2.27 (m, 2K), 2.02-1.98 (m, 1H), 1.61-1.57 (n, 4H), 1.39 (in, 6H), 1.25-1.15 (m, 1H) ppm; MS (ES) 503.32 (M+H); 1-(6,7-dimethoxyquinazoline-4-yl)-N 3 -(5,7,8,9-tetrahydrospiro[cyclohepta[b]pyridine-6,2' 35 [1,3]dioxolane]-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #74; 1 H-NMR 88 WO 2008/083354 PCT/US2007/089153 (DMSO-d, 300 MHz) 9.28 (br. s, 1H), 9.06 (s, 1H), 8.81 (d, J = 12.9 Hz, 1H), 8.18 (br. s, 2H), 7.53 (d, J= 17.4 Hz, 1H), 7.37 (d, J = 12.9 Hz, 1H), 3,99 (s, 3H), 3.94 (s, 3H), 3.88-3.86 (m, 4H), 2.93 (m, 2H), 2.89 (m, 2H), 1.89 (m, 2H), 1.62 (m, 2H) ppm; MS (ES) 491.19 (M+H); 5 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N 3 -(5,7,8,9 tetrahydrospiro[cyclohepta[b]pyridine-6,2'[1,3]dioxolane]-3-yi)-1 H-1,2,4-triazole 3,5-diamine, compound #75; 'H-.NMR (DMSO.-d, 300 MHz) 10.37 (br. s, 1H), 8.77 (s, 1H), 8.27 (s, 1H), 8.24 (s, 1H), 8.09 (br. s, 2H), 3.95--3.88 (m, 4H), 3.23 (s, 2H), 3,12-3.10 (in, 2H), 2.39 (s, 3H), 1,98-1.96 (m, 2H), 1.74 (m, 2H) ppm; MS 10 (ES) 485.66 (M+H); 1-(2-chioro-7-methylthieno[3,2-d]pyrimidine-4-y)-N-(5,6,8,9tetrahydrospiro[cyclohepta[b]pyridine-7,2'-[1,3]dioxolane]-3-yl)-1 H-1,2,4-triazole 3,5-diamine, compound #76; 'H-NMR (DMSO-d-, 300 MHz) 10.35 (br. s, 1H), 8.83 (s, 1H), 8.27 (s, 1H), 8.18 (s, 1H), 8.08 (br. s, 2H), 3.95-3.94 (m, 4H), 3.04 15 (im, 2H), 3.90 (m, 2H), 2.39 (s, 3H), 1.84 (m, 4H) ppm; MS (ES) 485.05 (M+H), 483.15 (M-H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-N 3 -(7-(pyrrolidin-1-yi)-6,7,8,9 tetrahydro-5H-cyclohepta[b]pyridin-3-y!)-1H-1,2,4-triazole-3,5-diamine, compound #77; 'H-NMR (DMSO-d 6 , 300 MHz) 10.13 (br. s, 1H), 8.82 (s, 1H), 8.25 (s, 1H), 20 8.06 (br. s, 2H), 3.49 (m, 4H), 3.26 (m, 1H), 3.14-3.07 (m, 4H), 2.39 (s, 3H), 1.98 (n, 4H), 1.85 (In, 2H), 1.62-1.50 (m, 2H) ppm; MS (ES) 485.05 (M+H), 496.09 (M), 494.32 (M-H); 1-(6,7-dimethoxyquinazoline-4-yl)-N 3 -(6-(3-(3-(diethylamino)pyrrolidin-i yl)propeny)pyridin-3-y)-1 H-1,2,4-triazole-3,5-diarnine, compound #78; 'H NMR 25 (DMSO-d6, 300 MHz) 9.64 (s, IH), 9.05 (s, IH), 8.86 (s, 1H), 8.77 (s, 1H), 8.24 (m, 2H), 7,94 (d, 1H), 7.35 (s, 2H), 6.52 (s, 2H), 3.98 (s, 6H), 3,32-3.01 (m, 7H), 2.53 (m, 8H), 1.87 (m, 2H), 1.61 (m, 2H) ppm; MS (ES) 545.25 (M+H), 543.26 (M-H); 1-(6,7-diiethoxyquinazoline-4-yl)-N-(6-(3-(3-(dimethylamino)pyrrolidin-1 30 yl)propenyl)pyridin-3-yi)-1H-1,2,4-triazole-3,5-diamine, compound #79; 1 H NMR (DMSO-d 6 , 300 MHz) 9.61 (s, IH), 9.01 (s, IH), 8.86 (s, 1H), 8.79 (s, 1H), 8.23 (s, 2H), 8.17 (s, 1H), 7.92 (d, IH), 7.36 (m, IH), 6.51 (n, 2H), 3.98 (s, 6H), 3.12 (m, 2H), 2.92 (in, 2H), 2.51-2.25 (m, 3H), 1.75 (m, 2H), 1,42 (m, 2H), 1,21-1.01 (m, 2H) ppm; MS (ES) 517.19 (M+H), 515.02 (M-H); 35 1-(6,7-dimethoxyquinazoline-4-y)-NC-(6-(3-piperidin-1-ylpropeny)pyridin-3-yl)-1H-1,2,4 89 WO 20081083354 PCT/IJS2007/089153 triazole-3,5-diarnine, compound #80 1 H NMVR (DMSO-dr 6 , 300 MHz) 9.65 (s, 1 H), 9.05 (s, 1 H), 8.84 (s, 1IH), 8.81 (s, 1 H), 8.24 (s, 2H), 8.19 (s, 1 H), 7.96 (d, 1 H), 7.32 (in, 1IH), 6.50 (in, 2H), 3,91 (s, 61-), 3.13 (m,. 2H), 2.23 (mn, 4H-), 1.63-1.47 (mn, 6H) ppm; MS (ES) 488.56 (M+H), 486.57 (M-H); 5 1 -(6,7-dirnettioxyquinaizolinie-4-yl)-NW-(6-(3-(4-pyrrolidin-1 -ylpiperidin-1 yI)propenyl)pyridin-3-yl)-1 H-I 2,4-triazoie-3,5-diamine, compound #81; -!H NMR (DMSQ-d6, 300 MHz) 9,60 (s, 1 I), 9.06 (s, 1 H), 8.82 (s, 1 H), 8.81 (s, 1IH), 8.32 8. 13 (mn, 4H), 7.91 (in, 1H), 7.36 (in, 2H), 6.53 (in, 2H), 3.95 (s, 6H), 3.15 (mn, 2H), 2.91 (in, 2H), 2.73 (in, 4H), 2.44 (in, 3H), 1 .92 (in, 2H), 1.85 (in, 2H), 1.67-1I.18 10 (in, 4H) ppm; MS (ES) 557.27 (M+H), 555.52 (M-H); I -(2-chloro-7-methyithieno[3,2-1ijpyrimidin-4-yi)-NP-(6-pyrrolidin-1 -y-5,6,7,8 tetra hyd roq uinolin-3-yl)- I H-I 1,2,-triazole-3,5-d ia mine, compound #82; 1 -(2-chloro-7-inethylthieno[3,2-d]pyrimidine-4-yI)-N 3 -(6-(1 -bicycdo[2.2.1I]heptan-2ylpiperidin-4-yI)pyridine-3-y)-1 H-I ,2,-triazole-3,5-diamine, compound #83-, 1 H 15 NMR (DMSQ-d 6 , 300 MHz) 9.81 (in, 1 H), 8.92 (mn, I H1), 8.26 (in, 1 H), 8.05 (in, 3H), 7.33 (in. 1 H), 3.53 (mn, 1IH), 3.02 (ri, 4H), 2.37 (s, 3H), 2.26 (in, 2H), 2. 05 (in. 6H), 1.56 (mn, 4H), 1.39 (mn, 3H) ppm; MIS (ES) 536.2 (M+H); 1 -(7-methylthieno[3,2-pyrimfidir-4-y)-W-(6-(I-rnethypperidin-4-ylamino)-5.-,6,7,8= tetra hyd roq uinoin-3-yi)- 1H-I ,2,4-triazole-3,5-d ia mine, compound #84; 20 1 -(7-inethylthieno3,.2-dpyrimidin-4-y)-N 3 -(6-pyrrolidin-1 -yi-5,6 ,7,8-tetrahydroquinoin-3 yI)-1 H-I ,2,4-triazole-3,5-diamine, Compound #86; I -(2-chloro--7-methylthieno[3,2-d]pyrimidine-4-yi)-V3-(6- 1-,iethiylpiperidin-4-yi)-5,6,7,8 tetrahydro-1 ,6-naphthyridih3-y>-1 H-I ,2,4-triazole-3,5-d iaimine, compound ft.86; I -(2-chloro-7-niethylthieno[3,2-d]pyriinidin-4-yi )-NY-(6-(piperidin-4-ylca rbonyl)-5,6 7.6 25 tetrahydro-1 ,6-naphthyridin-3-yI)-1 H-I ,2,4-triazole-3,5-diainine, compound #87; 1I-(7-inethylthieno[3,2.-d]pyrimidine-4-y)-N 3 -(6-(I -bicyclo[2.2. 1]heptan-2-ylpiperidini-4 yl)pyridine-3-yi)-I H-I ,2,4-tlriazole-3,5-diamine, compound #88; 1 H NMR (DM50 d 6 , 300 MHz) 9.57 (in, 1IH), 8.89 (in, 2H), B8.18 (mn, 3H), 8.03 (in, 1IH), 7.25 (in, 1IH), 2.98 (mn, 3H1), 2.42 (s, 3H), 2,22-1 .22 (in, 17H) ppm; MS (ES) 502.2 (M+H); 30 1 -(.7-inethylthieno[3,2-dlpyrimidine-4-y).N 3 -- (6-(4-(cyclopropyimethyI)piperazin- 1 yI)pyridine-3-yI)-I H-I ,2,4-triazole-3,.5--diainine, compound #89; 1 H NMR (DM30 dc 6 , 300 MHz) 9.15 (mn, 1 H), 8.86 (mn, 1IH)v 8.49 (mn, 1IH). 8.12 (in, 3H), 7.95 (in, 11-), 6.86 (in, 1 H), 3.38 (in, 4H), 2.52 (in, 4H), 2.41 (s, 3H), 2.19 (in, 2H), 0-84 (mn,1IH), 0.46 (mn, 2H), 0.07 (mn, 2H) ppm; MIS (ES) 463.1 (MV+H); 35 1 -(6, 7-dinietloxyquinazoline-4-y),-N 3 -(6-(3-(4-cyclopentylpiperazin- I -yl)propenyl)pyridin go WO 2008/083354 PCT/US2007/089153 3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #90; 'H NMR (DMSO-d 6 , 300 MHz) 9.65 (s, 1H), 8.94 (s, IH), 8.67 (s, 1H), 8.65 (s, 1H), 8.23-8.11 (m, 4H), 7.89 (m, 1lH), 7.31 (m, 2H), 6.59 (n, 2H), 3.88 (s, 6H), 3.18 (m, 2H), 2.91-2.73 (m, 6H), 2.39 (m, 311), 1.88 (m, 2H), 1.89 (m, 2H), 1.69-1.09 (m, 4H) ppm; MS (ES) 557.21 5 (M+H), 555.47 (M-H); 1-(2-chloro-7-metihylthierio[3,2-d]pyrimidin-4-yl)-N-(2-(4-pyrrolidin-1 ylpiperidin-1 yl)pyrimidin-5-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #91; 'H-NMR (DMSO de, 300 MHz) 9.35 (br. s, 1H), 8.75 (s, 2H), 8.28 (s, 1H), 7.99 (br. s, 2H), 4.69 4.64 (m, 2H), 3.42-3.32 (m, 2H), 3.11-3.09 (m, 2H), 2.87 (t, J= 12.6 Hz, 2H), 10 2.42 (m, 1H), 2.37 (s, 3H), 2.13-2.09 (m, 2H), 2.00 (m, 2H), 1.84-1.80 (m, 2H), 1.52-1.50 (m, 2H) ppm; MS (ES) 512.16 (M+H); 1-(7-methyithieno[3,2-d]pyrimidine-4-y)-N-(6-(1 -(bicyclo[2.2. 1]heptan-2-yl)-5 methylpiperidin-4-yl)pyridine-3-y)-1H-1,2,4-triazole-3,5-diamine, compound #93, 1H NMR (DMSO-d 6 , 300 MHz): 942 (s, 1H, exch. With D20), 9.00 (broad s, 1H, 15 exch. with D20), 8.88 (s, 1H), 8.43 (s, 1H), 8.18 (s, 1H), 8.11 (broad s, exch. with D20), 8.05 (S, 1H),3.30-3.60 (m, 4H), 3.10-3.30 (m, 3H), 2.59 (m, 1H), 2.49 (s, 311), 2.39 (s, 2H), 2.30 (m. 4H), 1.99 (m, 1H), 1.54 (m, 3H), 1.38 (m, 3H), 1.20 (m, 1H). MS(ES) 517.26 (M+H); 1-(7-methylthieno[3,2-d]pyrimidine-4-yI)-N-.(6-(4-(cyclopropylmethyl)piperazin- 1-yl)-5- 20 methylpyridine-3-y)-1H-1,2,4-triazole-3,5-dianine, compound #94, 'H NMR (DMSO-d 6 , 300 MHz) 9.44 (s, 1H), 9,89 (s, 1H), 8.44 (s, 1H), 8.19 (s, 1H), 8.14 (br s, 2H), 8.05 (s, 1H), 3.60 (m, 2H), 3.42 (m, 2H), 3.16 (m, 4H), 2.42 (s, 3H), 2.32 (s, 3H), 1.08 (m, 1H), 0.66 (m, 2H), 0.38 (m, 2H) ppm; MS (ES) 477.2 (M+H); 25 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N-(6-(4-(cyclopropylimethyl)piperazin-1 yl)-5-methylpyridin-3-y)-1 H-1i,2,4-triazole-3,5-diamine, compound #95; 1H NMR (DMSO-de, 300 MHz) 9.55 (s, 1H), 8.42 (s, 1H), 8.29 (s, 1H), 7,99 (m, 3H), 3.60 (m, 2H), 3.42 (m, 2H), 3.19 (in, 6H), 2.37 (s, 3H), 2.32 (s, 3H), 1.09 (m, 1H), 0.66 (m, 2H), 0.39 (m, 2H) ppm; MS (ES) 511.2 (M+H); 30 1-(7-methylthieno[3,2-dpyrimidin-4-yl)-N-(6-(1 -m ethylpiperidin-4-yI)carbonyl-5,6,7,8 tetrahydro- 1, 6-naphthyridin-3-yl)-1 H- 1,2,4-triazole-3,5-diamine (formic acid salt), compound #96; 11H NMR (DMSO-d 6 , 300 MHz) 9.56 (s, 1H), 8.88 (s, 1H), 8.67 (s, 1H), 8.15 (m, 3H), 7.92 (d, 1H), 4.72 (d, 2H), 3.82 (m, 2H), 2.89 (n, 1H), 2.79 (m, 4H), 2.42 (s, 3H), 2.18 (s, 3H),1.97 (m, 2H), 1.62 (m, 4H) ppm; MS (ES) 505.15 35 (M+H); 91 WO 2008/083354 PCT/US2007/089153 1-(7-methylthieno[3,2-d]pyrimidin-4-y)-N 3 -(6-cyclopentyl-5,6,7,8-tetrahydro-1,6 naphthyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine (formic acid salt), compound #97; 'H NMR (DMSO-d 6 , 300 MHz) 9.47 (s, IH), 8.87 (s, 1H), 8.64 (s, IH), 8.22 (s, 1H), 8.17 (s, 1H), 8.12 (s, 2H), 7.85 (s, 2H), 3.66 (s, 2H), 2.79 (s, 4H), 2.71 (t, 5 1 H), 2.42 (s, 3H), 1.91 (s, 2H), 1.66 (s, 2H), 1.50 (m, 4H) ppm; MS (ES) 448.21 (M+H); 1-(7-methylthieno[3,2-d]pyrimidin-4-y)-N 3 -(6-(1 -methylpiperidin-4-yl)carbonylamino 5,6,7,8-tetrahydroquinolin-3-y)-1 H-1,2,4-triazole-3,5-diamine (formic acid salt), compound #98; 1 H NMR (DMSO-d 6 , 300 MHz) 9.43 (s, 1H), 8.87 (s, IH), 8.64 (s, 10 1H), 8.14 (m, 3H), 7.85 (m, 2H), 2.82 (m, 61-), 2.42 (s, 3H), 2.27 (t, 3H), 2.08 (m, 4H), 1.93 (m, 1H), 1 95 (m, IH), 1.66 (m, 4H) ppm; MS (ES) 519.35 (M+H); 1-(7-methylthierio[3,2-d]pyrimidin-4-yi)-N(6-cyclopentylamino-5,6,7,8 tetrahydroquinolin-3-yl)-1 H-1,2,4-triazole-3,5-diamine (formic acid salt), compound #99; 111 NMR (DMSO-d 6 , 300 MHz) 9.46 (s, 1H), 8.88 (s, IH), 8.66 (d, 15 1H), 8.14 (m, 4H), 7.84 (d,1H), 3.12 (Im, 2H), 2.85 (m, 4H), 2.43 (s, 3H), 2.15 (m, 1 H), 1.92 (m, 2H), 1.67 (m, 3H), 1.50 (n, 4H) ppm; MS (ES) 462.30 (M+H); 1-(2-chloro-7-rmethylth ieno[3,2-d]pyriiid in-4-y)-N-(6-cyclohexylamino-5,6,7,8 tetrahydroquinolin-3-yl)-1H-1i,2,4-triazole-3,5-diamine (formic acid salt), compound #100; 1 H NMR (CDC 3 , 300 MHz) 9.53 (s, 1H), 8.63 (s, IH), 8.26 (s, 20 2H), 7,96 (s, 2H), 7.77 (s, 1H), 6.60 (s, IH), 3.00 (n, 2H), 2.75 (m, 4H), 2.37 (s, 3H), 2.05 (in, 2H), 1.90 (m, 2H), 1.65 (m, 2H), 1.58 (m, 2H), 1.26 (m, 2H), 1.08 (m, 2H) ppm; MS (ES) 510.14 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N 3 -(6-cyclopropylmethyl-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine (formic acid salt), 25 compound #101; 1 H NMR (DMSO-d 6 , 300 MHz) 9.61 (s, 1H), 8.60 (s, 1H), 8.24 (s, 1H), 7.96 (s. 2H), 7.88 (s, 1H), 3.76 (s, 2H), 2.85 (s, 4H), 2.37 (s, 3H), 0.96 (n, 1H), 0.54 (d, 2H), 0.19 (d, 2H) ppm; MS (ES) 468.09 (M+); 1-(2-chloro-7-methylthieno[3,2-dpyrimidin-4-yl)-W-(6-bicyclo[2.2.1]heptan-2-yl-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-1H-1,2,4-triazole-3,5-diarnine (formic acid salt), 30 compound #102; 'H NMR (DMSO-d 6 , 300 MHz) 9.58 (s, 1H), 8.63 (s, 1H), 8.22 (s, 1H), 7.11 (s, IH), 7.96 (s, 2H), 7.80 (s, 1H), 3.54 (s, 1H), 2.81 (m, 3H), 2.41 (s, 1H), 2.34 (s. 3H), 2.27 (t, 1H), 2.16 (s, 1H), 1.74 (m, 2H), 1.50-1.17 (m, 5H), 0.96 (d, 2H) ppm; MS (ES) 508.13 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-W-(6-bicyclo[2.2.1 ]heptan-2-yl-amino 35 5,6,7,8-tetrahydroquinolin-3-y)-1H-1 ,2.4-triazole-3,5-diamine (formic acid salt), 92 WO 2008/083354 PCT/US2007/089153 compound #103;'H NMR (DMSO-d 6 , 300 MHz) 9,53 (d, 1H), 8.63 (m, 1H), 8.24 (d, 1H), 8.15 (s, 1H), 7.97 (s, 2H), 7.79 (s, 1H), 2.97 (m, 2H), 2,82 (m, 2H), 2.71 (n, 2H), 2.38 (s, 3H), 2.28 (s, 1H), 2,10 (m, 2H), 1.87 (t, IH), 1.71 (m, 2H), 1.48 (m, 1H), 1.33 (s, IH), 1.26 (m, 3H), 0.74 (t, 1H) ppm; MS (ES) 522.17 (M+); 5 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-P-(6-bis-(cyclopropylmethy)amino 5,6,7,8-tetrahydroquinolin-3-y)-1 H-1,2,4-triazole-3,5-diamine (formic acid salt), compound #104; 1 H NMR (DMSO-d, 300 MHz) 9.59 (s, 1H), 8.68 (s, 1H), 8.22 (s, 1H), 7.97 (s, 2H), 780 (s, 1H), 6.51 (s, 1H), 2.90(m, 8H), 2.38 (s, 3H), 2.14 (m, 1H), 1.82 (s, 2H), 1.05 (s, 2H), 0.58 (s, 4H), 0.28 (s, 4H) ppm; MS (ES) 10 53627 (M+); I -(7-methylthieno[3,2-d]pyrimidin-4-yi)-N 3 -(7-(pyrrolidin-1 -yl)-6,7,8,9-tetrahydro-5H cyclohepta[b]pyridine-3-yl)-1 H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #105; 1 H-NMR (CDCI/MeOD-4, 300 MHz) 8.66 (s, 1H), 8.50 (s, 1H), 8.03 (s, 1H),. 7.78 (%. 1H), 7.64 (s, 1H), 3.24 (m, 1H), 3.19 (m, 4H), 3.01 (m, 1H), 15 2.72-2.87 (m, 3H), 2.34 (s, 3H), 2.50 (m, 1H), 1.91 (m, 4H), 1.50 (m, 2H); MS (ES) 462.14 (M+H); 1-(7-mnethylthieno[3,2-d]pyrimidin-4-y)-NA(2-(3-(S)-methyl-4-( 1 S,2S,4R) bicyclo[2.2.1]heptan-2-ylpiperazin-1-yi)-3-methylpyridin-5-yl)-1 1-1-1,2,4-triazole 3,5-diamine (trifluoroacetic acid salt), compound #106; 'H-NMR (DMSO-d, 300 20 MHz) 9.43 (s, 1H), 8.88 (s, IH), 8.45 (n, 1H), 8.18 (m, IH), 8.13 (broad s, 1H), 8.04 (m, 1 H), 3.66 (m, 2H), 3.28 (m, 4H), 2.56 (m, 1 H), 2.49 (m, 4H), 2.42 (s, 3H), 2.34 (s, 3H), 2.30 (m, 1 H), 2.00 (m, 11H), 1.52 (d, 3H), 1.35-1,60 (m, 4H), 1,26 (m, 1H); MS (ES) 531.17 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyriinidin-4-yl)-N-(2-(3-(S)-methyl-4-(2S) 25 bicyclo[2.2. 1 ]heptan-2-ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H-1,2,4-triazole 3,5-diamine (trifluoroacetic acid salt), compound #107; 1 H-NMR (DMSO-de, 300 MHz) 9,34 (s, 1 H), 8.43 9s, I H), 8.23 (s, 1 H), 8.01 (s, 1 H), 7.86 (s, 1 H), 2.58 (m, IH), 2.52 (s, 3H), 2.49 (m, 4H), 2.40 (s, 3H), 2.35 (m, 4H), 2.03 (m, IH), 1 53 (d, 3H), 1.40-1.65 (n, 7H), 1.26 (m, 1H); MS (ES) 565.12/566,55 (M+H); 30 1 -(thieno[3,2-d]pyri midin-4-y)-, -(2-(3-(S)-methyl-4-(2S)-bicyclo[2.2. 1 ]heptan-2 ylpiperazin-1 -yl)-3-methylpyridin-5-yl)- 1 H-1.2,4-triazole-3, 5-diaimine (trifluoroacetic acid salt), compound #108; 1 H-NMR (DMSO-dr, 300 MHz) 9.25 (s, 1 H), 8.86 (s, 1H), 8.49 (d, 1H), 8.44 (s, 1H), 8.03 (m, 1H), 7.59 (m, 1H), 3.31 (m, 3H), 2.58 (m, 1H), 2.49 (m, 4H), 2.36 (s, 3H), 2.32 (m, 1H), 2.00 (m, 1H), 1.54 (d, 35 3H), 1.42-1.61 (m, 7H), 1.25 (m, 1H); MS (ES) 517.17(M+H); 93 WO 2008/083354 PCT/US2007/089153 1-(2-chloro-7-methylthieno[3,2-d]pyrim idin-4-yI)-N-(2-(4-(2S)-bicyclo[2.2.1 ]heptan-2.

ylpiperazin-1-yl)-3-chlioropyridin-5-y)-1H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid), compound #109; 'H-NMR (CDCIMeOD-4, 300 MHz) 8.24 (m, 1H), 3.20 (m, 1H), 7.68 9s, IH), 3.53 (m, 1H), 3.13 (m, 1H), 2.51 (m, 1H), 2.34 (s, 3H), 2.27 5 (m, 1 H), 1.76-1.90 (m, 4H), 1.38-1.56 (m, 11 H); MS (ES) 571.09 (M+H); 1-(7-methylthierio[3,2-djpyrimnidin-4-yl)-N 3 -(2-(4-(2S)-bicyclo[2.2. 1]heptan-2-ylpiperazin 1-yl)-3-chloropyridin-5-yl)-1H-1,2,4-triazole-3,5-diaminrie (trifluoroacetic acid salt), compound #110; 'H-NMR (CDCs/ MeOD-4, 300 MHz) 8.73 (s, 1 H), 8.29 (s, 1 H), 8.21 (s, 1H), 7.65 (s, 1H), 3.23 (m, 1H), 3.15 (m, 1H), 2.50 (m, 1H), 2.40 (s, 3H), 10 2.27 (m, IH), 1.75-1.91 (m, 4H), 1.38-1.53 (m, 11H); MS (ES) 537.15 (M+H); 1-(7-methylthieno[3,2-d]pyriimidin-4-yl)-N-(2-(4-(2S)-bicyclo[2.2.1 ]heptan-2-ypiperazin 1 -yl)-3-methylpyridin-5-y)-1 H-1,2,4-triazole-3,5-diamine, compound #111; H NMR (DMSO-d 6 , 300 MHz) 9.27 (s, IH), 8.86 (s, 1H), 8.38 (s, 1H), 8.17 (s, 1H), 8.10 (s, 2H), 7.97 (s, 1H), 2.97 (m, 4H), 2.48 (m, 7H), 2.28 (s, 3H), 2.14 (m, 1H), 15 1.71 (in, 2H), 1.15-1.36 (m, 6H), 0.87 (m, 2H); MS (ES) 517.21 (M+H); 1-(4-methylthieno[3,2-d]pyridazine -7-yl)-N3-(2-(4-(1 S,2S,4R)-bicyclo[2.2.1 iheptan-2 yipiperazin-1 -yl)-3-methylpyridir-5-yl)-1 H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #112; "H-NMR (DMSO-de, 300 MHz) 10.91 (s, 1 H, exchanges with D 2 0), 9.20 (broad s, 1 H, exchanges with D20), 8.54 (s, 20 1H), 8.41 (d, 1H), 8.00 (s, 1H), 7.79 (d, 1H), 3.51 (m, 6H), 3.24 (m, 4H), 2.87 (s, 3H), 2.60 (m, 1H), 2.49 (m, 2H), 2.29 (s, 3H), 1.98 (m, 1H), 1.60 (m, 2H), 1.40 (m, 2H), 1.23 (m, 1H); MS (ES) 517.13 (M+H); 1-(6,7--dimethoxyquinazoline-4-yl)-N 3 -(2-(3-(4-isopropylpiperazin-1 -yl)propen- 1 yl)pyridine-5-yl)-1H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), 25 compound #113; 1 H NMR (DMSO-de, 300 MHz) 9.55 (s, 1H), 8.91 (s, 1H), 8.61 (s, 1H), 8.61 (s, 1H), 8,21-8.01 (m, 4H), 7.78 (m, 1H), 7.19 (m, 2H), 6.45 (m, 2H), 3.71 (s, 6H), 3.12 (m, 2H), 2.72-2.58 (n, 6H), 2.21 (m, 3H), 1.92 (m, 2H), 1.79 (m, 2H), 1.58-1.05 (im, 2H) ppm; MS (ES) 531 .20 (M+H), 529.41 (M-H); I -(6,7-dimethoxyquinazoline-4-yl)-N 3 -(2-(4-cyclopropylimethyl-3-(S)-methylpiperazn-1 30 y!)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine (bis trifluoroacetic acid salt), compound #114; 1H NMR (DMSO-dG, 300 MHz) 9.22 (s, 1H), 9.10 (s, IH), 8.80 (s, I H), 8.69 (s, 1 H), 8.26 (s, 2H), 7.76 (d, 1 H), 7,35 (s, 1 H), 7.00 (d, 1 H), 3.97 (s, 6H), 3.75 (m, 1H), 3.46-2.82 (n, 5H), 2.48 (s, 3H), 1.39-1.18 (im, 3H), 1.06 (m, IH), 0.65 (m, 2H), 0.40 (m, 2H) ppm: MS (ES) 517.23 (M+H), 515.49 (M-H); 35 1 -(2-chloro-7-nethylthieno[3,2-d]pyriindi n-4-y)-NMt(2-(4-cyclopropylmethyl-3-(S) 94 WO 2008/083354 PCT/US2007/089153 methylpiperazin-1 -yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #115; 'H NMR (DMSO-d, 300 MHz) 9.26 (s, 1H), 8.44 (s, IH), 8.24 (s, 1H) 8.13 (s, 1H), 7.94 (m, 2H), 6.88 (d, 1H), 3.86 (m, 2H), 3.71 (m, 1H), 3.52-2.86 (m, 4H), 2.48 (s, 3H), 2.36 (s, 3H), 2.11 (m, 1H), 1,03 (d, 2H), 0.84 (m, 1H), 0.45 (m, 2H) 5 ppm; MS (ES) 511.16 (M+H); 1-(7-iethylthieno(3,2-d]pyrimidin-4-y)-N-(2-(4-cyclopropyimethyl-3-(S)-methylpiperazin 1-yl)pyridin-5-yl)-1H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #116; 'H NMR (DMSO-d 6 , 300 MHz) 9.63 (s br, 1H), 9.36 (s, 1H), 8.88 (s. 1H), 8.54 (s, 1H), 8.14 (s, 2H), 8.04 (d, 1H), 7.10 (d, 1H), 4.31 (m, 2H), 3.76 10 (m, 1H), 3.52-2.86 (m, 4H), 2.48 (s, 3H), 2.41 (s. 3H), 1.33 (m, 2H), 1.07 (s, 1H), 0.65 (Im, 2H), 0.35 (d, 2H) ppm; MS (ES) 477.19 (M+H), 475.30 (M-H); 1-(2-chloro-7-methylthieno[3,2-d]pyrirnidin-4-yl)-N 3 -(2-(4-cyclopropylmethyl-3-(S) methylpiperazin-1 -yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diaminie formic acid salt, compound #117 (formic acid salt of' compound #115); 'H NMR (DMSO-d, 300 15 MHz) 9.26 (s, 1H), 8.44 (s, 1H), 8.24 (s, 1 H) 8.13 (s, 1H), 7.94 (m, 2H), 6.88 (d, 1 H), 3.86 (m, 2H), 3.71 (m, 1 H), 3.52-2.86 (m, 4H), 2.48 (s, 3H), 2.36 (s, 3H), 2.11 (im, 1H), 1.03 (d, 2H), 0.84 (in, 1H), 0.45 (m, 2H) ppm; MS (ES) 511,12 (M+H), 509.34 (M-H); 1-(7-methylthieno[3,2-d]pyrimidin-4-y)-N-(2-bromopyridin-5-yl)-1 H-1,2,4-triazole-3,5 20 diamine (trifluoroacetic acid salt), compound #118; 'H NMR (DMSO-d , 300 MHz) 9.84 (s, 1H), 8.89 (s, 1H), 8.80 (s, 1H), 8.20 (s, 2H), 8.16 (s, 1H), 8.00 (d. IH), 7.58 (d, 1H), 2.48 (s, 3H) ppm; MS (ES) 404.86 (M+H); 1-(7-methylthieno[3,2-dpyrimidin-4-yl)-N-(2-(3-(pyrrolidin-1 -yl)propen-1 -yl)pyridin-5-yl) 1H-1,2,4-triazole-3,5-diamine (formic acid salt), compound #119; 'H NMR 25 (DMSO-de, 300 MHz) 9.87 (s, 1H), 8.41 (s br, 1H), 8.89 (s, 2H), 8.23-8.12 (m, 4H), 7.59 (d, 1H), 6.81 (d, 1H), 6.58 (m, 1H), 3.92 (m, 2H), 3.43 (m, 2H), 2.89 (m, 2H), 2.54-2.41 (m, 6H), 1.85-1.23 (m, 5H) ppm; MS (ES) 434.15 (M+H), 432.22 (M-H); 1.-(7-nethylthieno[3,2-d]pyrirnidin-4-yl)-N-(2-(3-(3-dimethylaminopyrrolidin-1 -yl)propen 30 1 -yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-dianine (formic acid salt), compound #120; H NMR (DMSO-d, 300 MHz) 9.72 (s, 1H), 8.98 (m, 2H), 8.17 (m, 2H), 8.17-8.05 (m, 4H), 7.45 (d, 1H), 6.65 (d, 2H), 3.18 (m, 2H), 2.72 (rn, 1H), 2.44 (m, 2H), 2.30 (m, 2H), 2.25 (s, 6H), 2.19 (m, 5H), 1.77 (m, 1H), 1.52 (m, 1H) ppm; MS (ES) 477.19 (M+H), 475.25 (M-H); 35 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-N-(2-(3-(3-diethylaminopyrroidin-1 -yl)propen-1 95 WO 2008/083354 PCT/US2007/089153 yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine (bis formic acid salt), compound #121; 'H NMR (DMSO-d 6 , 300 MHz) 9.81 (s, 1H), 8.98 (m, 2H), 8.22 (m, 2H), 8.15-8.02 (m, 4H), 7.39 (d, IH), 6.59 (d, 2H), 3.22 (m, 2H), 2.71 (m, 1H), 2.46 2.38 (m, 5H), 2.30 (m, 1H), 2.23-2.17 (m, 5H), 1.76 (in, 1H), 1.52 (m, 1H), 1.03 (t, 5 6H) ppm; MS (ES) 505.21 (M+H), 503,39 (M-H); 1-(7-methylthieno[3,2-d]pyrimidin-4-yi)-N-(2-(3-(4-pyrroidin-1 -yl-piperidin-1 -yl)propen- 1 yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine (bis formic acid salt), compound #122; IH NMR (DMSO-d 6 , 300 MHz) 9.68 (s, IH), 8.87 (s, 2H), 8.45 (m, 1H), 8.31-8.08 (n, 3H), 7.58 (d, 1H), 6.79 (d, 1H), 6.59 (m, 1H), 3.74 (m, 2H), 3.50 (m, 10 2H), 3.04 (m, 2H), 2.53-2.31 (m. 6H), 1.95 (m, 2H), 1.57 (m, 6H) ppm; MS (ES) 517.23 (M+H), 515.38 (M-H); 1-(7-methylthieno[3,2-d]pyriiidin-4-yl)-N-(2-(3-(4-rmethylpiperazin-1-yi)propen-1 yi)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #123; 'H NMR (DMSO-d 6 , 300 MHz) 10.00 (s, 1H), 8.91 (s, 2H), 8.36-8.03 (m, 15 4H), 7.68 (d, 1H), 6.81 (m, 1H), 6.59 (m, 1H), 3.73 (m, 2H), 2.82 (m, 4H), 2.56 2.33 (m, 10H) ppm; MS (ES) 463.21 (M+H), 461.35 (M-H); 1-(7-iethylthieno[3,2-d]pyriiidin-4-y)-N 3 -(2-(3-(4-isopropylpiperazin-1-yi)propen-1 yi)pyridin-5-yl)-1H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #124; 'H NMR (DMSO-d 6 , 300 MHz) 9.86 (s, 1H), 8.781 (s, 2H), 8.39-8.12 (m, 20 4H), 7.62 (d, 1H), 6.79 (m, 1H), 6.55 (m, 1H), 3.70 (m, 2H), 2.81 (m, 2H), 2.56 2.39 (m, 10H), 1.05 (d, 6H) ppm; MS (ES) 491.23 (M+H); 1-(7-methylthieno[3,2-d]pyrimidin-4-y)-N-(2-(3-(4-cyclopentyl piperazin-1 -yl)propen-1 yl)pyridin-5-y)-1H-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #125; 'H NMR (DMSO-d 6 , 300 MHz) 10.43 (s, 1H), 8.91 (s, 2H), 8.43 (m, IH), 25 8.35-8.10 (m, 3H), 7.64 (d, 1H), 6.82 (d, 1H), 6.61 (m, IH), 3.76 (m, 2H), 3.51 (m, 2H), 3.06 (im, 2H), 2.55-2.33 (im, 6H), 1.99 (m, 2H), 1.59 (m, 6H) ppm; MS (ES) 517.29 (M+H), 515.53 (M-H); 1-(7-methylthieno[3,2-dipyrimidin-4-yl)-N 3 -(2-(3-(morpholin-4-yl )propen-1-yl)pyridin-5-y) 1H-1,2,4-triazole--3,5.-diamine (trifluoroacetic acid salt), compound #126; 'H NMR 30 (DMSO-de, 300 MHz) 9.89 (s, IH), 8.88 (s, 2H), 8.35-8.11 (m, 4H), 7,78 (d, 1H), 6.79 (m, 1H), 6.57 (m, IH), 3.74 (m, 2H), 3,62 (m, 4H), 2.56-2.29 (m, 7H) ppm; MS (ES) 450.17 (M+H), 448.26 (M-H); 1-(7-methylthieno[3,2-d]pyrimidin-4-y)-N-(2-(3-(piperidir.1 -yl)propen-1-yl)pyridin-5-y) 1H-1.2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #127; 1 H NMR 35 (DMSO-d 6 , 300 MHz) 9.94 (s, 1H), 8.45 (s br, 1H), 8.91 (s, 2H), 8.25-8.15 (m, 96 WO 2008/083354 PCT/US2007/089153 4H), 7.63 (d, 1 H), 6.84 (d, 1H), 6.60 (m, 1H), 3.90 (m, 2H), 3.42 (m, 2H), 2.92 (m, 2H), 2.52-2.43 (rn, 6H), 1.81-1.25 (m, 3H) ppm; MS (ES) 446.30 (M+H); 1-(7-methylthieno[3,2-d]pyrimidin-4-y)-N 3 -(2-(3-(4-(4-methylpiperazin-1-yl)piperidin-1 yl)propen-1 -yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine (formic acid salt), 5 compound #128; 1 H NMR (DMSO-de, 300 MHz) 9.72 (s, 1H), 8.98 (m, 2H), 8,17 (m, 2H), 8.17-8.05 (m, 4H), 7.45 (d, 1H), 6.65 (d, 2H), 3.21 (m, 3H), 2.98 (s, 3H), 2.60-2.07 (m, 12H), 1.79 (m, 2H), 1.46 (im, 3H), 1.13-1.04 (m, 2H) ppm; MS (ES) 546,26 (M+H), 544.37 (M-H); 1-(7-niethylthieno[3,2-d]pyrimidin-4-y)-N-(2-(3-(4-piperidin-1 -ylpiperidin-1 -yl)propen-1 10 yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine (formic acid salt), compound #129; 'H NMR (DMSO-d 6 , 300 MHz) 9.68 (s, 1H), 8.85 (m, 2H), 8.23 (m, 2H), 8.11-8.01 (m, 4H), 7.39 (d, 1H), 6.65 (d, 2H), 3.26 (Im, 3H), 2.64-2.05 (m, 12H), 1.81 (m, 2H), 1.43 (m, 3H), 1.15-1.07 (m, 4H) ppm; MS (ES) 531.27 (M+H), 529.24 (M-H); 1-(6-phenylpyrimidine -4-yl)-N-(3-methyl-2-(4-pyrrolidin-1 -ylpiperidin-1 -y1)pyridin-5-yl) 15 1H-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #130; H-NMR (DMSO-dr, 300 MHz) 9.30 (br. s, 1N), 9.00 (s, 1H), 8.46 (s, 1H), 8.16-8.14 (n, 2H), 7.96 (s, 1H), 7.93 (br. s, 2H), 7.79 (s, 1H), 7.60-7.57 (m, 3H), 3.37 (m, 4H), 3.12-3.08 (m, 4H), 2.75 (t, 1H), 2.15-2.02 (m, 4H), 1.86-1.73 (m, 4H) ppm; MS (ES) 497.22 (M+H); 20 1-(2-chloro-7-iethylthieno[3,2-d]pyrimidin-4-yl)-W-(2-(4-(piperidin-1 -ylmethyl)piperidin-1 yl)pyrinidin-5-yl)-1H-1,2,4-triazole-3,5-diamine (bis trifluoroacetic acid salt), compound #131; H NMR (CDCI,+CD 3 OD, 300 MHz) 7.86 (s, 1H), 7.44 (m, 4H), 4.70 (m, 2H), 3.60 (m, 2H), 2.96 (m, 4H), 2.80 (m, 2H), 2.48 (s, 3H), 2.14 (m, 1H), 1.93 (m, 6H), 1.33 (m, 4H); MS (ES) 540.14 (M+H); and 25 1-(2-chloro-7-iethylthieno[3,2-d]pyrimidrin-4-yi)-N-(6-(dinetiylaiinomethyl)carbonyi 5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine, compound #134. SYNTHETIC EXAMPLE 3 30 In a similar manner as described above utilizing the appropriately substituted starting materials and reagents, the following compounds of formula (Ib) were prepared: I -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N-(6-(4-(pyrroidin-1 -yl)piperidin-1 -yi)-5 methylpyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine, compound #92; 1 H-NMR (DMSO-d 6 , 300 MHz) 10.32 (s, 1H), 8.37 (s, 1H), 8.22 (s, 1H), 7.89 (s, 1H), 6.27 97 WO 2008/083354 PCT/US2007/089153 (br. s, 2H), 3.55 (m, 2H), 3.41-3.37 (m, 2H), 3.26 (m, 1 H), 3.11-3.08 (m, 2H), 2.76-2.71 (m, 2H), 2.36 (s, 3H), 2.28 (s, 3H), 2.15-2.11 (m, 2H), 2.02 (m, 2H), 1.86-1.73 (m, 4H) ppm; MS (ES) 525.20 (M); 1-(4-methylthieno[2,3-d]pyridazin-7-y)-N5-(2-(4-(1 S,2S,4R)-bicyclo[2(2. 1]heptan-2 5 ylpiperazin-1 -yl)-3-methypyridin-5-y)-1 H-i1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #132; 'H-NMR (DMSO-d 6 , 300 MHz) 10.94 (s, 1H, exchanges with D20), 9.00 (broad s, 1H, exchanges with D20), 8.55 (s, 1H), 8.40 (d, 1H), 8.00 (s, 1H), 7.79 (d, 1H), 3.51 (m, 6H), 3.20 (m, 4H), 2.86 (s, 3H), 2,61 (m, 1 H), 2,52 (m, 2H), 2,29 (s, 3H), 1.99 (m, 1H), 1.59 (n, 2H), 1.41 (m, 10 2H), 1.22 (m, 1 H); MS (ES) 517.13 (M+H); and 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-N 5 -(2-(3-(4-(4-methylpiperazin-1 -yl)piperidin-1 yl)propen-1 -yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-dianine (formic acid salt), compound #133; MS (ES) 546,29 (M+H), 544.52 (M-H). 15 TESTING OF THE COMPOUNDS OF THE INVENTION The compounds of the invention were tested in the following assay for their ability to inhibit Axl activity. PHOSPHO-AKT IN-CELL WESTERN ASSAY REAGENTS AND BUFFERS: 20 Cell culture plate: 96 well assay plate (Corning 3610), white, clear bottom, tissue culture treated. Cells: Hela cells. Starvation medium: For AxI stimulation: 0.5% FCS (fetal calf serum) in DMEM, plus AxI/Fc (extracellular domain of AXL fused to imunoglobulin Fc region) (R&D, 25 154-AL) 500ng/mL. For EGF (epidermal growth factor) stimulation: 0.5% FCS in DMEM (Dulbecco's modified Eagles medium). Poly-L-Lysine 0.01% solution (the working solution): 10pg/iml, dilute In PBS (phosphate buffered saline). 30 AxI antibody cross-linking: 1st: Mouse anti-Axi (R&D, MAB154), 2 frd: Biotin-SP-conjugated AffiniPure goat anti-mouse IgG (H+L) (Jackson 98 WO 2008/083354 PCT/US2007/089153 ImmunoResearch #115-065-003). Fixing buffer: 4% formaldehyde in PBS. Wash buffer: 0.1% TritonX-100 in PBS. Quenching buffer: 3% H 2 0 2 , 0.1% Azide in wash buffer, Azide and hydrogen peroxide 5 (H 2 0 2 ) are added fresh. Blocking buffer: 5% BSA in TBST (tris buffered saline plus 0,1% Tween 20). Primary antibody: Rabbit anti-human Phospho-Akt antibody (Cell Signaling 9271): 1x250 diluted in blocking buffer. Secondary antibody: HRP (horse radish peroxidase)-conjugated Goat anti-Rabbit 10 secondary, stock solution: Jackson ImmunoResearch (Goat anti-Rabbit HRP, #111-035-144 ) 1:1 diluted in glycerol, store at -20* C. The working solution: lx 2000 dilution of stock in blocking buffer. Chemiluminescent working solution (Pierce, 37030): SuperSignal ELISA (enzyme linked immunosorbant assay) Pico Chemiluminescent substrate. 15 Crystal Violet solution: Stock : 2.5% Crystal violet in methanol, filtered and kept at ambient temperature. The working solution: dilute the stock 1:20 with PBS immediately before use. 10% SDS: working solution: 5% SDS (sodium dodecylsulfate), diluted in PBS METHODS: 20 Day 1: A 96 well TC (tissue culture treated) plate was coated with 10pg/mL poly-L Lysine at 374C for 30 min, washed twice with PBS, and air-dried for 5 minutes before cells were added. Hela cells were seeded at 10,000 cells/well and the cells were starved in 100 pL starvation medium containing Axl/Fc for 24 hrs. 25 Day 2: The cells were pre-treated with test compounds by adding 100 pL of 2X test compound to the starvation medium on the cells. The cells were incubated at 370C for I hr before stimulation. The cells were stimulated by Axi-antibody cross-linking as follows: A 5X 1 St/2"" 30 Axl antibody mixture was made (37.5pg/mL 18Y 100pg/mL 2"n) in starvation medium and nutated at 40C with thorough mixing for 1-2 hours for clustering. The resulting mix was warmed to 37 0 C. 50pL of 5X Axl 1" /2'd of antibody cluster was added to the cells and the cells were incubated at 37*C for 5 min. 99 WO 2008/083354 PCT/US2007/089153 After 5 minutes stimulation, the plate was flicked to remove medium and the plate was tapped onto paper towels. Formaldehyde (4.0% in PBS, 100 pL) was added to fix the cells and the cells were incubated at ambient temperature for 20 min without shaking. 5 The cells were washed with a plate washer buffer to remove the formaldehyde solution. The plate was flicked to removed excess wash buffer and tapped onto paper towels. Quenching buffer (100 pL) was added to each well and the cells were incubated at ambient temperature for 20 minutes without shaking. The cells were washed with a plate washer buffer to remove the quenching 10 buffer. Blocking buffer (100 pL) was added and the cells were incubated at ambient temperature for at least an hour with gentle shaking. The cells were washed with a plate washer buffer and diluted primary antibody (50 pL) was added to each well (blocking buffer was added to the negative control wells instead). The plates were incubated overnight at 4* C with gentle shaking. 15 Day 3: The wash buffer was removed, diluted secondary antibody (100 pL) was added, and the cells were incubated at ambient temperature for 1 hour with gentle shaking. During the incubation, the chemiluminescent reagent was brought to ambient temperature. 20 The secondary antibody was removed by washing the cells 1X with wash buffer, 1X with PBS by plate washer. The PBS was removed from the plate and the chemiluminescent reagent (80 pL: 40 pL A and 40 pL B) was added to each well at ambient temperature. The resulting chemiluminescence was read with a Luminomitor within 10 minutes 25 to minimize changes in signal intensity. After reading the chemiluminescence, the cells were washed IX with wash buffer and 1X with PBS by plate washer. The plate was tapped onto paper towels to remove excess liquid from wells and air-dried at ambient temperature for 5 minutes. Crystal Violet working solution (60 pL) was added to each well and the cells were 30 incubated at ambient temperature for 30 min. The crystal violet solution was removed, and the wells were rinsed with PBS, then washed 3X with PBS (200 pL) for 5 minutes each. 5% SDS solution (70 pL) was added to each well and the cells were incubated on a shaker for 30 min at ambient temperature. 35 The absorbance was read at 590 nM on a Wallac photospec. The 590nM 100 WO 2008/083354 PCT/US2007/089153 readings indicated the relative cell number in each well. This relative cell number was then used to normalize each luminescence reading. The results of the ability of the compounds of the invention to inhibit Axl activity, when tested in the above assay, are shown in the following Tables 1-2 wherein the level 5 of activity (i.e., the iC50) for each compound is indicated in each Table. The compound numbers in the Tables referred to the compounds disclosed herein as being prepared by the methods disclosed herein: 101 WO 20081083354 PCT/IJS2007/089153 - - - - - - ------------------------------------------------

-

4<\ 00 -~ -~ -, - --------------- w 0 0 0 T 0 z i 1L ON : No \~ mi 00 4 N -Y 0 05 0 S 0 - ' a-1n m0. -,(6 =;I ) 7" x-~ s 0<4, _____ ___1- __L_ S____;___ E : WO 20081083354 PCT/IJS2007/089153 - - - ----------- -------- ----- --- --------- ------- --- ----- - ----- --- -- ----- ------- -- --- ---- --- - >5 ce 0 c. 75 CT 0C .) 5 ,5, N C'!~ NLNo N' _ 10 a)C5 z7 --- -- --- -- --- -- -- WO 20081083354 PCT/IJS2007/089153

------------------

- ----- ---------- -- -- -- ---- ----- - : --- ---- I------- -------- ---------------------------------- /-----------i M ---- --- 20 0l \ ) 00 i~ Z//) /-/ 'z iI I I i CN v 6C ED~ 4 t i -i iC C3-C3 -, 'T IN((D 0 i5 IN :5t-, z -5

S

WO 20081083354 PCT/IJS2007/089153 Iz Z Iiz -- ----- -- ----- z ' z z - --- --- -- -- E% -:a 0 DC4( E .2 7 : --- 8 l m F E >,: ' Z 5,~z T~ 4 U) D U ', ,E 16LU WO 20081083354 PCT/IJS2007/089153 - --------- :L C)) 0 *)C z z C(N (N CO(N o~ ~ t,~ _9- c , -, E C s : :a z - Ll E 40 -atE*0 (N '-: (N E 2 00 z - ,,M -X '- C c- ,-r 1 -, 4> c WO 20081083354 PCT/IJS2007/089153 0 / C D 0- 0 r J C N /Z 0N E CC 2 -z - i cm -. / _r a 6~ 16 -6I L() CL -5; CL N~ 2r!~~5~Q'0~i - -------- ------- ------------- WO 20081083354 PCT/IJS2007/089153 f --- -- -- ---------- / zz CN0 r v-A A co 0 ) U\yj ) :1 1z <~0) z m

/I

-z - ------ ----- ------ ------ 04 0 oc 1 o N- 0 EE 'IE N -C> ~~ c m F =S 6.o :6 (D 20 2Y E 00 >, ~ "L6 -X >.o C W CL V co) ----- ---- --- ---- WO 20081083354 PCT/IJS2007/089153 u < ---- - ----- ----- ------ ------ ----- ------ ------ ----- ------ ---- oz0 C)) \ vt-A Acm Z -5 ii C /Z E L..g 2 2 V -o- -- ----- ---- ------------------ ---------------- WO 20081083354 PCT/IJS2007/089153 z A A - 4z il, I-T 0-" 2:- 4 -:0): 0 1 z--\' E24 -E E:- WN E K E~~: c6 I E ? z CL E '2 (D ms:c ~ 29

UC

WO 20081083354 PCT/IJS2007/089153 --------------------- ------ =LCN /I5/z o00 = vr-AA UU <~0 i - - - - ----- - - - - -- - - -- -- - - - - - --- - - - -- - - - - - - - - - - - 2-Z z / ' -- - ---- - /0i 0 '0 -ID \Z Ncu E 6 L. q s= E ~-- C. -; .- N A ~ > E C) >,N 0 C CU co- 6A (DC ~~2.C E E ci~ M ---------------- -0----------- WO 20081083354 PCT/IJS2007/089153 0 1 _ _--------__--- ~ 0 I- / zN z i K-it / £

/

.4- 4 - 4K: 0 t .. -0 - =. E:: 75K Z 06 c CL Q) >0'~ IQ --------------- -1 ~ L~L>, i * 3i

~-

0 v> & 0> 0i L ~~~~~ ~ ~ -------------------- L---------I WO 20081083354 PCT/IJS2007/089153 -- --- ------- --------- --- --- -- - -- - LL i 0 - ' z2 / --- ----- - - E / S I z-0 4 4 s; -Y>- & co C, -E E N I VZ c 0 .9 cN E cL aN 0 Cs~ L N 2 m 00 "0 2 o E '5Z --- --- - - --- ------ o M co 0 -- ------------ WO 20081083354 PCT/IJS2007/089153 - --------- ----- --- --- ----- 0 < ---- ----- ------ ---- CIr~ L \\ -- - --------------- -- - Z / ---- --- ---- --- -- -- -- - ---- OU') It64 : ! 1,~4, _ 4 C' (DU5 Ui 2-14 WO 20081083354 PCT/IJS2007/089153 -- ---- - --- ---- ----- ---- --- --- ----- ---- ---- ----- -- ----- ---- ----- --- --- --- ----- ---- ---- -- < < < - -------------- --------------- -- -------- --- 0 --- ----------------------- 2t z / <aJ~c0 0L C)C z Ct., Z--! A:;U T, ~ C"5L -TC I T m ~:y z z c L : E 'Oa -u CLz- ON / ~ ! ~2 E~ J- NE~ 5, 4 4n 4nIn E 9C WO 20081083354 PCT/IJS2007/089153 - -- - --------------------

-------------

/ z ~ 00 a C)I ' 0 0 V A Aw ----------- -- ----- -- -- --- -- -- -- 2, -' -1 o oc E~ (D 0D0 X 0 WO 20081083354 PCT/IJS2007/089153 u < --- /-- / - / ----- 0 V) 0 - / I < CD -I -- - ---- 4*t 05 ID E ~ ~ -~'0' z CL, 5 L6~ c(Y)- IC C s E 65 ~ i~C SN 0 0 6_ 02 z 6: 0D2 2~ ON -0 ---. o CL -- - ------ ... CL c - ----------- ---------- WO 20081083354 PCT/IJS2007/089153 - - - - - - - - ~mQ0 :E Z

-

,,~)z::0 z I z zj zm -- --- ------- ------ Ii Z~i -im& i<) c D7 E '5 , '5E - u 10 ___________________________c WO 20081083354 PCT/IJS2007/089153 - --- - - - - C)-A (I U - ---- z-I --- -- -- -- - -- E- C 4 ( D C O)A ~ C . 0 N E - 6 mcE , _ _ 0 ~ N~ ' _ E CL enl) -- - - - - - - -- - - - -- - - - - ---- - -- -- --- -- --- -- --- -- ----- WO 20081083354 PCT/IJS2007/089153 --------- --------

---

-: ----------- <: < -- -- ---- S--- - 0----- - ------------ - - - ----- ---- Z4 - 'I 0 0 CDA 0 0 0 Z 0fr 0 0 - - - ----

---

IZ

CL -u /: m/c x 0 -ad 4 K CL 00 Z R CN -a-, -- -------- --- - --- - -S -~ --- -- WO 20081083354 PCT/IJS2007/089153 a: 3: m:a \z 0 { L) 00 -- ----------- I -- -- 4 Ix -- E :s, 2: ' x It Z 5, ) 17 a:D -5; a: a EE rI.E E E r C 5V( a4 _2 4 > -c o c v, '~ ~ 2(4 ~o' clL~) 0 2L -- --- --- -- --- --- --- --- --- WO 20081083354 PCT/IJS20071089153 -- - -- - -- - -- - -- - -- - -- - -- - - -- - - < <: < -- -- -- - ---- -- -- --- - - T-u - ---------- 0 V' A A <. ( ------ 7 ----------------- ------ oc- CD 7~c r,:.~E 3 o, 'D A ~ ~ Lh( CN (D -a : a a ~ 00 CL 00 co CIDC -- ----------- ---------- WO 20081083354 PCT/IJS2007/089153 cS - ----- N I I z I' m 00 --------- - - z z (D a a:CC I? ZZ Z-, E c) c o N .

). . U~~ _J __ 2_ __ WO 20081083354 PCT/IJS2007/089153 --------------------------------------------------- ---------- Z I-~E .< L -I *l / E Z\/ -- ---- -- - -- --- 10 V ----------- -------- WO 20081083354 PCT/IJS2007/089153 -- ---- - < <5 m1 Z=\ M Z V A A Q) <oo/

T-'

bU f -- ---------------- --------- -I ---- 04! C, z _ c _ -f 'F.- 0: Q) 2 : E iL E E.9 C. -~ r>r 12 9 2 77 0C CLo -- ---- -- ----- - -- --- ---- ---- -i - --- -- --- -- - WO 20081083354 PCT/IJS2007/089153 -------- -- V-A A U) > <~0 \ \4 I-~ 24 2: 2 2 v7 -- E4 E 2 t c E E 2. Ev 2. 0 0 0 WO 20081083354 PCT/IJS2007/089153 'S Z 0 =L 0 \ vt-A A ~) J -Z" Cu/ r Zz I z CuN \ .4 ZA ~ ~ ~~a E~3~ C " mI Ec-T9C : C m c:E_ E' c- 7, z~ ~ ~ za$. LL Z ' ( U ID T C E ET LO "r -0 0 NS WO 20081083354 PCT/IJS2007/089153 - -- -- -- -- --- -- -- -- --

---------

£ N 1 00 ------- ---- /-------- I-I SI Q) ID - 6 Q-'Q) 2 ONO~- E .Oex csf .2 N~N Z: E Er

CD

WO 20081083354 PCT/IJS2007/089153 o Z Vt-A A 0 <mo -Z zK -Z z E N z Cc C)- 2 w2 o 0) N N E2 ~c CD CL co-3 V/ -- --------- ------- WO 20081083354 PCT/IJS2007/089153 < <2 =L 0 z Z / Z < LMA 0 -i ----------- / 0- , z ZI) z z 7 c: E a CO zO ~ O~~N~C E E 4E '5 ;,N -. -5;N -. 0 WO 20081083354 PCT/IJS2007/089153 - --------- u < < =L DZ \ MZ V~-AA oZ * / ------- X I 4 -- ---- ---- - CDI %Z6 -__ &-;c; 0~ > 2~~ ->,. w _'7 0- 2 E~'T~ Ev >12 -0 CLC2-0 WO 20081083354 PCT/IJS2007/089153 ----------- ----------- -------- ~ ~ ~ ------------- --- :r 1: Z v -A A <~O I-z U 0 ID D ~~~ Z EV~ c-O- Nl a 0 -F 2 o- 0 0 C4 - - CLW 0 8W IL) Y 0) >' 2 - ----------------- WO 20081083354 PCT/IJS2007/089153

-------

- - -C - --- --- ---- -------- ----- A A U z eo zI / ~E ~~Z7 -6-' 5 _C + CL m _---- 4-------- -------- __ _ -- --- --- --- -- -- --- ---- WO 20081083354 PCT/IJS2007/089153 0!00 0 -) 0 z f A zz * 0 i~ EN ->N ;I 6 c m E- WO 20081083354 PCT/IJS2007/089153 - -------------------- 0 a: a: < -- --- --- ------ - -----:a 0 0! VAA zz 0 Z__ L? E /? ;l ZM k '-- Cco NA: I, COL) F4~j~ ~ Z- ~ ~1) L MN 'o ZI!: >CL-~ >1 C E E~ ----------------------- -- ------- CLE - --- ------ - ----- --- --- --- -- H:\re\tevoven\NfRPo'Il\DCC\REC\602840_LOC17/0?220 - 136 * * * * * All of the U.S. patents, U S patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entireties. Although the foregoing invention has been described in some detail to facilitate understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims. Accordingly, the described embodiments are to be considered as illustrative and not restrictive, and the invention is not to be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any forn of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims (44)

1. A compound of formula (1): N-l N N R1 R R (4 wherein: R 1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R, -C(O)N(R6)R', and -C(=NR 6 )N(R)R7; R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -0R 8 , -R 9 -O-R 10 -OR, -R 9 -0-R 0 -O-R-R 8 , -R 9 -0-R 10 -CN, -R 9 -O-R 10 -C(O)0R 8 , -R 9 -0-R-C(O)N(R 6 )RL, -R 9 -0-R'-S(0)pR 8 (where p is 0, 1 or 2), -R 9 -0-R 1 -N(R 6 )R 7 , -R 9 -O-R 10 -C(NR 11 )N(R 1 )H, -R 9 -OC(O)-R, -R 9 -C(O)R3, -R 9 -C(O)0R 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -C(O)-R 10 -N(R 6 )R 7 , -R 9 -N(R)R 7 , - -R-N(R)C(O)OR, -R 9 -N(R 6 )C(O)-R 0 -N(R 6 )R', -R 9 -N(R 6 )C(O)R, -R9-N(R6)S(O)tR (where t is 1 or 2), -R 9 -S(O)iOR (where t is 1 or 2), -R 9 -S(O)pR 8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(Rt)R 7 (where t is 1 or 2); R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroary are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted araikenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted 137 WO 2008/083354 PCT/US2007/089153 heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 13 -OR1

2 -R 13 -OC(O)-R", -R"-O-R" -N(R )2, -R -N(R ) 2 , -R13C( O)R 1, -RI,3C(O)OR 11, -R"3-C(O)N(R"12)2, -R 1-C( O)N(R")--R 1 N(R 12)R' , -R13C( O)N(R"2)-RI 4OR 1, -R13 N(R 1)C( O)OR", -R"-N(R"12)C(O)R", -R 1 -N(R 12 )S(O)R 12 (where t is 1 or 2), -R 13 -S(O)tOR 12 (where t is 1 or 2), -R 1 -S(O)pR 2 (where p is 0, 1 or 2), and -R 1

3-S(O),N(R 1 )2 (where t is 1 or 2); each RO and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocycylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 10 -OR", -R'O-CN, -R 1 '-NO 2 , -R 1 -N(R) 2 , -R'-C(O)OR' and -R 0 -- C(O)N(R) 2 , or any R6 and R?, together with the common nitrogen to which they are both attached, form an optionally substituted N heteroaryl or an optionally substituted N-heterocyclyl; each RO is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cyclioalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R 9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain: each R 1 0 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched 138 WO 2008/083354 PCT/US2007/089153 alkenyiene chain and an optionally substituted straight or branched aikynylene chain; each R 11 is hydrogen, alkyl, cyano, nitro or -OR3 each R1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two Rs, together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 1 3 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R 14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof. 2. The compound of Claim 1, which is a compound of formula (la): R3 N-N S N RI wherein: R', R 4 and R are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R, -C(O)N(R")R, and -C(=NRI)N(R)R T ; R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -Re-OR, -R9-O-R'-OR. 139 WO 2008/083354 PCT/US2007/089153 -R 9 -O-R 1 OQO-RloORa, -R-O-RIO-CN, -R 9 -O-R 1 "-C(O)OR', -R 9 -O-R 10 -C(O)N(R6)R 7 , -R 9 -O-R 0 -S(O)pR 3 (where p is 0, 1 or 2), -RC-O--RN(R 6 )R7, 9 -R-C(NR 11 )N(R'")H, -R 2 -OC(O)-R, -R-C(O)R, -R 9 -C(O)OR 8 , -R9-C(O)N(R 6 )R 7 , -R9-C(O)-R N(R6)R', -R 9 -N(R 6 )R 7 , -R9-N(R 6 )-R 0 -N(R 6 )R 7 , -R 9 -N(R 6 )C(O)OR8, -R 9 N(R3)C(O)-R O-N(R6)R7, -R 9 -N(R 6 )C(O)R, -R 9 -N(R 6 )S(O)tR 8 (where t is 1 or 2), -R9-S(O)OR 8 (where t is 1 or 2), -R 9 -S(O),Rp (where p is 0, 1 or 2), and -R 9 -S(O)tN(R")R7 (where t is 1 or 2); R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocycylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -Rl- OR1 2 , -R' 3 -OC(O)-R 12 , -R 3 _O-R 14 -N(R 12 ) 2 , -R 1 2 -N(R 12 ) 2 , -R'3C(O)R -R13C(O)ORK ~ C()R)2-R (O)N(R )-RNR)R13 -R 3-C(O)N(R )-R 4 -OR , -R' 3 -N(R )C(O)OR2, -Ri 3 -N(Rl)C(O)R 2 , -R 13 N(R 12 )S(O)tR 2 (where t is I or 2), -R'--S(O)OR1 2 (where t is 1 or 2), -R 1 -S(O)R 12 (where p is 0, 1 or 2), and -R 13 S(O)tN(R" 1 ) 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralky, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 10 -OR3, -R 1 -CN, -R 1 -NO, -R"-N(R) 2 , -R 10 -C(O)OR 8 and -R' 0 -C(O)N(R 8 ) 2 , or any R 6 and R', together with the common nitrogen to which they are both attached, form an optionally substituted N- 140 WO 2008/083354 PCT/US2007/089153 heteroaryl or an optionally substituted N-heterocyclyl; each Ra is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R 9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R 1 0 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R" is hydrogen, alkyl, cyano, nitro or -OR8; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 1 2, together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R 1 4 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain. 141 WO 2008/083354 PCT/US2007/089153 3. The compound of Claim 2, wherein: R', R 4 and R 5 are each independently selected from the group consisting of hydrogen, -C(O)N(R 6 )R 7 , and -C(=NR 6 )N(Rc)R 7 ; R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR3, -R 9 O-R 10 -OR 8 , -R9-O-R1"-O-R".-OR', -R9-O-R"-CN, -R9-O-R1'-C(O)OR'I -R9-O-R -C(O)N(R)R 7 , -R-O-R"--S(O)pR 8 (where p is 0, 1 or 2), -R9-O-R"'N(R")R , -- R9O-R"C(NR.')N(R1")H, -R'-OC(O)-R8, -R9-C(O)R', -R 9 -C(O)ORa, -R 9 .C(O)N(R6)R, -R9C(O)-R-N(R)R, -R 9 N(R )R, -R9-N(R6)-R'ON(Rc)R 7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-RIIIN(R6)R 7, -R9-N(R6)C(O)R 8 , -R 9 -N(R 6 )S(O)tR 8 (where t is 1 or 2), -R-S(O)OR' (where t is 1 or 2), -R9-S(O)pR3 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R )R' (where t is 1 or 2); R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyi, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylaikyl, -R' 3 OR", -ROC(O)-R", -R 1 -0-R" N(R) 2 , -R3N(R)2, -R CO)R -R 3C(O)OR 12 -R'3-C(O)N(R 12)2, -R 3 -C(O)N(R")-R 1 -N(R )R 13 , -R 13 -C(O)N(R)-R OR , -R 13 -N(R 2 )C(O)OR -R 13 -N(R 12 )C(O)R 2 , -R 1 'N(R 1 )S(O)tR 2 (where t is 1 or 2), -R 13 -S(O)tOR 12 (where t is I or 2), -R 13 -S(O)pR, (where p is 0, 1 or 2), and -R 1 3 -S(O)N(R2)2 (where t is I or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralky!, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R -ORa, -R 10 -CN, -R"'-NO 2 , -R 1 O-N(R8) 2 , -RO-C(O)OR 8 and -R' 0 =C(O)N(R 8 ) 2 , or any R 6 and R 7 , 142 WO 2008/083354 PCT/US2007/089153 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 G is independently an optionally substituted straight or branched alkylene chain; each R" is hydrogen, alkyl, cyano, nitro or -OR; each R 1 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylakyl, or two R 12 ', together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl: each R 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R'" is independently an optionally substituted straight or branched alkylene chain.

4. The compound of Claim 3, wherein: R 1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, -C(O)N(R 6 )R', and -C(=NR)N(R)R; R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyi, 2,3-dihydrobenzo[b][ 1,4]dioxinyl, 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyrido[3,2-d]azepinyl, 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, IH-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 7',8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridiny, and 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, 143 WO 2008/083354 PCT/US2007/089153 nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR', -R'-O-R 1 -OR", -R 9 -0-R'O-C-R 0 -OR8, -R 9 -Q-R 10 -CN, -R9-O-ROC(O)ORK -R'-Q-R 10 C(O)N(R 6 )R 7 , -R 9 -O-R"O-S(O)pR' (where p is 0, 1 or 2), -R9O-R'N(R)R 7, -O-R-QC(NR")N(R")H, -R"OC(O)-Ra, -R 9 -C(O)R 8 , -RE(OOR -S-CO)(R)R, -R'-C(O)-R'ON(R6)R', -R9-N(R6)R , -R'-N(R6)-R'-N(R6)R 7 , -R 9 -N(R")C(O)OR, -R 9 -N(R 6 )C(O)-R -N(R 6 )R , -R"-N(R 6 )C(O)R, -R"-N(R)S(O)tR 8 (where t is 1 or 2), -RkS(O) OR 8 (where t is 1 or 2), -R9-S(O),Ra (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R7 (where t is 1 or 2); R 3 is aryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylaikyl, -R- 3 OR , -R'OC(O)-R2, -R13O-R 1 N(R 12)2, -Rl 'N(R 1)2, -R3-C(O)R"? -R 1 3C( O)OR 1,-R'3C(O)N(R 2, -R '3C(O)N(R") '-R 1 N(R 12)R 1 -R'3C(O)N(R'2)-R14_R 12 -R 3N(R 12)C(O)OR 1, -R1N(R 12 )C(O)R 2 , -R 1 3 -N(R 12 )S(O)R 12 (where t is 1 or 2), -R 1 3-S(O)OR 1 2 (where t is 1 or 2), -R'3S(O),R 12 (where p is 0, 1 or 2), and -R S(O)tN(R 12 ) 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 0 -OR, -R"-CN, -R 10 -NO 2 , -R 1 Q-N(R') 2 , -R 10 -C(O)OR 8 and -R 1 -C(O)N(R 8 ) 2 , or any R 6 and R(, together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each Ra is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylaikyl; 144 WO 2008/083354 PCT/US2007/089153 each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R"O is independently an optionally substituted straight or branched alkylene chain; each R" is hydrogen, alkyl, cyano, nitro or -OR 8 ; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R ', together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R1 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R 14 is independently an optionally substituted straight or branched alkylene chain.

5. The compound of Claim 4, wherein: R1, R 4 and R 5 are each hydrogen; R 2 is 2,3-dihydrobenzo[b][1 ,4]dioxinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, -R 9 -OR8, -R'-OC(O)-R8, -R9-C(O)R, -R'-C(O)OR'. -- R9C(0)N(RS)R', -R9-N(R6)R', -R 9 -N(R)C(O)OR', -R 9 -N(R 6 )C(O)R 8 , -R 9 -N(R 6 )S(O)tR 8 (where t is 1 or 2), -R-S(O) OR 8 (where t is 1 or 2), -R9-S(O)pRa (where p is 0, 1 or 2), and -R-S(O),N(R 6 )R 7 (where t is 1 or 2); R 3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR 1 , -R -OC(O)-Rl, -R 1 -N(R') 2 -R-C(O)R", -R"-C(O)OR , -R'3-C(O)N(R )2, -R13N(R1')C(O)OR, -R'3-N(R')C(O)R, -R 13 -N(R )S(O)tR" (where t is I or 2), -R 1 "-S(O)tOR (where t is 1 or 2), -R 1 -S(O) R" (where p is 0, 1 or 2), and -R 1 '-S(O)tN(R") 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, 145 WO 2008/083354 PCT/US2007/089153 optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 -R 8 , -R -CN, -R 10 -NO 2 , -R 10 -. N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R"-C(O)N(R 8 ) 2 , or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each Ro is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 10 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two Rm, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

6. The compound of Claim 5, which is N3-(2,3-dihydrobenzo[b][1,4]dioxin-6 yl)-1-phenyl--1 H-1 ,2,4-triazole-3,5-diamine.

7. The compound of Claim 3, wherein: R, R 4 and R' are each independently selected from the group consisting of hydrogen, -C(O)N(R 6 )R 7 , and -C(=NR 6 )N(R)R 7 ; R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl, 6,7,8,9-tetrahydr-5H-pyrido[3,2-d]azepinyl, 5,6,7,8-tetrahydro-1,6-naphthyrdinyl, 146 WO 2008/083354 PCT/US2007/089153 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 7',8'-dihydro-5'H-spiro[[1, 3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyi, and 6,7,8,9-tetrahydro-5H-cycohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalikenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R'-OR', -Rq-0-R 1 -0R", -R0O-R0O-REORS, -R-O--R 1 CN, -R 9 -O-R 10 C(O)0OR, -R9-0-RC(O)N(R 6 )R 7 , -R 9 -O-R 10 -S(O)pR 8 (where p is 0, 1 or 2), -R 9 -O-R 10 -N(R 6 )R -R'-O-R 10 -C(NR 11 )N(R" )H, -R-OC(O)-R', -R-C(O)R8, -R 9 -C(O)OR 8 , -R 9 -C(O)N(R6)R 7 , -R 9 C(O)-R 0 =N(R 6 )R 7 , -R9-N(R6)R", -R9-N(R6)-R'ON(Rc)R', -R9-N(R6)C(O)OR, -R9-N(R6)C(O)-R'DN(R6)R , -R 9 -N(R')C(O)R", -R-N(R 6 )S(O)R8 (where t is 1 or 2), -R0-S(O)tOR' (where t is I or 2), -R'-S(O)pR6 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R6)R 7 (where t is 1 or 2); R 3 is heteroaryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 OR , -R 13 -OC(O)-R", -R O-R -N(RG~ -R -N(R'2)2 -R13C(O)R" -R'3C(O)OR , -R1 C(O)N(RG~ -R'3C(O),N(R )-R -N(R )RS -R-3C(O)N(R )-R' OR , -R -N(R )C(O)OR, -R 13 -N(R 2 )C(O)R' 2 , -R' 3 -N(R 2 )S(O)R 2 (where t is 1 or 2), -R 3 S(O)iOR 12 (where t is 1 or 2), -R 1 -!S(O)R 12 (where p is 0, 1 or 2), and -R 13 =S(O)tN(R 12 ) 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R' 0 -OR, -RiuCN, -R 10 -NO 2 , -R" 0 -N(R 8 ) 2 , -R" 0 -C(O)OR' and -R 1 KC(O)N(R") 2 , or any R7 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; 147 WO 2008/083354 PCT/US2007/089153 each Ra is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R' 1 is hydrogen, alkyl, cyano, nitro or -OR8; each R2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two RI, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R" 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R 14 is independently an optionally substituted straight or branched alkylene chain.

8. The compound of Claim 7, wherein: R1, R 4 and R' are each independently selected from the group consisting of hydrogen, -C(O)N(R 6 )R 7 , and -C(=NR 6 )N(R)R 7 ; R is a heteroaryl selected from the group consisting of benzoxazoly, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 4,5-dihydro-1 H-benzorb]azepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyrdo[3,2-d]azepiny, 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, IH-pyrrolo[2,3-b]pyrdinyl, benzo[b]thiophenyl, 7'.8-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, and 6,7,8,9-tetrahydrocyclohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyi, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted 148 WO 2008/083354 PCT/US2007/089153 heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR8, -R'-O-R 0 -OR', -R9-O-R -O-R0-OR8, -R 9 -O-R"-CN, -R*-O-R 1 -C(O)OR 8 , -R 9 -O-R 0 -C(O)N(R 6 )R", -R 9 -O-R 1 -S(O)pR8 (where p is 0, 1 or 2), -R 9 -O-R 10 -N(R-)R7, -Rq-O-R 10 -C(NR 1 1)N(R 11 )H, -R 9 -OC(O)-R", -R 9 -C(O)R, -R-C(O)OR', -R9-C(O)N(R 6 )R', -R 9 -C(O)-R 1 -N(R6)R', -R 9 -N(R6)R , -R -N(R )-Rl-N(Rb)R7, -R9-N(R)C(O)ORs, -R9-N(R6)C(O)~R"-N(R")R", -R 9 -N(R 6 )C(O)R, -R9-N(R 6 )S(O)R 8 (where t is 1 or 2), -R9-S(O)OR (where t is 1 or 2), -R 9 -S(O)pR 8 (where p is 0, 1 or 2), and -R 9 -S(O)+N(R 6 )R7 (where t is 1 or 2); R is selected from the group consisting of pyridinyl, pyrimidinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-dpyrimidinyl, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-dpyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R" 1 -OR , -R 1 3-OC(O)-R", -R 1 -O-R -N(R ) 2 , -R 13 -N(R ) 2 , -R -C(O)R , -R 1 -=C(O)OR , -R"--C(O)N(R"') 2 , -R'--C(O)N(R'2)-R" -N(R )R"3, -R"3-C(O)N(R")-R -OR,-RN()()R, -R 13 -N(R 12 )C(O)R 12 , -R 13 -N(R 12 )S(O)jR 2 (where t is 1 or 2), -R 3 S(O)tOR 12 (where t is 1 or 2), -R 1 -S(O)R 12 (where p is 0, 1 or 2), and -R 1 3-S(O)N(R 12 ) 2 (where t is 1 or 2); each RW and Rt 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 0 -OR, -R 10 -CN, -R"-NO 2 , -R 10 -N(R). -R 1 0 -C(O)OR" and -Rlu-C(O)N(R 8 ) 2 , or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroary or an optionally substituted N-heterocyclyl; each R 6 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocycylalkyl, optionally substituted 149 WO 2008/083354 PCT/US2007/089153 heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R") is independently an optionally substituted straight or branched alkylene chain; each R 11 is hydrogen, alkyl, cyano, nitro or -OR8; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 1 2 , together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R 14 is independently an optionally substituted straight or branched alkylene chain.

9, The compound of Claim 8, wherein: R', R 4 and R' are each hydrogen; R 2 is selected from the group consisting of benzoib]thiophenyl, 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl, 2,3-dihydrobenzo[b] [1 ,4]dioxinyl and benzoxazolyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R;-OR', -R 9 -OC(O)-R, -R-C(O)Ra, -R 9 -C(O)OR 8 , -R1-C(O)N(R 6 )R 7 , -R 9 -N(R 6 )R 7 , -R9-N(R6)C(O)OR', -R 9 -. N(R 6 )C(O)R, -R 9 -N(R')S(O)R 8 (where t is 1 or 2), -Re-S(O)tOR3 (where t is 1 or 2), -R'-S(O)pR 8 (where p is 0, 1 or 2), and -R"-S(O)hN(R 6 )R7 (where t is 1 or 2); R3 is selected from the group consisting of isoquinolinyl, quinazolinyl and thienor3,2 d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 150 WO 2008/083354 PCT/US2007/089153 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R --OR, , -R -OC(O)-R', -Rls-N(R 12)2, -R'3-C(O)R 1, -R 1-C( O)OR", -R"-C(O)N(R")2, -R 1 1-N(R)C(O)OR 2 , R 3 -N(R 2 )C(O)R 2 , -R"-N(R' 2 )S(O)tR 2 (where t is 1 or 2), -R 1 -S(O)tOR 12 (where t is 1 or 2), -R 13 -S(O),R 12 (where p is 0, 1 or 2), and -R 13 -S(O)IN(R 2 (where t is 1 or 2); each RG and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalky, -R 10 -OR3, -R 1 -CN, -R 10 -NO 2 , -R 10 N(R 8 ) 2 , -R 1 0 -C(O)OR8 and -R 1 -C(O)N(R3) 2 , or any R6 and R', together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 0 is independently an optionally substituted straight or branched alkylene chain; each R2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R . together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

10. The compound of Claim 9 selected from the group consisting of: 1 -(isoquinolin-1-yl)-N3(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-y)-1 H-1,2,4-triazole 151 WO 2008/083354 PCT/US2007/089153 3,5-diamine; 1-(6-chloroq uinazolin-4-y)-N-(2-(pyrrolidin-1 -ylmethyl)benzo[d]oxazol-5-yl)-I H-1,2,4 triazole-3,5-diamine; NW-(2,3-dhydrobenzo[b][1,4]dioxin-6-yl)-1 -(isoquinolin-1-yl)-1H-1,2,4-triazole-3,5 diamine; N3-(2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)-1-(6,7-dimethoxyquinazoin-4-yl)-1 H-1,2,4 triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-y)-NC-(4,5-dihydro-I H-benzo[b]azepin-2(3H)-on-8-yl)-1 H 1,2,4-triazoie-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yi)-N=(2-(1-(4-(2-(dimethylamino)ethyl)piperazin-1 yl)oxomethyl)benzo[b]thiophen-5-yl)-1 H-1,2,4-triazole-3,5-diamine;

11. The compound of Claim 8, wherein: R 1 , R 4 and R are each hydrogen; R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalky, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalky, optionally substituted heteroarylalkenyl, -Rc-OR, -R'-OC(O)-R8, -R 9 -C(O)R 8 , -R 9 -C(O)OR', -R 9 -C(O)N(R)R, -R"-C(O)-R 0 -N(R3)R , -. R 3 -- N(R6)R , -R3-N(R 6 )-R 1 -N(R6)R, -R 9 -N(R 6 )C(O)OR 8 , -R 9 -N(R')C(O)-R 0 -N(R6)R 7 , -R 9 -N(R 6 )C(O)R, -R 9 -N(R 6 )S(O)R 8 (where t is 1 or 2), -R3-S(O)tOR 8 (where t is 1 or 2), -R 9 -S(O)pR (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R (where t is 1 or 2); R 3 is selected from the group consisting of pyridinyl and pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of aikyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR 12 , -R 13 -OC(O)-R", -R '-N(R 1 2) 2 , -R" 3 -C(O)R 12 , -R-"-C(O)OR"2, -R 13C(O)N(R '2)2, -R!. N(R")C(O)OR 1, -R 1 N(R"2)C(O)R 1, -R 1 -N(R) 12 S(O)tR 2 (where t is 1 or 2), -R 13 -S(O),OR"' (where t is 1 or 2), -R'--S(O)R 12 (where p is 0, 1 or 2), and -R 1 ^-S(O)tN(R 12 ) 2 (where t is 1 or 2); 152 WO 2008/083354 PCT/US2007/089153 each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 0 -OR, -R 10 -CN, -R"-NO 2 , -R 1 -N(R) 2 , -R'-C(O)OR and -R 1 -C(O)N(R 8 ) 2 , or any Rr and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R'O is independently an optionally substituted straight or branched alkylene chain; each R2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two Rm, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

12. The compound of Claim 11 selected from the group consisting of: 1 -(5-trifluoromethyl pyridin-2-yl)-N 3 -(6-(4-cyclopropylmethylpiperazin-1 -yl)pyridin-3-yl) -1-H 1,2,4-triazole-3,5-diamine; and 1-(6-phenylpyrimidine -4-yl)-N(3-methyi-2-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-5-y) 1 H-1,2,4-triazole-3,5-diamine.

13. The compound of Claim 8, wherein: R 1 , R 4 and R are each independently selected from the group consisting of hydrogen, 153 WO 2008/083354 PCT/US2007/089153 -C(O)N(R 6 )R 7 , and -C(=NR 6 )N(R)R 7 ; R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -RO-OR', -R 9 -OC(O)-R8, -R9C(O)R3, -RC(O)OR8, -R 9 -C(O)N(R6)R T , -R9-C(O)-R 0 -N(R 6 )R , -R 9 -N(R 6 )R , -R 9 -N(Rc)-R*'O-N(R 6 )R , -R 9 'N(R6)C(O)ORs, -R9N(R)C(O)-R 0 -N(R 6 )R7, -R 9 -N(R-)C(O)R, -R 9 -N(R6)S(O)tR 8 (where t is 1 or 2), -R9S(O)tOR 8 (where t is 1 or 2), -R 9 -S(O)pR8 (where p is 0, 1 or 2), and -R9-S(O)jN(R 6 )R 7 (where t is 1 or 2); R 3 is quinazolinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 3 -OR , -Rl-OC(O)-R", -R" -N(R )%, -R"-C(O)R"2 -R1:3C(O)OR", -R"-C(O)N(R 12)2, -R 1 -N(R 12 )C(O)OR 12 , -R 13 -N(R 1 2 )C(O)RI2, -R N(R 12 )S(O)tRI 2 (where t is I or 2), -R 13 -S(O)OR 1 (where t is 1 or 2), -R 1 3S(O)R 12 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R 12 ) 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R'o-NO2, -R 10 -N(R 8 ) 2 , -RiuC(O)OR and -R"-C(O)N(R8)2, or any R6 and R', together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an 154 WO 2008/083354 PCT/US2007/089153 optionally substituted straight or branched alkylene chain; each R 10 is independently an optionally substituted straight or branched alkylene chain; each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalky, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two RS, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

14. The compound of Claim 13 selected from the group consisting of: 1-(6,7-dimethoxyquinazoline-4-yl)-N3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)piperazin-1 yl)pyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-y)-N-(6-(4-(4-methylpiperazn-1 -yl)piperidin-1 -yl)pyridin 3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(6,7-diniethoxyquinazoline-4-yl)-N 3 -(6-(4-cyclopentyl-1,4-diazepan-1 -yl)pyridin-3-yl) 1-1-,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-N 3 -(6-(4-pyrroldin-1 -ylpiperidin-I -yl)pyridine-3-yl)-1 H 1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-N-(6-(4-piperidin-1 -ylpiperidin-1 -yl)pyridine-3-yl)-1 H 1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-N3-(6-(4-(pyrroldin-1 -ylmethyl)piperidin-1 -yl)pyridin-3 yl)-i H-1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-y)-N-(6-(diethylaminoethylmethylamino)pyridin-3-y)-i H 1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-N3-(6-(2-diethylaminomethylpyrrolidin-1 -yl)pyridin-3 yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(6.7-dimethoxyquinazoline-4-y)-N-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin 3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yl)-N 3 -(6-(3-diethylaminopyrrolidin-1 -yl)pyridin-3-yi)-1 H 1,2,4-triazole-3,5-dia mine; 1-(6,7-dimethoxyquinazoline-4-yl)-N-(6-(4-(bicyclo[2.2.1 ]heptan-2-yl)-1,4-diazepan-I 155 WO 20081083354 PCT/IJS2007/089153 yI)pyrin-3-yl)-I H-I ,2,4-triazole-3,5-diamine; I -(2-methyiquinazolin-4-yi )-NA-(6-(4-( pyrrolidin- 1 -yI)piperidin- 1 -yI)-5-methyI pyridin-3-yi ) 1 H-I ,2,4-triazole-3,5-diamine; I -(6-fluoroq uinazolin-4-yl)-N 3 -(6-(4-(pyrrolidin-I -yI)piperidin-il -yI)--5-methylpyridin-3-yI) I H-i ,2,4-triazole-3,5-diamnine; 1 -(6, 7-dimethoxyquinazoline-4-yl)-P1 3 -(6-bromopyrid in-3-yi )-5-(3-(6-bromopyridin-3-yi )-2 cyanoguanadino)-1 H-i ,2,4-triazole-3-amine; 1 -(6,7-dimethoxyquinazoline-4-yl)-N 3 -(6-bromopyridin-3-yi)-I -1,2,4-triazoie-3, 5 d famine; I -(6, 7-dimethoxyquinazoline-4-yl)-N 3 -(6-(3-(4-(4-methylpiperazin-I -yl)piperidin-1 yl)propenyI)pyridin-3-yl)-I H-I ,2,4-triazole-3,5-diamine: 1 -(6, 7-dimethoxyquinazoline-4-y)-N 3 -(6-(3-(4-piperidin-I -yipiperidiri-I yl)propenyl)pyridin-3-yl)-i H-i ,2,4-triazole-3,5-diamine 1 -(6,7-d imethoxyq u inazo I: ne-4-y;)-N 3 -(6-(3-(4-d imethyla minop ipe rid in- 1 yl)propenyl)pyridin-3-yl )-!, H-I ,2,4-triazole-3,5-diamine; 1 -(6, 7-dimethoxyquinazoiine-4-yl)-N 3 -(6-(3-(3-(die'Lhylamino)pyrrolidin-I yl~propenyl)pyridin-3-yl)-I, H-I ,2,4-triazole-3,5-diamine; 1 .(6,7-dimethoxyquinazoline-4-y)-N'-(6-(3-(3-(dimretlylanmino)pyrrolidin-1 yI)propeny)pyridin-3-y1)-i H-i .2,4-triazole-3,5-diamine; I -(6,7-dimethoxyquinazoline-4-y)-V3-(6-(3-piperidin-1 -ylproperiyl)pyridin-3-y~i) H-i 2,4 triazole-3,5-diamine; I -(6,7-dimethoxyquinazoline-4-y)-N 3 -(6-(3-(4-pyrr-olidini-i -ylpiperidi-I yl)propeny~pyridin-3-yl)-i H-I ,2,4-triazole-3,5-diamr.ine; 1 -(6, 7-d imethoxyquir:azol ine-4-y1)-N 3 '-(6-(3-(4-cyclopentylpiperazi n-I -yl)propenyl )pyridin 3-yl)-I H-i ,2,4-triazole-3,5-d ia mine; 1 -(6, 7-dimethoxyquinazoline-4-yI )-N 3 '-(2-(3-(4-isopropylpiperaz~rn-i -yl)propen-i yl)pyridinie-5-yI)-i H-i ,2,4-triazole-3,5-diamine; and 1 -(6, 7-dirnethoxyqu inazoline-4-y1)-Nf-(2-(4-cyclopropylmethyl-3-(S)-methylpiperazifl-i yl)pyridin-5-yl)-I H-i ,2,4-triazole-3,5-diamine.

15. The compound of Claim 8, wherein: R', R 4 and R 5 are each hydrogen; R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, 156 WO 2008/083354 PCT/US2007/089153 optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-ORa, -R-OC(O)-R 8 , -R 9 -C(O)R', -R 9 -C(O)OR', -R9-C(O)N(R)R 7 , -R3-.C(O)-R 0 -N(R 6 )R , -R"-N(R 6 )R 7 , -,R9--N(R 6 )-R 10 .- N(Rc)R 7 , -R-N(R 6 )C(O)OR 8 , -R3-N(R)C(O)-R""-N(R 6 )R 7 , -R9-N(R3)C(O)R, -R 9 -N(R 6 )S(O)R 8 (where t is 1 or 2), -R 9 -S(O)iOR3 (where t is 1 or 2), -R9-S(O)pR 8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R 7 (where t is 1 or 2); R 3 is selected from the group consisting of isoquinolinyl and phenanthridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R- 3 -OR", -R OC(O)-R", -R -N(R 1 ) 2 -R IC(O)R, -R'-'C(O)OR 1, -R"3C(O)N(R 12)2 -R"-N(R")C(O)OR 12, -R'3N(R 1)C( O)R", -R3N(R 12 )S(O)tR 2 (where t is 1 or 2), -R 1 3S(O),OR1 2 (where t is 1 or 2), -R"-S(O)R 12 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R 12 ) 2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalky, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 "-OR8, -RlK CN, -R"-N0 2 , -R 0 -N(R) 2 , -R" 0 -C(O)OR and -R 1 QC(O)N(R), or any R6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R1 0 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, 157 WO 2008/083354 PCT/US2007/089153 haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyi, or two R 12 ", together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R"- is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

16. The compound of Claim 15 selected from the group consisting of: 1 -(isoquinolin-1-yl)-N 3 -(6-(4-(bicyclo[2.2.1]heptan-2-yl)piperazin-I -yl)pyridin-3-yl)-1 H 1,2,4-triazole-3,5-diamine; 1-(isoquinolin-1-yl)-N-(6-(4-methylpiperazin-1 -yl)pyridin-3-yl)-1 H-1,2,4-triazole-3,5 diamine; and 1 -(phenanthridin-6-yl)-N..(6-(4-(pyrroidin-1 -yl)piperidin-1 -yl)-5-rnethylpyridin-3-yl)-1 H I 2,4-triazole-3,5-diamine.

17. The compound of Claim 8, wherein: R", R 4 and R 5 are each hydrogen; R 2 is selected from the group consisting of pyridinyl and 1 H-pyrrolo[2,3-b]pyridiny, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR', -R9-OC(O)-R8, -R-C(O)R', -R9-C(O)OR, -R 9 -C(O)N(R6)R 7 , -RC(O)-Ru-N(R6)R7, -R-N(R)R N -R4-N(R 7 )R, -R-N(RO)C(O)OR 8 , -R 9 -N(R 6 )C(O)-Rc-N(R 6 )R 7 , -R 9 -N(R 6 )C(O)R 8 , -R 9 -N(R 6 )S(O)tR8 (where t is 1 or 2), -R 9 -S(O)OR 8 (where t is 1 or 2), -RG-S(O),R 8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R 7 (where t is 1 or 2); R 3 is selected from the group consisting of thieno[3,2-d]pyrimidinyl and thieno[3,2 d]pyridazinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally 158 WO 2008/083354 PCT/US2007/089153 substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -ROR , -R OC(O)-R^, -R -N(R )2, -R'3C(O)R , -R-'3C(O))ORE,-E()(" -R 12N(R)C(O)OR 1 , -R-N(R1 2 )C(O)R 12 , -RN(R")S(O)R (where t is 1 or 2), -R"3-S(O)tOR 12 (where t is 1 or 2), -RKS(O) R 2 (where p is 0, 1 or 2), and -R 1 3-S(O)tN(R 12 ) 2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R' 0 -OR, -R 10 CN, -R"'NO2, -R 1 -- N(R3) 2 , -R 10 -C(O)OR" and -R'c-C(O)N(R8) 2 , or any R" and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyla kyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two RI, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R" 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. 159 WO 20081083354 PCT/IJS2007/089153

18. The compound of Claim 17 seleted from the group consisting of: I -(2-chloro-7-methylthieno[3,2-dlpyrimidine-4-yi)-N 3 -(6-(4-cyclopenty-I ,4-d iazepan-I yI)pyridin-3-yi)-i H-I ,2,4-triazole-3,5-diamine; I =(2-chloro-7-methylthieno[3,2-djpyrimidine-4-y )-AI-(E-(4-m et bypi perazi n-i -yl)pyridin-3 yl)-i H-I ,2,4-triazole-3,5-diamine; I -(2-chloro-7-methylthieno[3,2-dlpyrimidine-4-y)-NW-(6-(4-(pyrrolidin-1 -yl)piperidin-I yl)pyridine-3-l)--1 H.-I,2,4-triazole-3,5-diamine; I -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yI)-N 3 '-(6-(4-(4-methyipiperazin y!)piperidin-i -yI)pyridine-3-yI)-1 H-I ,2,4-triazole-3,5-diamine; I -(2-chloro-7-methylthieno[3,2-d]pyrimid ine-4-y )-NV 3 -(6-(4-( bicyclo[2.2. I ]heptar.-2 yl)piperazin-i -yl)pyridin-3-yly-I H- 1, 2,-triazole-3,5-d ia mine; I -(2-c~hdoro-7-methylthieno[3,2-d]pyrimidine-4-y)-N 3 -(6-(4-piperidin- I -yipiperidin-i yIlpyridine-3-yl)-i H-i ,2,4-triazole-3,6-diarnine; I -(2-chloro-7'-methylthieno[3,2-d]pyrimid in-4-yI)-N 3 -(I H-pyrrolo[2,3-b]pyhdin-5-yl)-I H I ,2,4-triazole-35-diam:.ne; I -(2-chiloro-7-rnetiyltiieno[3,2-djpyrimid in-4-yI)-N 3 -(6-(4-(pyrrolidini-lI-ylmethyl )piperidin I -yI)pyridin-3-yl)-1 H-I ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno [3,2-d~pyrim id i n-4-yl)-N-(6-(4-(aze pan-l1-yl)piperidin-1 yl)pyridin-3-yi)-I H-i ,2,4-triazole-3,5-diamine; I -(2-ctiloro-7-rnettyltthierio[3,2-djpyrirnid ir-4-yI)-N 3 -(6 (diethylamyinroetthylrnethyaino)pyridin-3-y)-I H-i ,2,4-triazole-3,5-diamine; I -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N 3 -(6-(2-diethylarninomethypyrrolidin-i yllpyridin-3-yl)-l H-i ,2,4-triazole-3,5-d ia mine; I -(2-chiloro-7'-rneihylthierio[3,2-d]pyrirnidin-4-yl-At 3 -(6-(4-(pyrrolidin-I -yl)piperidin-i -yi)-5 methylpyridin-3-yl)-I H-I ,2,4-triazole-3, 5-diarnine; I -(2-chloro-7-methylthieno[3,2-djpyrimidin-4-yl)-N 3 -(6-(3-diethylaminopyrrolidin- yI)pyridin-3-yl)-1 H-i ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7 -methylthieno[3,2-d]pyrimidin-4-y>-N 3 -(6-(4-(bicyclo[2.2. I Jheptan-2-yI)-I 4 diazepan-i -yl)pyridin-3-yI)-i H-I 2,4-triazole-3, 5-diam-ine; 1 -(2-chloro-7-methylthieno [3,2-d] pyrim id in-4-yl}-N 3 -(6-(4-cyclo pro pyl m ethylp iperazi n- 1 yI)pyridin-3-yI)- 1 H-i ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-djpyrim id ine-4-yI )-N 3 -(6-(5-bicyclo[2 .2. 1 ]heptan-2 ylocta hyd ropyrrol[3A4-c]pyrrolyl)pyridine-3-y )- I H-i,2,4-triazole-3, 5-di amine; I -(2-chloro-7-methylthieno[3,2-d pyrimid in-4-yI)-N 3 -(6-(4-eyclopropyl piperazin-I yl)pyridin-3-yl)-i H-i 1,2.4-triazole-3,5-d ia mine; 160 WO 20081083354 PCT/IJS2007/089153 I -(2-chloro-7-methylthieno[3,2-dlpyrimidine-4-yI),-W 3 -(5-methy-6-(4-bicyclo[2 .2.1 ]heptan 2-yipiperazin-I -yI)pyridine-3-y)-1 H-i 1,2,4-triazole-3,5-diamnine; I -(7-methylthiengo[3,2-d]pyrmid ine-4-yi )-N 2 -(5-rethyl-6-(4-bicycio[2.2. I lheptan-2 ylpiperazin-l -yI)pyridine-3-yl)-I H-I 2,4-tnriazole-3,5-diamine; I -(7-methylthieno[3,2-dlpyrlmidine-4-yi)-N' 3 -(6-(4-((l S,23,4R)-bicyclo[2.2. I]heptan-2 yI)piperazin-1 -yI)pyridln-3-yl)-l H-I ,2,4-triazole-3,5-dlamine; I -(2--chloro-.7-methythieno[3,2-d]pyrimidirie-4-y Af;V-(6-(lI-bicyclo[2.2, I ]heptan-2 ylpiperidin-4-y )pyridine-3-yi)1-i H-I ,2,4-triazole-3.15-diarnine; I -(7-methythieno[3,2-d]pyrimidine-4-y)-N 3 -(6-( I -bicyclo[2.2. I ]heptari-2-yipiperidin-4 yl)pyridine-3-yi)-I H-I 1.2,4-triazo le-3, 5-d ia mine; I -(7-methylthieno[3,2-d]pyrimidine--4-y)--N 3 .- (6-(I -(biCYGIO[2.2. 1 Iheptan-2-yi)-5 rnethylpiperdin-4-y)pyidine-3-.y)--l H-I,2,4-tr'iazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidine-4-yI)-P-(6-(4-(cycopropylmethyl)piperazin-I yl)pyridine-3-yI)-I H1-I,2,4-triazole-3,5-diamine; I -(7-methyith ieno[3,2-dlpyrim idine-4-yI )-N 3 -(6-(4-(cyclopropyl methyl)piperazin-1 -yl)-5 methylpyrid ine-3-yI>1i - I 2,4-triazole-3 15--diamine; I -(2-chiloro-7-methylthieno[3,2-dlpyrimid in-4-y!)-N 3 -(6-(4-(cyclopropyl methyl)piperazin-1 yi)-5-methylpyridin-3-ylI)-l H-I ,2,4-triazole-3,5-diamine; I -(7-methylthieno[3, 2-d]pyrimidin-4-yi )-N3-(2-(3-(S)-methyI-4-( IS, 2S:4R) bicyck4[2.2. 1 ]ieptarn-2-ylpiperazin- I-yI)-3-methylpyrid'i n-5-yl)-I H-I 2,4-triazole 3,5-diamnine; I -(2-chloro-7-methylthienof3,2-d]pyrim idin-4-yI)-N3-(2-(3-(S)-methyI-4-(2S) bi cyclol2.2. I] ]heptan-2-yl pipe razi n- I -yl)-3-methyl pyrid in-5-,y)- 1 H-i 2,4-triazole 3,5-diamine; I -(thienof3,2-dlpyrimidirn-4-yl)-N-(2-(3-(S)-methyl-4-(2S)-bicyclo[2.2. 1 Iheptan-2 ylpiperazin-l -yi-3-methylpyridin-5-yl)-1 H-I ,2,4-triazole-3,5-diamine; I -(2-chloro-7-methylthieno[3,2-d]pyrim idin-4-yl)-N 3 -(2-(4-(2s)-bicydlo[2.2. I ]heptan-2 ylpiperazin-I -yl-3-chloropyridin-5-yl)-I H-i ,2,4-triazole-3,5-cliamriine; I -(7-methylthieno[3,2-dlpyri midi n-4 -yI )-NV-(2-(4-(2S)-biyclo[2 .2.1 ]heptan-2-yipiperazi n 1 -yl)-3-chloropyridin-5-yl )- I H-1 .2,4-triazole-3,5-diamine; I -(7-methylthieno[3,2-d]pyrimidin-4-yi )-N 3 P-(2-(4-(2S)-bicyclo[2 .2. 1 ]heptan-2-ypi perazin 1 -yl )-3-methylpyridi n-5-yi )- I H-I ,2,4-triazole-3, 5-diamine; I -(4-methylthieno[3,2-d]pyridazi-ne -7-yi)-NI 3 -(2-(4-(I S,2,4R)-bicyclo[2,2. I ]heptan-2 ylpiperazin-I -yI)-3-methylpyridin-5-y)-1 H-I ,2,4-triazole-3,5-diamine; I -(2-chloro-7-methylthieno[3,2-d]pyrimid in-4-yI)-N 3 -(2-(4-cyclopropDyir ethyl-3-(S) 161 WO 20081083354 PCT/IJS2007/089153 methylpiperazin-i -yl)pyridin-5-yl)-i -i 12,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-y )(,32-(4-cyclopropylmehyl-3-(S)-methylpiperazin 1 -yI)pyridin-5-yl)-i H-i ,2,4-triazole-3, 5-diamine; 1 -(2-chloro-7-methylth ieno[3,2-d~pyrimidin-4-yl)/t\1-(2-(4-cyclopropylmethyk-3-(S) methylpiperazin-i -yl)pyridin-5-yI)-i H-i ,2,4-triazole-3,5-diamine; 1 -(7-metlhylth ieno [3,2-d] pyri mid in-4-yi)-NW-(2-brom opyrid in-5-yl)-1 I-- 1,2,4-triazoie-3,5 diamine; I -(7-methyit ieno[3, 2-d]pyrimnidin-4-y)-N 3 -(2-(3-(pyrro~iidirn-I -yl)propen- i-yl )pyrid in-5-yl) 1 H-i ,2,4-triazole-3,5-diamine; I =(7-methylthieno[3,2-dlpyrimidin-4-yi)-N3-(2-(3-(3-dimethylarminopyrrol~din-l -yl)propen 1 -yI)pyridin-5-yI)-1 H-I ,2,4-triazolo-3, 5-diamine; S-(7-rnethyl-thieno[3,2-dpyrimidin-4-yi)-N3 -(2-(3-(3-diethylarninopyrrolidini-1 -yl)propeni-I yI)pyridin-5-yI)-Il H-i ,2,4-triazole-3,5-diamine; I -(7-methylthieno[3,2-dipyrimidin-4-yi!)- J3-(2-(3-(4-pyrrolidin-i -yl-piperidin-i -yl)propen-i yl)pyridin-5-yi)-i H-i ,2,4-triazole-3,5-diamine; I -(7-methyith ienio[3,2-dipyrirniidirn-4-y )-Nl3-(2-(3-(4-methylpiperazin-I -yl )propen- I yI)pyridin-5-yi)-i H-i ,2,4-triazole-3,5-diamnine, I -('7-methyith ienof3, 2-dipyrimyidirn-4-y )-MI-(2-(3-(4-isopropylpiperazi n-I -yl )propen-I yI),pyridin-5-yl)-i H-i ,2,4-triazole-3,5-diamine; I -(7-mnethylth ieno [3,2-d! pyri mid in-4--yl)-AN3-(2-(3-(4-cyclope ntyl pi~erazi n- 1 -yI)propen-i yI)pyridin-5-yl)-i H-i ,2,4-triazole-3,5-d ia mine; I -(7-methylth ie no[3,2-d]pyri mid in-4-yl)-N3-(2-(3-(m orpho i n-4-yl)pro.Den-i1 -yl)pyridin-5-yl) I H-I ,2,4.-triazole-3,5-di:amine; 1 -(7-metthylthieno[3, 2-dlpyrimidin-4-y )-NV 3 -(2-(3-(piperidin-I -yllpropen-1 -yi pyridin-5-y ) iHq-i,2,4.-triazole-3,5-di!amine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yI)-N 3 P-(2-(3-(4-(4-methylpiperazin-I -yI)piperidin-i yI)propen-I -yl)pyridin-5-yl)-i H-i,2,4-triazole-3,5-diamine; and I -(7-methylth ie no[3,2-d]pyri mid in-4-yl)-NV3-(2-(3-(4-pipe rid in-i1 -yl p iperid in- I -yI)prOpen- I yl)pyridin-5-yl)-I H-i ,2,4-triazole-3,5-diamine.

19. The compound of Claim 8, wherein: R', R and R5 are each hydrogen; R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano. nitro, halo, haloalkyl. alkyl, optionally substituted cycloalkyl, 162 WO 2008/083354 PCT/US2007/089153 optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR', -R9-OC(O)-R', -R9-C(O)Ra, -R 9 -C(O)OR3 -R9-C(O)N(R)R , -R9-C(O)-RE'-N(R6)R', -R 9 -N(R6)Rr, -R 9 -N(R6)-RQ.N(R6)R , -R9-N(R')C(O)OR', -R'-N(R6)C(O)-R"ON(RW)R', -R9-N(R')C(O)R', -R 9 -N(R)S()iR 8 (where t is 1 or 2), -R 9 -S(O)iOR 8 (where t is 1 or 2), -R-S(O) R' (where p is 0, 1 or 2), and -R9-S(O)tN(Rr)R (where t is 1 or 2); R 3 is selected from the group consisting of furo[3,2-c]pyridinyl and 6,7-dihydro-5H cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 0R 1 , -R 3 -OC(O)-R , -R -N(R' 2 ) 2 , -R 3 -C(O)R , -R CO)OR, -R CO)N(R )2, -R"-N(R")C(O)OR, -R"-N(R")CO)R", -R 13 -N(R' 2 )S(O)iR 12 (where t is 1 or 2), -R 3 S(O)OR 2 (where t is 1 or 2), -R 13 S(O)R 12 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R 12 ) 2 (where t is 1 or 2); each R 6 and R' is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R"-ORa, -R 1 -- CN, -R""-N0 2 , -R 10 -N(R 8 ) 2 , -Rl 0 -C(O)OR 8 and -R 1 -C(O)N(R 8 ) 2 , or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; 163 WO 2008/083354 PCT/US2007/089153 each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 12 l, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R" 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

20. The compound of Claim 19 selected from the group consisting of: 1-(furo[3,2-c]pyridine-4-yil)-N3-( 6 -(4-(pyrrolidin-1-yl)piperidin-1-yl)-5-methylpyridin-3-yl) 1H-1,2,4-triazole-3,5-diamine; and 1-(6,7-dihydro-5H-cyclopenta[j4,5]thieno[2,3-dpyrim idin-4-y'i)-N 2 -(6-(4-(pyrrolidin-1 yl)piperidin-1 -yl)-5-methylpyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine.

21. The compound of Claim 8, wherein: R 1 , R 4 and R' are each hydrogen; R 2 is 6,7,8,9-tetrahydro-5H-pyrido[3,2-dazepinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroaryalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR, -R'-OC(O)-R, -R9-C(O)R 8 , -RK~C(O)OR', -R"-C(O)N(R')R , -R9-C(O)-R'0-N(Re)R 7, -R9-N(R')R7, -R9-N(R')-R "-N(R')R 7, -R*-N(R')C(O)ORW, -R9-N(R 6 )C(O)-R 0 -N(R')R7, -RS-N(R6)C(O)R, -R"-N(R 6 )S(O)tR (where t is 1 or 2), -R9-S(O)tOR' (where t is I or 2), -R 9 -S(O)pR8 (where p is 0, 1 or 2), and -R 9 -S(O);N(R 6 )R 7 (where t is 1 or 2); R 3 is selected from the group consisting of thieno[3,2-dpyrimidinyl and quinazolinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally 164 WO 2008/083354 PCT/US2007/089153 substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 3 -- OR, -R 1 OC(O)-R 1 , -R 1 N(R 1 ) 2 , -R 3 C(O)R 1 , -R 13 C(O)OR 12 , -R 3 _C(O)N(R 1 2 ) 2 , -R 1 3N(R 1 2 )C(O)OR 1 2 , -R 3 -N(R 2 )C(O)R 2 , -Rl 3 'N(Rl2)S(O)tR 2 (where t is 1 or 2), -R 13 S(O)tOR 12 (where ' is 1 or 2), -- R 1 S(O)R 12 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R 12 ) 2 (where t is I or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR', -R 10 -CN, -R"-NO 2 , -R 1 -N(R) 2 , -R 10 -C(O)OR and -REC(O)N(R) 2 , or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R ', together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

22. The compound of Claim 21 selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-dIpyrimidine-4-yl)-NC(7-cyclopentyl-6,7,8,9-tetrahydro 5H-pyrido[3,2-d]azepin-3-yl)-1H-1,2,4-triazole-3,5-diamine; and 165 WO 2008/083354 PCT/US2007/089153 1-(6,7-dimethoxyquinazoline-4-yl)-N-(7-cycliopentyl-6,7,8,9-tetrahydro-5H-pyrdo[3,2 d]azepin-3-yl)-1 H-1,2,4-triazole-3,5-diamine.

23. The compound of Claim 8, wherein: R 1 , R 4 and R" are each hydrogen; R2 is 5,6,7,8-tetrahydro-1,6-riaphthyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R9-OC(O)-R 8 , -Ra-C(O)R', -R 9 -C(O)OR8, -R-C(O)N(R6)R, -R9-C(O)-R")-N(R6)R 7, -R9-N(R6)R-", -R'-N(R6)-R"O-N(R')R7, -R--N(R')C(fO)OR", -R 9 -N(R 6 )C(O)-R"-N(R 6 )R 7 , -R 9 -N(R')C(O)R8, -R 9 "N(R 6 )S(O)iR (where t is 1 or 2), -R 9 -S(O)OR6 (where t is 1 or 2), -R 9 -S(O),R 8 (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R 7 (where t is 1 or 2); R 3 is selected from the group consisting of isoquinolinyl and thieno[3,2-d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 --OR , -R"-OC(O)-R , -R"-N(R ) 2 , -R' -C(O)R, -R 13 -C(O)OR 12 , -R 13 =C(O)N(R 12 ) 2 , -Rid-N(R. 2 )C(O)OR 2 , -R -N(RI)C(O)R2, -R 1 -N(R)S(O)iR 12 (where t is 1 or 2), -R 13 S(O)tOR 12 (where t is 1 or 2), -R 3 -S(O)R 12 (where p is 0, 1 or 2), and -R 3 -S(O),N(R 2 ) 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -RE-OR 8 , -R OCN, -R"-N0 2 , -R 1 -N(R) 2 , -R 10 -C(O)OR" and -R 1 -C(O)N(R8) 2 , or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; 166 WO 2008/083354 PCT/US2007/089153 each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R1 is independently an optionally substituted straight or branched alkylene chain; each R1 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylaikyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 12 ', together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 1 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

24. The compound of Claim 23 selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-NC(6-methyl-5,6,7,8-tetrahydro-1,6 naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; I -(isoquinolin-1 -yl)-N 3 -(6-methyl-5,6,7,8-tetrahydro-1,6-naphthyridin-3-y)-1 H-1,2,4 triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-N-(6-benzyl-5,6,7,8-tetrahydro-1,6 naphthyridin-3-y)-1 H- 1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyr mid ine-4-yl)-N 2 -(6-(ethylcarboxy)-5,6,7,8-tetrahydro 1,6-naphthyridin-3-yl)-1 H- 1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-y)-i3-(6-(dimethylaminomethylcarbonyl) 5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-I H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimid ine-4-yl)-NT(5,6,7,8-tetrahydro-1,6-naphthyridin 3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimid ine-4-yl)-V 3 -(6-(dimethylaminomethylcarbonyl) 5,6,7,8-tetrahydro-1,6-naphthyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimid i ne-4-y)-NC(6-(2-dimethylaminoethyl)- 5,6,7,8 167 WO 2008/083354 PCT/US2007/089153 tetrahydro-1 ,6-naphthyridin-3-y)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methythieno[3,2-d]pyrimidine-4-yl)-N3-(6-cyclopentyl-5,6,7,8-tetrahydro 1,6-naphthyrdin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methyithieno[3,2-d]pyrimidin-4-y)-N 3 -(6-(1 -methylpiperidin-4-ylcarbonyl) 5,6,7,8-tetrahydro-1,6-naphthyridin-3-yi)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-rnethylthierio[3,2-dpyrimidirie-4-y)-N3-(6-(1 -methylpiperidin-4-yl)-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-NP-(6-(piperidin-4-ylcarbonyl)-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-I H- 1,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-NQ-(6-(I -methylpiperidin-4-yl)carbony-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-I H-1,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-N'-(6-cyclopentyl-5,6,7,8-tetrahydro-1,6 naphthyridin-3-yl)-1 H-1,2,4-triazoie-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N 3 -(6-cyclopropylmethyl-5,6,7,8 tetrahydro-1,6-naphthyridin-3-yl)-1 H-1,2,4-triazole-3,5-diarine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N1-(6-bicyclo[22. 1]heptan-2-yl-5,6,7,8 tetrahydro- 1,6-naphthyridin-3-yi)-1H-1,2,4-triazole-3,5-diamine; and 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N 3 -(6-(dimethylaminomethyl)carbonyl 5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-I H-1,2,4-triazole-3,5-diamine.

25. The compound of Claim 8, wherein: R 1 , R 4 and R5 are each hydrogen; R 2 is selected from the group consisting of 6,7,8,9-tetrahydro-5H-cyclohepta[bpyridinyl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, 5,6,7,8-tetrahydroquinolinyl, and 7',8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-y, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R-OR', -R9-OC(O)-R", -R-C(O)R, -R-C(O)OR 8 , -R9-C(O)N(Rb)RT, -R -C(O)-R 1 N(R 6 )R , -R 9 -N(Rb)R , -R-N(R )-.R 10 -N(R 6 )R 7 , -R'-N(R 6)C(O )OR', -R9-N(R6)C(O)-R"-N(R3)R 7, -R9-N(R 6)C( O)R", -R9-N(R6)S(O)tR 8 (where t is 1 or 2), -R9-S(O)jOR (where t is 1 or 2), -R 9 -S(O)rR 8 168 WO 2008/083354 PCT/US2007/089153 (where p is 0, 1 or 2), and -R 9 -S(O),N(R 6 )R 7 (where t is 1 or 2); R 3 is thieno[3,2-dlpyrimidinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkeny, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 3-OR' 2 , -R" 3 -OC(O)-R' -R 13 -N(R 1 2 ) 2 , -R 1-C(O)R 12 , -R '-C(O)OR, -R 1-C(O)N(R")2, -R2N(R)C(O)OR 1 , -R'-N(R")C(O)R 12 , -R 13 -N(R 12 )S(O)iR 1 2 (where t is 1 or 2), -R 3 -S(O)tOR 12 (where t is 1 or 2), -R 1 3-S(O)pR 1 2 (where p is 0, 1 or 2), and -R 13 -S(O)tN(R 12 ) 2 (where t is 1 or 2); each R 6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -RlO-OR', -R 1 -CN, -R 10 -NO 2 , -R 1 -N(R8) 2 , -RO-C(O)ORB and -R 1 -C(O)N(R 8 ) 2 , or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R" is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R , together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an 169 WO 20081083354 PCT/IJS2007/089153 optionally substituted straight or branched alkylene chain.

26. The compound of Claim 25 selected from the group consisting of: I -(2-chloro-7-methylthienoI3,2-d]pyrimidine-4-y)-NW-(6-(pyrrolidin-I ylcarbonyl)-5,6,7,8 tetrahydroquinolin-3-yl)-I H-i 2,4-triazole-3,5-diarnine; I -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-y)-N 3 -(6-(2-(dimelhylamino)-I oxyethylamino)-5,6,7,8-tetrahydr.quinolin-3-yi- H-I ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-rn ethyl thienio[3,2-d]pyri mid in-4-yl)-N 3 -(6-am i no-5,6,7,8-tetrahyd roq u 1nol in 3-yI)-1 H-i ,2,4-triazole-3,5-dilam ine; 1 -(2-chloro-7-rnethylthieno[3,2-d]pyrimidine-4-yl)-N 3 -(6-(I -methylpiperidin-4-ylamino) 5,6,7,8-terahydroquinolin-3-y)-1 H- i,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-rmethylthieno[3,2-d~pyrirn idini-4-yl)-N'-(7' 8'-dihydro-V'H spiro[[1 ,3]dioxolane-2,6'-quinoline]-3-yl)-1 1-1-I ,2,4-triazole-3,5-diamine; I -(2-chloro-7-rnethylthieno[3,2-d]pyrimidin-4-yl)-NW-(6-(pyrrolidi n-I -yi)-4b,5,6,7,7a,8 hexahydropentaleno[2, I -bjlpyridin-3-yI)-1 H-I ,2,4-triazole-3,5-d ia mine; 1 -(2-chloro-7-rnethyl th ieno[3,2-L~pyri mn id ln-4-yl )-N3.-(6-(4 -methyl pi perazi n-I1 -yl)-5, 6 , 7,8 tetra hyd roq uinoli n-3-yl)-I1 H-I ,2,4-triazole-3,5-dianmine; 1 -(2-chloro-7-rnethylthieno[3,2-d~pyrirnid in-4-yI )-N'-(6-cyclopentylamino-5,5, 7,8 tetrahydroq~uinolin-3-y)-l H-1, 2,4-triazole-3,5-d ia mine; 1 (-hoo7mtytin[,-~yrmdn--l-3(-proii- -yI)-6,7,8,9 tetra hyd ro-5H-cyclohepta[b]pyrid in-3-yl)-1 H-I ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-djpyrirnidin-4-yl)-N 3 -(6-pyrrolidin-I -yl-567,8 tetrahydroq uinolin-3-yi)-l H-I ,2,4-triazole-3,5-diamine; 1 -(7-metLhylthieno[3,2-dlpyrimidin-4-y)-N 3 -(6-( I -methylpiperidin-4-ylamino)-5,6,7, 8 tetrahydroquinolin-3-y!i)-I H-I ,2,4-triazole-3,5-diamine; 1 -(7-methylth ieno [32-pyri mid in-4-y)-PP(6-pyrro id in- 1 -yi-5,6,7,8-tetrahydroquinolin-3 yI)-l H-1 .2,4-triazole-3,5-diamine; I -(7-methylthieno[3,2-d]pyrimidin-4-yI)-N 3 -(6-( 1 -mnethyl pipe rid iri-4-yI)ca3rbonylamino 5,6,7,8-tetrahydroquinolin-3-yl)-1 H-, ,2,4-triazole-3,5-d ia mine; I -(7-methyllthieno[3,2-d~pyrimidin-4-y)-N'V-(6-cyclopentylamino-5,6, 7,8 tetrahydroquinolin-3-yI)-I H-I ,2,4-tLriazole-3. 5-diamine; I -(2-chloro--7-methylthieno[3,2-d]pyrimidin-4-yl)-N 3 -(6-cyclohexylamino-5,6,7,8 tetrahydroquinolin-3-yI)-I H-I ,2,4-triazole-3, 5-diarnine; I -(2-chloro-7-methylthieno'3,2-dpyrimidin-4-yl)-N 3 -(6-bicyclo[2 .2.1 ]heptan-2-yi-amino 170 WO 2008/083354 PCT/US2007/089153 5,6,7,8-tetrahydroquinolin-3-yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N-(6-bis-(cyclopropylmethyl)amino 5,6,7,8-tetrahydroquinolin-3-y)-1H-1,2,4-triazole-3,5-diamine; and 1-(7-methylthieno[3,2-d]pyrimidin-4-y)-N-(7-(pyrrolidin-1 -yl)-6,7,8,9-tetrahydro-5H cyclohepta[b]pyridine-3-yl)-1 H-1,2,4-triazole-3,5-diamine.

27. The compound of Claim 8, wherein: R, R 4 and R 5 are each hydrogen; R 2 is pyrimidinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylaikenyl, -R9-OR 8 , -R 9 -OC(O)-R, -R"-C(O)R8, -Rg-C(O)OR , -R 9 -C(O)N(Rc)R , -R 9 -C(O)-R" 0 -N(R 6 )R , -R 9 -N(R)R , -RNR -7N(SR, -R9-N(R")C(O)ORa,. -RE-N(R6)C(O)-R'0-N(R")R', -R9-N(R)C(O)R, -R9-N(R6)S(O)tR 8 (where t is 1 or 2), -R'-S(O)tOR (where t is 1 or 2), -R2-S(O),R 8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R 7 (where t is 1 or 2); R 3 is selected from the group consisting of quinazolinyl and thieno[3,2-dpyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycly, optionally substituted heterocyclyalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R -OR , -R":'-OC(O)-R , -R -N(R") 2 , -R':-C(O)R, -R-CO)R, -R'3-C(O))N(R"12)2, -R' -N(R 12)C(O)OR 1, -R"-N(R 1)C(O)R 1, -R 1 3-N(R")S(O)R 12 (where t is 1 or 2), -R"-S(O),OR' (where t is 1 or 2), -R- 13 S(O),R 12 (where p is 0, 1 or 2), and -R 1 3 -S(O),N(R 12 ) 2 (where t is I or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 -OR, -R"-CN, -R 0 -NO 2 , -R 1 0 -N(R') 2 , -R 10 -C(O)OR and -R"-C(O)N(R) 2 , or any R6 and R , 171 WO 2008/083354 PCT/US2007/089153 together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl. optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R- is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R', together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

28. The compound of Claim 27 selected from the group consisting of: 1-(6,7-dimethoxyquinazoline-4-y)-N3-(2-(4-pyrrolidin-1 -ylpiperidin-1 -yl)pyrimidin-5-yl)-1 H 1,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-y)-N-(2-(4-piperidin-1 -ylmethylpiperidin-1 -yl)pyrimidin-5 yl)-1 H-1,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-cdpyrimidin-4-yl)-N-(2-(4-pyrrolidin-1 ylpiperidin-1 yl)pyrimidin-5-y)-1H-1,2,4-triazole-3,5-diamine; and 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-N-(2-(4-(piperidin-I -ylmethyl)piperidin-1 yl)pyrimidin-5-yl)-1.H-1,2,4-triazole-3,5-diamine. 172 WO 2008/083354 PCT/US2007/089153

29. The compound of Claim 1, which is a compound of formula (Ib): R 3 N-N \ -: N N N (ib) wherein: R', R 4 and R are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)Ra, -C(0)N(R)R , and -C(=NR 6 )N(R)R 7 ; R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R9-0-R'-OR", -R 9 -O-R 10 -O-R 1 -OR 8 , -R 9 -O-RIO-CN, -R 9 -0-R 1 -C(O)OR 8 , -R 9 O-.R 0 .- C(O)N(Rc)R', -R 9 -O-R 10 -S(O)pR8 (where p is 0, 1 or 2), -R9-O-R'ON(R6)R, -Rq-0-R'OC(NR1")N(R'I)H, -R"'OC(O)-R8, -R9-C(0)R8, -R-C(O)ORa, -R 9 -C(O)N(R')R 7 , -R 9 -C(O)-R =N(R6)R 7 , -R 9 -N(R 6 )Rl, -R9-N(R 6 )-R 1 O-N(R 6 )R 7 , -R9-N(R)C(O)OR 8 , -R 9 -N(R')C(O)-R 0 -EN(R 6 )R 7 -R9-N(R 6 )C(O)Ra, -R 9 -N(R')S(O)tR 8 (where t is 1 or 2), -R 9 -S(O)tOR (where t is 1 or 2), -R 9 -S(O),R" (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R7 (where t is 1 or 2); R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkyny, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylaikynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R'-OR", -ROC(O)-R2, -R3--N(R12)2, -R-N(R12)2, 173 WO 2008/083354 PCT/US2007/089153 -R-C(O)R -R"-CO)OR -R'-C(O)N(R )21,-R-C(O)(G-MNR) -R'.-C(O)N(R"12)-R 14OR 1, -R'3-N(R 1)C(O)OR , -R"-N(R )CO)R", -R 13 -N(R 12 )S(O)R 12 (where t is 1 or 2), -R 13 -S(O)tOR 1 2 (where t is 1 or 2), -R"-S(O),R (where p is 0, 1 or 2), and -R'-S(O)tN(R 2 ) 2 (where t is 1 or 2); each R" and R is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyi, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylaikenyl, optionally substituted heteroarylalkynyl, -RI 0 -OR 8 , -R'1 0 -CN, -R 10 -NO 2 , -R 10 -N(R 8 ) 2 , -R 1 -C(O)OR' and -R 1 -C(O)N(R') 2 , or any R 6 and R, together with the common nitrogen to which they are both attached, form an optionally substituted N heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R 9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R 1 0 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; 174 WO 2008/083354 PCT/US2007/089153 each R" is hydrogen, alkyl, cyano, nitro or -ORB; each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 1 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 1 3 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R 1 4 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain.

30. The compound of Claim 29, wherein: R 1 , R 4 and R are each independently selected from the group consisting of hydrogen, -C(O)N(R 6 )R?, and -C(=NR4)N(R6)R'; R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R3OR8, -R 9 -O-R 1 D-O-R - 0 OR8, -R-O-R 10 -CN, -R-O-R-C(O)OR', -R9-O-R-C(O)N(R)R 7 , -R-O-R 1 -S(O),Ra (where p is 0, 1 or 2), -R9-0-R"_-N(R6)R , -R'-O-R'0-C(NR'1)N(R1")H, -R"-'OC(0)-RaI, -RO-C(O)Ra: -R"O-C(O)OR', -- R9C(O)N('R6)R7, -R0--C(O)-R1')N(R6)R', -- R9-N(R6)R , -R"-N(RG)--R'0N(RB)R , -R9-N(Rr1)C(O)OR-* .- R'-N(R(3)C(O)-.R'ON(R6)R , -R 9 -N(R 6 )C(O)R, -R 9 -N(R 6 )S(O),R 8 (where t is 1 or 2), -R-S(Oj)OR 8 (where t is I or 2), -R 9 -S(O),R 8 (where p is 0, 1 or 2), and -R 9 -S(O)4N(Rb)R7 (where t is I or 2); R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, 175 WO 2008/083354 PCT/UJS2007/089153 haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 1 3 OR", -R 1 KOC(O)-R' 2 , -R 3 O--R 14 N(R 12 ) -R'3N(R )2, -R 3C(O)R",; -R13C(O)OR,-RC)NRs -R'3C(O)N(R 1)N-R 1 N(R 12)R", -R 13C(O)N(R 12)-R"4OR 1 , -R1 N(R 1)C(O)OR 2, -R 3 N(R 2 )C(O)R 12 , -R 13 -N(R 1 2 )S(O)lR 12 (where t is 1 or 2), -R-S(O)tOR 1 (where t is 1 or 2), -R 1 -S(O),R 2 (where p is 0, 1 or 2), and -R S(O)iN(R 2 ) 2 (where t is I or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted araikyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 0 -OR2, -R'<CN, -R 10 -NO 2 , -R"'-N(R) 2 , -R 1 -C(O)OR' and -R 1 Q-C(O)N(R 8 ) 2 , or any R 6 and R T , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R 1 0 is independently an optionally substituted straight or branched alkylene chain; each R 1 is hydrogen, alkyl, cyano, nitro or ~OR8; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 12 'S, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 3 is independently selected from the group consisting of a direct bond and an 176 WO 2008/083354 PCT/US2007/089153 optionally substituted straight or branched alkylene chain; and each R 14 is independently an optionally substituted straight or branched alkylene chain.

31. The compound of Claim 30, wherein: R 1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R', and -C(=NR6)N(R6)R'; R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b][1,4]dioxinyi, 4,5-dihydro-1 H-benzofb]azepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyrido[3,2-d]azepinyl, 5,6,7,8-tetrahydro-1,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzo[b]thiophenyl, 7 ,8dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoine]-3-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, and 6,7,8,9-tetrahydro-5H-cycloheptab]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R>ORF, -R'-OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR', -R9-C(O)N(R')R , -R9-C(O)-R"-N(R6)R , -R'-N(R6)R , -R'-N(RS)-R'O-N(R6)R, -R9-N(R')C(O)OR8, -R9-N(R6)C(O)-R"-N(R6)R 7, -R9-N(R')C(O)R8, -R9-N(R 6 )S(O)tR8 (where t is 1 or 2), -R 9 -S(O),OR' (where t is 1 or 2), -R-S(O)pR' (where p is 0, 1 or 2), and -R 9 -S(O)tN(R)R 7 (where t is 1 or 2); R 3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, aikenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 3 -OR 2, -R 3 -OC(O)-R", -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -R'3-C(O)OR'2 -R 3-C(O)N(R)2 -R"-N(R )C(O)ORS -R"-N(Rl)C(O)R12 -R 13 -N(R"')S(O)tR (where t is 1 or 2), -R 13 -S(O)tOR 2 (where t is 1 or 2), -R' -S(O)pR (where p is 0, 1 or 2), and -R -S(O)N(R ') 2 (where t is 1 or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, 177 WO 2008/083354 PCT/US2007/089153 haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR, -R 1 -CN, -IR 1 '-NO 2 , -Rk-N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R 1 -C(O)N(R8) 2 , or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each RU is independently an optionally substituted straight or branched alkylene chain; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R1 2 ", together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R 1 3 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

32. The compound of Claim 30, wherein: R R 4 and R 5 are each independently selected from the group consisting of hydrogen, -C(O)N(R 6 )R 7 , and -C(=NR)N(R)R 7 ; R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[b[1,4]dioxinyl, 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl, 6,7,8,9-tetrahydro-5H-pyrido[3,2-djazepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-bpyridinyl, benzo[b]thiophenyl, 7',8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quincline]-3'-yl, 178 WO 2008/083354 PCT/US2007/089153 4b,5,6,7, 7a,8-hexahydropentaleno[2,1-b]pyridinyl, and 6,7,8,9-tetrahydro-5H-cyclohepta[bpyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylaIkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -RO-OR', -R 9 -OC(O)-R, -R 9 -C(O)R, -R-C(O)OR, -R-C(O)N(R 6 )R , -R9-C(O)-REc-N(R')R , -R9-N(R6)R , -R"-N(R')-R-N(R 6 )R , -R-N(R6)C(O)OR', -R*-N(R 6 )C(O)-R 0 -N(R 6 )R -R'-N(R 6 )C(O)RS, -R 2 -N(R 8 )S(O).R 8 (where t is 1 or 2), -R 9 -S(O)OR 8 (where t is 1 or 2), -R 9 -S(O) Ra (where p is 0, 1 or 2), and -R 9 -S(O)tN(R 6 )R (where t is 1 or 2); R 3 is a heteroaryl selected from the group consisting of pyridinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-djpyrimidinyl, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5H-cyclopenta[4,5]theno[2,3-a] pyrimidnyl, and furo[3,2-cpyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 OR", -R'KOC(O)-R , -R 13 -N(R) 2 , -Rl 3 C(O)R, -RECO)OR, -R" C(0)N(R")2, -R -N(R )C(O)OR"2, -R"-N(Rl")C(O)R, -R13N(R 12 )S(O)R 12 (where t is 1 or 2), -R 13 -S(O):OR 12 (where t is 1 or 2), -R3-S(O)pR 12 (where p is 0, 1 or 2), and -R 13 -S(O),N(R 12 ) 2 (where t is I or 2); each R6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 0 -OR 8 , -R 10 -CN, -R"-N0 2 , -R 10 -N(R3) 2 , -RiOC(O)OR8 and -R'-C(O)N(R) 2 , or any R 6 and R , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted 179 WO 2008/083354 PCT/US2007/089153 heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R"' is independently an optionally substituted straight or branched alkylene chain: each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroary and optionally substituted heteroarylalkyl, or two R 12 S, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; and each R" is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.

33. The compound of Claim 32 selected from the group consisting of: 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-NW-(6-(4-(pyrrolidin- 1 -yl)piperidin-1 -yl)-5 methylpyridin-3-y)-1 H-12,4-triazole-3,5-diamine; 1-(4-methylthieno[2,3-d]pyridazin-7-y)-N-(2-(4-(I S,2S,4R)-bicyclo[2.2.1 ]heptan-2 ylpiperazin-1-yl)-3-methylpyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine; and 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-N 5 -(2-(3-(4-(4-methylpiperazin-1-yl)piperidin-l yl)propen-1 -yl)pyridin-5-yl)-1 H-1,2,4-triazole-3,5-diamine.

34. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (1): R,9 R2 NJN N R' R4 wherein: R, R4 and R 5 are each independently selected from'! the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R', -C(O)N(R)R, and -C(=NR 6 )N(R 6 )R 1 ; R 2 is a heteroaryl optionally substituted by one or more substituents selected from the 180 WO 2008/083354 PCT/US2007/089153 group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR 8 , -R9-O-R"-OR', -R9-O-R 1 c-O-RI-3OR', -R 9 -O-R 10 CN, -R 9 -0-R 1 -C(O)OR', -R-O--Rlc-C(O)N(R')R7, -R"-O-R 1 KS(O)pR 8 (where p is 0, 1 or 2), -R9-O-R"-N(R')R', -R'-O-R OC(NRI1)N(R")H, -R'-OC(O)-Ra, -RW-C(O)RW, -RW-C(O)OR3, -R9-C(O)N(R'3)R7, -R9-C(O)-R ON(R6)R', -R9-N(Rc)R', -R"-N(R)-R 10 -N(RS)R 1 , -R 9 -N(R6)C(O)OR8, -R'-N(R 6 )C(O)-R" 0 -N(R 6 )R, -R"-N(R 6 )C(O)R", -R9-N(R6)S(O):R8 (where t is 1 or 2), -R 9 -S(O)tOR8 (where I is 1 or 2), -R 9 -S(O)pR (where p is 0, 1 or 2), and -R 9 -S(O).N(R 6 )R7 (where t is 1 or 2); R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 1 3-OR 12 , -R 13 -OC(O)-R1 2 , -RO 3 -- R 1 -N(R 12 ) 2 , -R E 3 N(R 12 ) 2 , -R'3C(O)R 1, -R'3C(O)OR 12 -R 13C( O)N(R2)2, -R"-C(O)N(R")-R 1 N(R '2)R13 -R"-C(O)N(R )-R OR' -R -N(R )CO)OR 0, -RN(R'2)C(O)Rl -R 13 -N(R")S(O)R1 2 (where t is 1 or 2), -R 1 -S(O)IOR 12 (where t is 1 or 2), -R 13 S(O)R 1 2 (where p is 0, 1 or 2), and -R 13 -S(O):N(R 12 ) 2 (where t is 1 or 2); each R and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocycly, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally 181 WO 2008/083354 PCT/US2007/089153 substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 0 -OR8, -RIO-CN, -R 10 -NO 2 , -R 10 -N(R) 2 , -R-C(O)OR 8 and -R' 0 -C(O)N(R 8 ) 2 , or any R" and R , together with the common nitrogen to which they are both attached, form an optionally substituted N heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted araikenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R 9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain: each R 1 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R 1 is hydrogen, alkyl, cyano, nitro or -OR 8 ; each R 1 2 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two Rl1',' together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 1 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and 182 WO 2008/083354 PCT/US2007/089153 each R 14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.

35. A method of treating a disease or condition associated with Axl activity in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of a compound of formula (1): R 3 N-I-N R/R N N R1 R wherein: R 1 , R 4 and R are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R 8 , -C(O)N(R)R, and -C(=NR 6 )N(R 6 )R7; R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R* 9 -OR 8 , -R 9 -O-R'"-OR', -R 9 -O-R 10 -O-R 1 0 -OR8, -R 9 -O-RO-CN, -R-O--R'c-C(O)OR 8 , -R 9 -O-R 10 -C(O)N(R 6 )R 7 , -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R'Q-N(R6)R 7, -R*-0-R'"-C(NR")N(R")H, -R'-OC(O)-Ra, -Rg-C(O)R', -R 9 -C(O)OR, -R 9 -C(O)N(R')R 7 , -R'-C(O)-R"'-N(R 6 )R 7 , -R'-N(RC)R', -R 9 -N(R 6 )-RQ-N(R 6 )R, -R 9 -N(R 6 )C(O)OR, -RP-N(R 6 )C(O)-R -N(R 6 )R , -R 9 -N(R6)C(O)RB, -R9-N(R')S(O)tRa (where t is I or 2), -R-S(O) OR (where t is 1 or 2), -R'-S(O)pR 8 (where p is 0, 1 or 2), and -R)-S(O)tN(R 6 )R' (where t is 1 or 2); R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted 183 WO 2008/083354 PCT/US2007/089153 aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 13 -OR 7 -R _OC(O)-R., -R 13 -O-R -N(R ) 2 : -R 1 N(R ) 2 , -R:3C(O )RI12 -R 13C( O)OR2, -R'3C(O)N(R 12)2 -R'--C(O)N(R" )-R--N(R 12)R13 -R 1-C(O )N(R 12)-R 14OR'2 -R'3N(R"1)C(O )OR 12 -R"-sN(R 12)C(O)R1.2 -R 1 -N(R 12 )S(O)R 12 (where t is 1 or 2), -R S(O)tOR1 2 (where t is 1 or 2), -R-S(O)PR (where p is 0, 1 or 2), and -R S(O)tN(R") 2 (where t is I or 2); each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocylyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R 1 0 -OR8, -RlcCN, -R'-NO 2 , -R 1 'E-N(RF)2, -Rlo-C(O)OR' and -RluC(O)N(R) 2 , or any R3 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N heteroaryl or an optionally substituted N-heterocyclyl; each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyi, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; 184 WO 2008/083354 PCT/US2007/089153 each R 9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R 10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R' 1 is hydrogen, alkyl, cyano, nitro or -OR 8 ; each R 12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R 12 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl; each R 1 3 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R 14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.

36. The method of Claim 35 wherein the disease or condition is alleviated by the modulation of Axi activity.

37. The method of Claim 35 wherein the disease of condition is alleviated by a increase in Axi activity.

38. The method of Claim 35 wherein the disease of condition is alleviated by a decrease in Axi activity. 185 WO 2008/083354 PCT/US2007/089153

39. The method of Claim 38 wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy of prematurity, kidney disease, osteoporosis, osteoarthritis and cataracts.

40. The method of claim 38, wherein a manifestation of the disease or condition is solid tumor formation in said mammal.

41. The method of Claim 40, wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer and uveal melanoma.

42. The method of claim 38, wherein a manifestation of the disease or condition is liquid tumor formation in said mammal.

43. The method of claim 42, wherein the disease or condition is myeloid leukemia or lymphoma.

44. The method of Claim 38 wherein the disease or condition is endometriosis. 186